

International Gastric Cancer Congress 2023

IGCC 2023




Date June **14** (Wed) - **17** (Sat), 2023

Venue **PACIFICO Yokohama**

Congress President **Yuko Kitagawa**

Department of Surgery,
Keio University School of Medicine

Supported by **City of Yokohama**



<https://site2.convention.co.jp/igcc2023/>



痛みの、そばに、アセリオ。

本剤の効能又は効果
経口製剤及び坐剤の投与が困難な場合における
疼痛及び発熱



解熱鎮痛剤
アセトアミノフェン 静注液

アセリオ 静注液 1000mg/バッグ

acelio Bag for Intravenous Injection 1000mg

劇薬、処方箋医薬品 注意—医師等の処方箋により使用すること

薬価基準収載

アセトアミノフェンは
マルチモーダル鎮痛に
使われる薬剤の一つです。

【警告】

(1)本剤により重篤な肝障害が発現するおそれがあることに注意し、1日総量1500mgを超す高用量で長期投与する場合には、定期的に肝機能等を確認するなど慎重に投与すること(「2.重要な基本的注意(9)」の項参照)。(2)本剤とアセトアミノフェンを含む他の薬剤(一般用医薬品を含む)との併用により、アセトアミノフェンの過量投与による重篤な肝障害が発現するおそれがあることから、これらの薬剤との併用を避けること(「2.重要な基本的注意(7)」及び「8.過量投与」の項参照)。

【禁忌】(次の患者には投与しないこと)

(1)重篤な肝障害のある患者[重篤な転帰をとるおそれがある。](2)本剤の成分に対し過敏症の既往歴のある患者(3)消化性潰瘍のある患者[症状が悪化するおそれがある。](4)重篤な血液の異常のある患者[重篤な転帰をとるおそれがある。](5)重篤な腎障害のある患者[重篤な転帰をとるおそれがある。](6)重篤な心機能不全のある患者[循環系のバランスが損なわれ、心不全が悪化するおそれがある。](7)アスピリン喘息(非ステロイド性消炎鎮痛剤による喘息発作の誘発)又はその既往歴のある患者[アスピリン喘息の発症にプロスタグランジン合成阻害作用が関与していると考えられる。]

■効能又は効果 経口製剤及び坐剤の投与が困難な場合における疼痛及び発熱(効能又は効果に関連する使用上の注意)経口製剤及び坐剤の投与が困難で、静注剤による緊急の治療が必要である場合等、静注剤の投与が臨床的に妥当である場合に本剤の使用を考慮すること。経口製剤又は坐剤の投与が可能になれば速やかに投与を中止し、経口製剤又は坐剤の投与に切り替えること。

■用法及び用量 下記のとおり本剤を15分かけて静脈内投与すること。<成人における疼痛>通常、成人にはアセトアミノフェンとして、1回300～1000mgを15分かけて静脈内投与し、投与間隔は4～6時間以上とする。なお、年齢、症状により適宜増減するが、1日総量として4000mgを限度とする。ただし、体重50kg未満の成人にはアセトアミノフェンとして、体重1kgあたり1回15mgを上限として静脈内投与し、投与間隔は4～6時間以上とする。1日総量として60mg/kgを限度とする。<成人における発熱>通常、成人にはアセトアミノフェンとして、1回300～500mgを15分かけて静脈内投与し、投与間隔は4～6時間以上とする。なお、年齢、症状により適宜増減するが、原則として1日2回までとし、1日最大1500mgを限度とする。<2歳以上の幼児及び小児における疼痛及び発熱>通常、2歳以上の幼児及び小児にはアセトアミノフェンとして、体重1kgあたり1回10～15mgを15分かけて静脈内投与し、投与間隔は4～6時間以上とする。なお、年齢、症状により適宜増減するが、1日総量として30mg/kgを限度とする。<用法及び用量に関連する使用上の注意>1.本剤の投与に際しては、投与速度を厳守すること(本剤の有効性及び安全性は本剤を15分かけて静脈内投与した臨床試験において確認されている。【臨床成績】の項参照)なお、本剤の投与速度及び投与量により、循環動態に影響を及ぼすことが明らかに予想される患者には投与しないこと。2.乳児、幼児及び小児の1回投与量の目安は下記の通り、「1.慎重投与」及び「2.重要な基本的注意」の項参照)

体重	5kg	10kg	20kg	30kg
1回投与量の目安	3.75mL	7.5～15mL	20～30mL	30～45mL

3.乳児、幼児及び小児に対する1回あたりの最大用量はアセトアミノフェンとして500mg、1日あたりの最大用量はアセトアミノフェンとして1500mgである。

■使用上の注意 1.慎重投与(次の患者には慎重に投与すること)1)アルコール多量常飲者[肝障害があらわれやすくなる(「3.相互作用」の項参照)。]2)絶食・低栄養状態・摂食障害等によるグルタチオン欠乏、脱水症状のある患者[肝障害があらわれやすくなる。]3)肝障害又はその既往歴のある患者[肝機能が悪化するおそれがある。]4)消化性潰瘍の既往歴のある患者[消化性潰瘍の再発を促すおそれがある。]5)血液の異常又はその既往歴のある患者[血液障害を起こすおそれがある。]6)出血傾向のある患者[血小板機能異常が起こることがある。]7)腎障害又はその既往歴のある患者[腎機能が悪化するおそれがある。]8)心機能異常のある患者[症状が悪化するおそれがある。]9)過敏症の既往歴のある患者(10)気管支喘息のある患者[症状が悪化するおそれがある。](11)高齢者(「2.重要な基本的注意」及び「5.高齢者への投与」の項参照)(12)小児等(「2.重要な基本的注意」及び「7.小児等への投与」の項参照) 2.重要な基本的注意 (1)本剤の使用は、発熱、痛みの程度を考慮し、最小限の投与量及び期間にとどめること。(2)解熱鎮痛剤による治療は原因療法ではなく、対症療法であることを留意すること。原因療法があればこれを行うこと。(3)投与中は患者の状態を十分観察し、副作用の発現に留意すること。本剤の投与直後には経口製剤及び坐剤に比べて血中濃度が高くなることから、過度の体温下降、虚脱、四肢冷却等の発現に特に留意すること。特に高熱を伴う高齢者及び小児等又は消耗性疾患の患者においては、投与後の患者の状態に十分注意すること。(4)高齢者及び小児等には副作用の発現に特に注意し、必要最小限の使用にとどめるなど慎重に投与すること。(5)感染症を不顕性化するおそれがあるので、感染症を合併している患者に対して用いる場合には必要に応じて適切な抗菌剤を併用し、観察を十分に行い、慎重に投与すること。(6)他の消炎鎮痛剤との併用は避けることが望ましい。(7)本剤とアセトアミノフェンを含む他の薬剤(一般用医薬品を含む)との併用により、アセトアミノフェンの過量投与による重篤な肝障害が発現するおそれがあることから、特に総合感冒剤や解熱鎮痛剤等の配合剤を併用する場合はアセトアミノフェンが含まれていないか確認し、含まれている場合は併用を避けること。またアセトアミノフェンを含む他の薬剤と併用しないよう患者に指導すること(「警告(2)」及び「8.過量投与」の項参照)。(8)アセトアミノフェンの高用量投与により副作用として腹痛・下痢がみられることがある。本剤においても同様の副作用があらわれるおそれがあり、疼痛又は発熱の原疾患に伴う消化器症状と区別できないおそれがあるので、観察を十分に行い、慎重に投与すること。(9)重篤な肝障害が発現するおそれがあるので注意すること。1日総量1500mgを超す高用量で長期投与する場合には定期的に肝機能検査を行い、患者の状態を十分に観察すること。高用量でなくとも長期投与する場合には定期的に肝機能検査を行うことが望ましい。また、高用量で投与する場合には特に患者の状態を十分に観察するとともに、異常が認められた場合には、減量、休薬等の適切な措置を講ずること。 3.相互作用 併用注意(併用に注意すること)薬剤名等:アルコール(飲酒)、クマリン系抗凝薬(ワルファリン)、イソニアジド、カルバマゼピン、フェニバルビタール/フェニトイン/アリドミン/リファンピシン 4.副作用 市販後の使用成績調査および乳幼児を対象とした特定使用成績調査における安全性解析対象症例433例中、副作用発現症例は37例(8.5%)で、主な副作用は肝機能検査値異常15例(3.5%)、肝機能障害7例(1.6%)、悪心・嘔吐5例(1.2%)、血小板減少3例(0.7%)であった(再審査終了時)。(1)重篤な副作用 1)ショック(頻度不明)、アナフィラキシー(頻度不明):ショック、アナフィラキシー(呼吸困難、全身紅潮、血管浮腫、蕁麻疹等)があらわれることがあるので、観察を十分に行い、異常が認められた場合には直ちに投与を中止し、適切な処置を行うこと。 2)中毒性表皮壊死融解症(Toxic Epidermal Necrolysis: TEN)(頻度不明)、皮膚粘膜眼症候群(Stevens-Johnson症候群)(頻度不明)、急性汎発性発疹性膿疱症(頻度不明):中毒性表皮壊死融解症、皮膚粘膜眼症候群、急性汎発性発疹性膿疱症があらわれることがあるので、観察を十分に行い、異常が認められた場合には投与を中止し、適切な処置を行うこと。 3)喘息発作の誘発(頻度不明):喘息発作を誘発することがある。 4)劇症肝炎(0.2%)、肝機能障害(1.6%)、黄疸(頻度不明):劇症肝炎、AST(GOT)、ALT(GPT)、γ-GTPの上昇等を伴う肝機能障害、黄疸があらわれることがあるので、観察を十分に行い、異常が認められた場合には投与を中止し、適切な処置を行うこと。 5)顆粒球減少症(頻度不明):顆粒球減少症があらわれることがあるので、観察を十分に行い、異常が認められた場合には投与を中止し、適切な処置を行うこと。 6)間質性肺炎(頻度不明):間質性肺炎があらわれることがあるので、観察を十分に行い、咳嗽、呼吸困難、発熱、肺音の異常等が認められた場合には、速やかに胸部X線、胸部CT、血清マーカー等の検査を実施すること。異常が認められた場合には投与を中止し、副腎皮質ホルモン剤の投与等の適切な処置を行うこと。 7)間質性腎炎(頻度不明)、急性腎障害(頻度不明):間質性腎炎、急性腎障害があらわれることがあるので、観察を十分に行い、異常が認められた場合には投与を中止し、適切な処置を行うこと。 2021年4月改訂(第7版)

●その他の使用上の注意等については、製品電子添文をご参照下さい。



製造販売元: テルモ株式会社 〒151-0072 東京都渋谷区幡ヶ谷2-44-1 www.terumo.co.jp
資料請求先: テルモ株式会社 テルモ・コールセンター ☎ 0120-12-8195 (平日9:00-17:45受付)

IGCC 2023 Program Committee

Ajani, Jaffer A	U.S.A.	Mansfield, Paul F.	U.S.A.
Allum, William	United Kingdom	Matsuda, Satoru	Japan
Baba, Hideo	Japan	Mönig, Stefan Paul	Switzerland
Boku, Narikazu	Japan	Muro, Kei	Japan
Chen, Lin	China	Nilsson, Magnus	Sweden
de Manzoni, Giovanni	Italy	Ochiai, Atsushi	Japan
Fujishiro, Mitsuhiro	Japan	Rha, Sun Young	Republic of Korea
Grabsch, Heike Irmgard	Netherlands	Roviello, Franco	Italy
Hartgrink, Henk	Netherlands	Ryu, Min-Hee	Republic of Korea
Hiki, Naoki	Japan	Sano, Takeshi	Japan
Hyung, Woo Jin	Republic of Korea	Seto, Yasuyuki	Japan
Ikoma, Naruhiko	U.S.A.	Shen, Lin	China
Immanuel, Arul	United Kingdom	Shitara, Kohei	Japan
Irino, Tomoyuki	Sweden	So, Jimmy	Singapore
Janjigian, Yelena	U.S.A.	Strong, Vivian	U.S.A.
Ji, Jiafu	China	Takeda, Flavio Roberto	Brazil
Takeji, Yoshihiro	Japan	Takeuchi, Hiroya	Japan
Kassab, Paulo	Brazil	Terashima, Masanori	Japan
Kawakubo, Hirofumi	Japan	Van Hillegersberg, Richard	Netherlands
Kinoshita, Takahiro	Japan	Yang, Han-Kwang	Republic of Korea
Kitagawa, Yuko	Japan	Yoshida, Kazuhiro	Japan
Kodera, Yasuhiro	Japan	Yoshikawa, Takaki	Japan
Lordick, Florian	Germany		

IGCC 2023 Upper GI Summit – EGJ Cancer Consensus Conference – Expert Panel Member

Bhandari, Pradeep	United Kingdom	Mönig, Stefan Paul	Switzerland
Chau, Ian	United Kingdom	Mukaisho, Ken-ichi	Japan
de Manzoni, Giovanni	Italy	Muro, Kei	Japan
Doki, Yuichiro	Japan	Nilsson, Magnus	Sweden
Gotoda, Takuji	Japan	Oh, Do-Youn	Republic of Korea
Grabsch, Heike Irmgard	Netherlands	Rha, Sun Young	Republic of Korea
Hara, Hiroki	Japan	Ryu, Min-Hee	Republic of Korea
Ho, Khek Yu	Singapore	Sano, Takeshi	Japan
Hofstetter, Wayne L.	U.S.A.	Sharma, Prateek	U.S.A.
Ishihara, Ryu	Japan	Shen, Lin	China
Janjigian, Yelena	U.S.A.	Shitara, Kohei	Japan
Ji, Jiafu	China	Singh, Rajvinder	Australia
Kassab, Paulo	Brazil	Smyth, Elizabeth Catherine	United Kingdom
Kato, Ken	Japan	So, Jimmy	Singapore
Kawakami, Hisato	Japan	Takahari, Daisuke	Japan
Kitagawa, Yuko	Japan	Takeuchi, Hiroya	Japan
Kodera, Yasuhiro	Japan	Terashima, Masanori	Japan
Koike, Tomoyuki	Japan	Van Hillegersberg, Richard	Netherlands
Kurokawa, Yukinori	Japan	Wainberg, Zev	U.S.A.
Kusano, Chika	Japan	Wijnhoven, Bas	Netherlands
Law, Simon	Hong Kong	Xiao, Zili	China
Lee, Yeong Yeh	Malaysia	Xu, Rui-Hua	China
Lordick, Florian	Germany	Yahagi, Naohisa	Japan
Lorenzen, Sylvie	Germany	Yang, Han-Kwang	Republic of Korea
Mansfield, Paul F.	U.S.A.		

IGCC 2023 Upper GI Summit – EGJ Cancer Consensus Conference – Systematic Review Member

Booka, Eisuke	Japan	Makino, Tomoki	Japan
Hatta, Waku	Japan	Matsuda, Satoru	Japan
Kanda, Mitsuro	Japan	Nakayama, Izuma	Japan
Kato, Motohiko	Japan	Narita, Yukiya	Japan
Kawazoe, Akihito	Japan	Suzuki, Sho	Japan
Maekawa, Akira	Japan	Yamamoto, Shun	Japan

IGCC Upper GI Summit – EGJ Cancer Consensus Conference – Executive Committee

Kitagawa, Yuko	Japan	Yoshida, Masahiro	Japan
Gotoda, Takuji	Japan	Kawakubo, Hirofumi	Japan
Kato, Ken	Japan	Matsuda, Satoru	Japan

Upper GI Summit – EGJ Cancer Consensus Conference –

Supported by: the Tokyo Club

This conference will bring together 49 EGJ cancer experts from around the world to present their positions while exploring the latest opinions on clinical questions in surgery, medical oncology, and endoscopy, with the aim of working toward a consensus for the year 2023.

(no additional registration required beside the congress registration).

Final analysis results in a Japanese nationwide prospective study of esophagogastric junction cancer

Yukinori Kurokawa (*Gastroenterological Surgery, Osaka University, Japan*)

Chair

Surgery Session: Yuko Kitagawa (*Department of Surgery, Keio University School of Medicine, Japan*)

Bas Wijnhoven (*Surgery, Erasmus University Medical Center Rotterdam, Netherlands*)

Endoscopy: Takuji Gotoda (*Department of Gastroenterology, Nihon University Hospital, Japan*)

Pradeep Bhandari (*Gastroenterology, Queen Alexandra Hospital, Portsmouth Hospitals University NHS Trust, United Kingdom*)

Medical Oncology: Ken Kato (*Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Japan*)

Florian Lordick (*Department of Medicine and University Cancer Center Leipzig (UCCL), University of Leipzig Medical Center, Germany*)

Clinical Question

Surgery

- CQ1: Is the dissection of mediastinal and suprapancreatic lymph node stations required for GEJ cancers with 2-4 cm esophageal invasion?
- CQ2: Is it recommended to dissect the same lymph node region of GEJ squamous cell carcinoma and GEJ adenocarcinoma?
- CQ3: Is minimally invasive surgery recommended for GEJ cancer when a transthoracic approach is indicated?
- CQ4: Is surgical resection recommended for gastroesophageal junction cancer with oligo metastasis?

Endoscopy

- CQ1: Is white light endoscopy alone recommended for the detection of superficial neoplasia (cancer/HGD) at the GEJZ as compared to white light endoscopy combined with image-enhanced endoscopy?
- CQ2: Is white light imaging endoscopy recommended to determine the extent of superficial neoplasia (cancer/HGD) at the GEJZ?
- CQ3: When is endoscopic therapy considered curative for the treatment of superficial neoplasia (cancer/HGD) at the GEJZ?

Medical oncology

- CQ1: Is it recommended to adopt chemotherapy for gastric adenocarcinoma to esophageal adenocarcinoma and esophagogastric junction cancer?
- CQ2: What is the optimal perioperative treatment for resectable, locally advanced esophagogastric junction cancer?
- CQ3: What biomarkers are recommended to be tested before first-line for unresectable case?

June 15 (Thu.) / 11:35-12:05 / Room 1 (Main Hall)

Nishi-Takahashi Lecture

Chair: Yuko Kitagawa (*Department of Surgery, Keio University School of Medicine, Japan*)

NT Where are we now and where to go?

Takeshi Sano (*Gastroenterological Surgery, Cancer Institute Hospital, Japan*)

June 16 (Fri.) / 11:35-12:05 / Room 1 (Main Hall)

Jin Pok Kim Lecture

Chair: Han-Kwang Yang (*Department of Surgery, Seoul National University, Republic of Korea*)

JPK Surfing the thin wave of R-Evolution

Giovanni de Manzoni (*Department of Surgery, Dentistry, Paediatrics and Gynaecology, University of Verona, Verona, Italy*)

June 15 (Thu.) / 13:35-14:05 / Room 1 (Main Hall)

Presidential Lecture

Chair: Takeshi Sano (*Gastroenterological Surgery, Cancer Institute Hospital, Japan*)

PL Advancing Upper GI Oncology as Global Citizens

Yuko Kitagawa (*Department of Surgery, Keio University School of Medicine, Japan*)

June 15 (Thu.) / 14:05-14:25 / Room 1 (Main Hall)

Masaki Kitajima Memorial Lecture

Chair: Yuko Kitagawa (*Department of Surgery, Keio University School of Medicine, Japan*)

MK1

Seigo Kitano (*Oita University, Japan*)

MK2

Han-Kwang Yang (*Department of Surgery, Seoul National University, Republic of Korea*)

Plenary Session

Chair: Yuichiro Doki (*Department of Gastroenterological Surgery, Osaka University, Japan*)

Giovanni de Manzoni (*General Surgery, University of Verona, Italy*)

PS1 Final analysis results in a Japanese nationwide prospective study of esophagogastric junction cancer

Hiroya Takeuchi (*Department of Surgery, Hamamatsu University School of Medicine, Japan*)

PS2 Neoadjuvant docetaxel, oxaliplatin and S-1 (DOS) combination chemotherapy for resectable adenocarcinoma of esophagogastric junction

Takuro Saito (*Department of Gastroenterological Surgery, Osaka University, Osaka, Japan*)

PS3 Randomized Controlled Trial Comparing the Short-term Outcomes of Enhanced Recovery After Surgery and Conventional Care in Laparoscopic Distal Gastrectomy (GISSG1901)

Yulong Tian (*Department of General Surgery, Affiliated Hospital of Qingdao University, Qingdao, Shandong, People's Republic of China*)

PS4 A randomized phase II study comparing S-1 plus oxaliplatin with S-1 monotherapy for elderly patients with advanced gastric cancer: WJOG8315G

Hirokazu Shoji (*Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan*)

PS5 Long-term quality of life and nutritional results of stomach-preserving surgery after sentinel node evaluation in patients with early gastric cancer: a multicenter, randomized phase 3 trial (SENorITA)

Bang Wool Eom (*National Cancer Center, Republic of Korea*)

PS6 Outcomes of anastomotic leakage after gastrectomy: A European study on behalf the GASTRODATA group

Simone Giacopuzzi (*Department of Surgical, Odontostomatologic, Maternal and Child Sciences, University of Verona, Italy*)

June 15 (Thu.) / 8:00-9:00 / Room 1 (Main Hall)

Multidisciplinary 1 : Overviewing guidelines - East versus West -

Chair: Florian Lordick (*Department of Medicine and University Cancer Center Leipzig (UCCL), University of Leipzig Medical Center, Germany*)

Takeshi Sano (*Gastroenterological Surgery, Cancer Institute Hospital, Japan*)

Sung Hoon Noh (*Surgery, Gangnam Severance Hospital, Yonsei University Health Medicine, Republic of Korea*)

Multidisciplinary 1-1 The Western Approach to Perioperative Treatment of Gastric Cancer

Florian Lordick (*Department of Oncology and University Cancer Center Leipzig, University of Leipzig Medical Center, Leipzig, Germany*)

Multidisciplinary 1-2 Multidisciplinary treatment strategy for gastric cancer

Narikazu Boku (*Department of Oncology and General Medicine, IMSUT Hospital, Institute of Medical Science, University of Tokyo, Japan*)

Multidisciplinary 1-3 Guidelines on gastric cancer: same evidence, different recommendations?

Bas Wijnhoven (*Erasmus University Medical Center Rotterdam, Netherlands*)

Multidisciplinary 1-4 Japanese Gastric Cancer Treatment Guidelines: How is it different from the NCCN guidelines?

Yasuhiro Kodera (*Department of Gastroenterological Surgery, Nagoya University, Aichi, Japan*)

June 15 (Thu.) / 9:00-10:00 / Room 1 (Main Hall)

Multidisciplinary 2 : Reviewing landmark clinical trials

Chair: Mitsuru Sasako (*Surgery, Yodogawa Christian Hospital, Japan*)

Stefan Paul Mönig (*Upper GI Surgery, University Hospital of Geneva, Switzerland*)

Sang-Uk Han (*Surgery, School of Medicine, Ajou University, Republic of Korea*)

Multidisciplinary 2-1 Reviewing landmark clinical trials

Henk Hartgrink (*Department of Surgery, Leiden University Medical Center, Netherlands*)

Multidisciplinary 2-2 Landmark clinical trials for gastric cancer from Asia

Masanori Terashima (*Shizuoka Cancer Center, Japan*)

Multidisciplinary 2-3 Current evidence of laparoscopic gastrectomy for advanced gastric cancer in Japan

Tsuyoshi Etoh (*Department of Gastroenterological and Pediatric Surgery, Oita University, Japan*)

Multidisciplinary 2-4 An update on the PERISCOPE II trial; A multicentre RCT comparing gastrectomy, CRS and HIPEC to systemic chemotherapy alone for gastric cancer patients with limited peritonitis carcinomatosis

Karen van der Sluis *(Department of Surgical Oncology, Antoni van Leeuwenhoek - Netherlands Cancer Institute, Amsterdam, Netherlands)*

June 15 (Thu.) / 14:30-15:45 / Room 1 (Main Hall)

Multidisciplinary 3 : Conversion surgery for metastatic gastric cancer 2

Chair: Lin Chen *(Senior Department of General Surgery, The First Medical Center, Chinese PLA General Hospital, China)*

Takaki Yoshikawa *(Department of Gastric Surgery, National Cancer Center Hospital, Japan)*

Multidisciplinary 3-1 Clinical Significance of Conversion Surgery Based on Criteria Determined by Clinical Trials for Gastric Cancer

Takaaki Arigami *(Department of Digestive Surgery, Breast and Thyroid Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan)*

Multidisciplinary 3-2 Predictive Factors and Long-Term Results of Conversion Surgery for Stage IV Gastric Cancer

Sho Sato *(Department of Surgery, Yokohama City University Gastroenterological Center, Japan)*

Multidisciplinary 3-3 The optimal strategy regarding conversion surgery by considering PD-L1 expression for patients with advanced gastric cancer

Yuichiro Miki *(Department of Gastroenterological Surgery, Osaka Metropolitan University, Japan)*

Multidisciplinary 3-4 Number of StageIV factor contributes to pivotal decision making in conversion surgery for StageIV gastric cancer

Ryo Ishida *(Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Japan)*

Multidisciplinary 3-5 Treatment outcomes and strategy for liver metastasis from gastric cancer

Satoshi Kamiya *(Department of Surgery, Tokyo Dental College Ichikawa General Hospital, Chiba, Japan / Division of Gastric Surgery, Shizuoka Cancer Center, Shizuoka, Japan)*

Multidisciplinary 3-6 Staging laparoscopy with peritoneal lavage to identify peritoneal metastases and free tumor cells in the management of locally advanced gastric cancer

Ioannis Rouvelas (*CLINTEC, Department of Surgery, Karolinska Institutet, Karolinska University Hospital, Sweden*)

June 15 (Thu.) / 16:50-17:50 / Room 1 (Main Hall)

Multidisciplinary 4 : Perioperative treatment for GEJ cancer

Chair: Yuichiro Doki (*Department of Gastroenterological Surgery, Osaka University, Japan*)

Arul Immanuel (*General and Upper Gastrointestinal Surgery, Newcastle upon Tyne Hospitals NHS Trust, United Kingdom*)

Multidisciplinary 4-1 Multimodal approach for the locally advanced esophagogastric junctional adenocarcinoma

Ken Kato (*Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Japan*)

Multidisciplinary 4-2 Perioperative treatment for esophago-gastric junction cancer

Florian Lordick (*Department of Oncology and University Cancer Center Leipzig, University of Leipzig Medical Center, Leipzig, Germany*)

Multidisciplinary 4-3 Multimodality approaches to gastroesophageal adenocarcinoma

Jaffer A Ajani (*GI Medical Oncology UT M. D. Anderson Cancer Center, Houston, Texas, U.S.A.*)

Multidisciplinary 4-4 Gastroesophageal junction

Takeshi Miwa (*Department of Surgery and Science, Faculty of Medicine, Academic Assembly, University of Toyama*)

June 16 (Fri.) / 8:35-9:50 / Room 1 (Main Hall)

Multidisciplinary 5 : Conversion surgery for metastatic gastric cancer 1

Chair: Giovanni de Manzoni (*General Surgery, University of Verona, Italy*)

Hitoshi Katai (*Department of Surgery, Tachikawa Hospital, Japan*)

Multidisciplinary 5-1 Oligometastatic gastric cancer - is there a place for surgery?

Stefan Paul Mönig (*Upper GI Surgery, University Hospital of Geneva, Switzerland*)

Multidisciplinary 5-2 Conversion surgery for stage IV gastric cancer

Kazuhiro Yoshida (*Gastroenterological surgery, Gifu University, Gifu, Japan*)

Multidisciplinary 5-3 Role of conversion surgery in stage IV gastric cancer; Korean experience

Hyuk-Joon Lee (*Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea*)

Multidisciplinary 5-4 Indication and timing of conversion surgery for gastric cancer: consideration from para-aortic node recurrence

Takeyuki Wada (*Department of Gastric Surgery, National Cancer Center Hospital, Tokyo, Japan*)

Multidisciplinary 5-5 Patterns, treatment, and prognosis of gastric cancer patients with hepatic metastases: A nation-wide multicentered cohort study in China (RECORD study)

Lin Chen (*Senior Department of General Surgery, The First Medical Center, Chinese PLA General Hospital, China*)

Multidisciplinary 5-6 Conversion gastrectomy after SOX+ intraperitoneal paclitaxel for the patients with peritoneal dissemination from gastric cancer -Outcome analysis by ascites volume-

Joji Kitayama (*Department of Surgery, Jichi Medical University, Japan*)

June 16 (Fri.) / 10:05-11:20 / Room 1 (Main Hall)

Multidisciplinary 6 : Treatment of peritoneal disease

Chair: Jimmy So (*National University Cancer Institute, National University Health System, Singapore*)

Paul F. Mansfield (*Surgical Oncology, U.T. MD Anderson Cancer Center, U.S.A.*)

Multidisciplinary 6-1 The treatment of peritoneal disease in gastric malignancy: A review of the evidence

Arul Immanuel (*General and Upper Gastrointestinal Surgery, Newcastle upon Tyne Hospitals NHS Trust, United Kingdom*)

Multidisciplinary 6-2 Combined intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis

Hironori Ishigami (*Department of Chemotherapy, The University of Tokyo Hospital*)

Multidisciplinary 6-3 Recent advances in management of gastric cancer with peritoneal metastasis

Jimmy So (*National University Cancer Institute, National University Health System, Singapore*)

Multidisciplinary 6-4 Development of systemic chemotherapy for gastric cancer patients with severe peritoneal metastasis in Japan

Nozomu Machida (*Department of Gastroenterology, Kanagawa Cancer Center, Kanagawa, Japan*)

Multidisciplinary 6-5 Intraperitoneal chemotherapy with paclitaxel and SOX for the patients with peritoneal metastases from gastric cancer -Outcome of prospective cohort study-

Hironori Yamaguchi (*Department of Clinical Oncology, Jichi Medical University, Japan*)

Multidisciplinary 6-6 Intraperitoneal Chemotherapy a treatment option in peritoneal metastatic gastric cancer

Beate Rau (*Surgical Department, University of Berlin, Germany*)

June 16 (Fri.) / 13:35-14:50 / Room 1 (Main Hall)

Multidisciplinary 7 : Updates of ongoing clinical trials

Chair: Masanori Terashima (*Division of Gastric Surgery, Shizuoka Cancer Center, Japan*)

Bas Wijnhoven (*Surgery, Erasmus University Medical Center Rotterdam, Netherlands*)

Multidisciplinary 7-1 What is the optimal chemotherapeutic treatment strategy for MSI-H gastric cancer?

Hisato Kawakami (*Department of Medical Oncology, Kindai University Faculty of Medicine*)

Multidisciplinary 7-2 Ongoing surgical and perioperative clinical trials in gastric and GEJ cancer in the West

Magnus Nilsson (*Division of Surgery and Oncology, CLINTEC, Karolinska Institutet, Sweden*)

Multidisciplinary 7-3 Updates of ongoing clinical trials for locally advanced gastric cancer

Takaki Yoshikawa (*Department of Gastric Surgery, National Cancer Center Hospital, Tokyo, Japan*)

Multidisciplinary 7-4 A randomized, controlled clinical trial comparing S-1 plus oxaliplatin and capecitabine plus oxaliplatin in patients with advanced gastric cancer after laparoscopic D2 gastrectomy

Yongjia Yan (*Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, China*)

Multidisciplinary 7-5 Randomized phase 2 trial of preoperative chemo(radio)therapy in gastric cancer: CRITICS-II interim results

Marcel Verheij (*Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, Netherlands / Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands*)

June 16 (Fri.) / 16:00-17:15 / Room 1 (Main Hall)

Multidisciplinary 8 : Optimal treatment strategy for gastric cancer in elderly patients 1

Chair: Yoshiyuki Fujiwara (*Division of Gastrointestinal and Pediatric Surgery, Tottori University, Japan*)

Carlos Alberto Malheiros (*Surgery, Santa Casa Institute of Education, Research and Innovation, Brazil*)

Multidisciplinary 8-1 Surgical outcomes of elderly patients with Stage I gastric cancer from the nationwide registry of the Japanese Gastric Cancer Association

Takeo Fukagawa (*Department of Surgery, Teikyo University School of Medicine, Japan*)

Multidisciplinary 8-2 Factors affecting prognosis in elderly patients with locally advanced gastric cancer: experience from China

Jiafu Ji (*Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing, China*)

Multidisciplinary 8-3 Optimal treatment for patients with resectable gastric cancer

Masanori Tokunaga (*Department of Gastrointestinal Surgery, Tokyo Medical and Dental University, Japan*)

Multidisciplinary 8-4 Muscle sparing advantage of stomach preserving gastrectomy for elderly patients

Masayoshi Terayama (*Department of Gastroenterological Surgery, Gastroenterological Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan*)

Multidisciplinary 8-5 Clinical significance of the gender-based treatment in elderly patients with gastric cancer

Hiroshi Arakawa (*Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan*)

Multidisciplinary 8-6 The prognostic factors of early gastric cancer in elderly patients after non-curative endoscopic resection

Hitoshi Harada (*Division of Gastrointestinal Surgery, Department of Surgery, Graduate School of Medicine, Kobe University, Hyogo, Japan*)

June 16 (Fri.) / 16:00-17:00 / Room 2 (501)

Multidisciplinary 9 : Ideal classification and staging modalities for GEJ cancer

Chair: Magnus Nilsson (*Division of Surgery, CLINTEC, Karolinska Institutet, Sweden*)
Yasuyuki Seto (*Gastrointestinal Surgery, The University of Tokyo Hospital, Japan*)

Multidisciplinary 9-1 Mediastinal Nodal Involvement After Neoadjuvant Chemoradiation For Siewert II/III Adenocarcinoma

Wayne L. Hofstetter (*Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, U.S.A.*)

Multidisciplinary 9-2 Clinical utility of preoperative PET-CT evaluation in locating esophagogastric junction cancer

Tomoki Makino (*Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Japan*)

Multidisciplinary 9-3 Preoperative detection of upper mediastinal lymph node metastasis in Siewert Type I/II gastroesophageal junction cancer

Yoshiaki Shoji (*Department of Gastroenterological Surgery, Tokai University School of Medicine, Japan*)

Multidisciplinary 9-4 Evaluating prognostic value and stage migration effects using a positive lymph node ratio in adenocarcinoma of the esophagogastric junction

Hajime Kamiya (*Department of Surgery, Kyoto Prefectural University of Medicine, Japan*)

June 17 (Sat.) / 8:25-9:25 / Room 1 (Main Hall)

Multidisciplinary 10 : Optimal treatment strategy for gastric cancer in elderly patients 2

Chair: Richard van Hillegersberg (*Heelkunde, UMC Utrecht, Netherlands*)
Jiafu Ji (*Department of GI Surgery, Peking University Cancer Hospital, China*)

Multidisciplinary 10-1 Is it better for gastric cancer patients aged 80 years or older to undergo gastrectomy?

Shunji Endo (*Department of Digestive Surgery, Kawasaki Medical School, Japan*)

Multidisciplinary 10-2 Validity and safety of curative laparoscopic gastrectomy for advanced gastric cancer in elderly patients

Yoshitake Ueda (*Comprehensive Surgery for Community Medicine, Oita University Faculty of Medicine, Japan*)

Multidisciplinary 10-3 Short- and long-term outcomes of gastrectomy for gastric cancer in elderly patients aged 85 years or older

Kazuaki Matsui (*Department of Surgery, National Hospital Organization Tokyo Medical Center, Tokyo, Japan*)

Multidisciplinary 10-4 Short-and long-term outcomes after gastrectomy in patients aged over 85 years

Ryo Tanaka (*Osaka Medical and Pharmaceutical University, Japan*)

June 17 (Sat.) / 9:25-10:10 / Room 1 (Main Hall)

Multidisciplinary 11 : Diagnosis and treatment strategy poorly cohesive cancer of GEJ

Chair: Giovanni de Manzoni (*General Surgery, University of Verona, Italy*)

Yasuhiro Kodera (*Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Japan*)

Multidisciplinary 11-1 Perioperative and surgical treatment strategy for poorly cohesive cancer of gastroesophageal junction

Mitsuro Kanda (*Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan*)

Multidisciplinary 11-2 Gastric Extent of Tumor Predicts Peritoneal Metastasis in Siewert II Adenocarcinoma

Wayne L. Hofstetter (*Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, U.S.A.*)

Multidisciplinary 11-3 Prevention and management of peritoneal disease in poorly cohesive GEJ

Magnus Nilsson (*Division of Surgery, CLINTEC, Karolinska Institutet, Sweden*)

June 15 (Thu.) / 8:20-9:50 / Room 3 (502)

Surgery 1 : Reconstruction after laparoscopic/robotic total gastrectomy (Sponsored Symposium 1)

Chair: Ichiro Uyama (*Advanced Robotic and Endoscopic Surgery, Fujita Health University, Japan*)
Seigo Kitano (*Oita University, Japan*)

Sponsored by: Mediaroid Corporation / Sysmex Corporation

Surgery 1-1 Intracorporeal esophagojejunostomy using linear staplers in robotic total gastrectomy for gastric cancer

Koichi Suda (*Department of Surgery, Fujita Health University, Japan / Collaborative Laboratory for Research and Development in Advanced Surgical Intelligence, Fujita Health University, Japan*)

Surgery 1-2 Safe reconstruction after minimally invasive total gastrectomy for gastric cancer: Technical considerations

Kazutaka Obama (*Department of Surgery, Kyoto University, Kyoto, Japan*)

Surgery 1-3 Reconstruction after total gastrectomy - Challenges and pitfalls

Guowei Kim (*Upper Gastrointestinal Surgery, Division of General Surgery, National University Hospital, Singapore*)

June 15 (Thu.) / 10:05-11:35 / Room 3 (502)

Surgery 2 : Surgical strategies for GEJ cancer (Sponsored Symposium 2)

Chair: Simon Law (*Surgery, The University of Hong Kong, China*)
Seiichiro Kanaya (*Department of Gastrointestinal Surgery, Japanese Red Cross Osaka Hospital, Japan*)

Sponsored by: Covidien Japan Inc.

Surgery 2-1 Surgical strategies for sievert type 2 GEJ cancer

Hirofumi Kawakubo (*Department of Surgery, Keio University School of Medicine, Japan*)

Surgery 2-2 Sharing surgical skills for EGJ cancer

Lijie Tan (*Thoracic Surgery Department, Zhongshan Hospital of Fudan University, China*)

Surgery 2-3 Minimally invasive surgery for gastro-esophageal junctional cancer

Hirokazu Noshiro (*The department of Surgery, Saga University, Saga, Japan*)

Surgery 2-4 Robotic transabdominal lower esophagectomy with U-shaped flap esophagogastrostomy for gastroesophageal junction cancer

Takeshi Omori (*Department of Gastroenterological Surgery, Osaka International Cancer Institute, Japan*)

June 15 (Thu.) / 14:30-16:00 / Room 3 (502)

Surgery 3 : Tips and Pitfalls in robotic surgery in advanced gastric cancer (Sponsored Symposium 3)

Chair: Kazuyuki Kojima (*Upper Gastrointestinal Surgery, Dokkyo Medical University, Japan*)

Shuji Takiguchi (*Department of Gastroenterological Surgery, Nagoya City University Hospital, Japan*)

Sponsored by: Intuitive Surgical G.K.

Surgery 3-1 Robotic gastrectomy with D2 lymph node dissection for advanced gastric cancer

Woo Jin Hyung (*Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea*)

Surgery 3-2 Robotic surgery for advanced gastric cancer in the era of multidisciplinary treatment

Takahiro Kinoshita (*Department of Gastric Surgery, National Cancer Center Hospital East, Kashiwa, Japan*)

Surgery 3-3 Robotic proximal gastrectomy with double-flap technique for esophago-gastric junctional cancer

Souya Nunobe (*Department of Gastric Surgery, Cancer Institute Hospital, Japan*)

Surgery 3-4 Achieving negative margins at the esophagus and duodenum in robotic gastrectomy

Naruhiko Ikoma (*The University of Texas MD Anderson Cancer Center, U.S.A.*)

June 15 (Thu.) / 16:50-18:05 / Room 3 (502)

Surgery 4 : Postoperative function, QOL and PROs

Chair: Chikara Kunisaki (*Surgery, Gastroenterological Center, Yokohama City University, Japan*)

Franco Roviello (*Surgical Oncology, University of Siena, Italy*)

Surgery 4-1 Introducing a value-based care concept: value of gastrectomy to be determined by patients, not by surgeons

Naruhiko Ikoma (*Surgical Oncology, UT MD Anderson Cancer Center, U.S.A.*)

Surgery 4-2 Postoperative course and QOL after surgery for upper gastric and esophagogastric junction cancer

Hiroshi Saeki (*Department of General Surgical Science, Gunma University, Maebashi, Japan*)

Surgery 4-3 Update of the EORTC QLQ-STO22: Phase 1 and 2

Mitsumi Terada (*Asian Partnerships Office, Department of International Clinical Development, National Cancer Center Hospital, Japan*)

Surgery 4-4 Leptin postoperative anorexia and its role in proximal gastric cancer development in obese

Tomaz Jagric (*Department for abdominal and general surgery, University clinical center Maribor, Slovenia*)

Surgery 4-5 Prognostic impact of long-term postoperative pneumonia in elderly patients with early gastric cancer

Ayako Kamiya (*Department of Gastric Surgery, National Cancer Center Hospital, Tokyo, Japan*)

Surgery 4-6 Nutritional and metabolic consequences of total (and subtotal) gastrectomy

Vivian Strong (*Department of Surgery, Memorial Sloan Kettering Cancer Center, U.S.A.*)

June 16 (Fri.) / 8:35-9:50 / Room 3 (502)

Surgery 5 : Laparoscopic/robotic gastrectomy for advanced gastric cancer 1

Chair: Do Joong Park (*Department of Surgery, Seoul National University Hospital, Republic of Korea*)

Naoki Hiki (*Department of Upper Gastrointestinal Surgery, Kitasato University School of Medicine, Japan*)

Surgery 5-1 Laparoscopic resections in 91 consecutive gastric cancer patients after neoadjuvant chemotherapy

Tomaz Jagric (*Department for abdominal and general surgery, University clinical center Maribor, Slovenia*)

Surgery 5-2 Minimally invasive surgical procedure for AGC invading adjacent structures: a dorsal approach

Hiroshi Okabe (*Department of Gastroenterological Surgery, New Tokyo Hospital, Chiba, Japan*)

Surgery 5-3 Robotic gastrectomy following preoperative chemotherapy for highly advanced gastric cancer

Tsuyoshi Tanaka (*Department of Surgery, Fujita Health University, Japan*)

Surgery 5-4 Robotic surgery for advanced gastric cancer: "precise" and "reliable" lymph node dissection technique

Hiroyuki Sagawa (*Department of Gastroenterological Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan*)

Surgery 5-5 Laparoscopic versus robotic gastric wedge resection for gastrointestinal stromal tumor: a retrospective study

Camille Brassat (*Division of Digestive and Transplant Surgery, Department of Surgery, University Hospital of Geneva, Geneva, Switzerland*)

Surgery 5-6 Surgical outcomes of laparoscopic and robotic gastrectomy for advanced gastric cancer

Yoshihiko Kawaguchi (*First Department of Surgery, Faculty of medicine, University of Yamanashi, Yamanashi, Japan*)

June 16 (Fri.) / 10:05-11:35 / Room 3 (502)

Surgery 6 : Indication and surgical procedure of proximal gastrectomy (Sponsored Symposium 4)

Chair: Hirofumi Kawakubo (*Department of Surgery, Keio University School of Medicine, Japan*)

Woo Jin Hyung (*Department of Surgery, Yonsei University College of Medicine, Republic of Korea*)

Sponsored by: Johnson & Johnson K.K.

Surgery 6-1 Laparoscopic proximal gastrectomy for esophagogastric junction cancer

Hiroya Takeuchi (*Department of Surgery, Hamamatsu University School of Medicine, Shizuoka, Japan*)

Surgery 6-2 y-shaped mSOFY method in proximal gastrectomy

Yukinori Kurokawa (*Department of Gastroenterological Surgery, Osaka University, Japan*)

Surgery 6-3 NI-shaped jejuno-gastrostomy in double-tract reconstruction after proximal gastrectomy for upper gastric cancer -laparoscopic and robotic procedure-

Noriyuki Inaki (*Department of Gastrointestinal Surgery, Kanazawa University, Kanazawa, Japan*)

Surgery 6-4 Tips and tricks of fusion surgery in robotic reduced port gastrectomy

Cheng-Ming Peng (*Da Vinci Minimally Invasive Surgery Center / Division of General Surgery, Department of Surgery, Chung Shan Medical University Hospital, Taichung, Taiwan*)

June 16 (Fri.) / 13:35-14:50 / Room 3 (502)

Surgery 7 : ERAS and nutrition after gastrectomy

Chair: Hideo Baba (*Department of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, Japan*)

Henk Hartgrink (*Department of Surgery, Leiden University Medical Center, Netherlands*)

Wojciech Kielan (*2nd Department of General Surgery and Oncological Surgery, Wroclaw Medical University, Poland*)

Surgery 7-1 Eras and nutrition after gastrectomy

Franco Roviello (*Surgical Oncology, University of Siena, Italy*)

Surgery 7-2 Postoperative nutritional status and its clinical significance in patients treated with gastrectomy for gastric cancer

Daisuke Ichikawa (*First Department of Surgery, University of Yamanashi, Japan*)

Surgery 7-3 ERAS-compliant clinical pathway is effective for perioperative management of gastrectomy

Yukinori Yamagata (*Department of Gastric Surgery, National Cancer Center Hospital, Tokyo, Japan*)

Surgery 7-4 A study on hypoglycemia, skeletal muscle, and malnutrition after gastrectomy

Keiji Nishibeppu (*Department of Surgery, Division of Digestive Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan*)

Surgery 7-5 Night home enteral nutrition as a novel enforced and physiologically effective nutrition therapy following total gastrectomy for gastric cancer

Tomoki Konishi (*Department of Surgery, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan*)

June 16 (Fri.) / 16:00-17:30 / Room 3 (502)

Surgery 8 : Sharing surgical skills for GEJ cancer (video session)

Chair: Richard van Hillegersberg (*Heelkunde, UMC Utrecht, Netherlands*)

Hyung-Ho Kim (*Surgery, Seoul National University Bundang Hospital, Republic of Korea*)

Surgery 8-1 Modified overlap esophagogastric tube reconstruction using barbed sutures after totally laparoscopic radical proximal gastrectomy

Zhiming Ma (*Department of Gastrointestinal Nutrition and Hernia Surgery, The Second Hospital of Jilin University, Changchun, China*)

Surgery 8-2 A novel esophagogastric reconstruction method and clinical outcomes after laparoscopic proximal gastrectomy: an IDEAL stage I prospective case series study

Yinkui Wang (*Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, China*)

Surgery 8-3 Robotic intramediastinal valvuloplastic esophagogastrostomy for esophagogastric junction cancer

Susumu Shibasaki (*Department of Surgery, Fujita Health University, Japan*)

Surgery 8-4 Right thoracoscopic esophagogastric anastomosis with overlapped pseudofunds flap for Siewert Type2 esophagogastric junctional cancer

Tsutomu Hayashi (*Department of Gastric Surgery, National Cancer Center Hospital, Japan*)

Surgery 8-5 Inventive approaches of mediastinoscopic and robotic surgery for esophago-gastric cancer to avoid pitfalls

Shuhei Komatsu (*Department of Digestive Surgery, Kyoto First Red Cross Hospital, Kyoto, Japan / Department of Digestive Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan*)

Surgery 8-6 TRI-approach for dissection and BI-defence for backflow: perfect procedure for esophagogastric cancer

Tetsuji Nobuhisa (*Red Cross Hospital, Himeji, Japan*)

Surgery 8-7 Robotic proximal gastrectomy with Ghrelin secretion area preservation and esophago-remnant gastric anastomosis reconstruction technique

Masaki Saito (*Department of Gastroenterological Surgery, Nagoya City University Graduate School of Medicine, Japan*)

Surgery 8-8 Laparoscopic proximal gastrectomy with double flap reconstruction for early GEJ cancer

Long Duy Vo (*The Gastro-Intestinal Surgery Department, University Medical Center, Ho Chi Minh city, Vietnam*)

Surgery 9 : Laparoscopic/robotic gastrectomy for advanced gastric cancer 2

Chair: Woo Jin Hyung (*Department of Surgery, Yonsei University College of Medicine, Republic of Korea*)

Takahiro Kinoshita (*Department of Gastric Surgery, National Cancer Center Hospital East, Japan*)

Surgery 9-1 Advantages of robotic gastrectomy for overweight patients with gastric cancer: a comparison study between robotic gastrectomy and conventional laparoscopic gastrectomy

Masaru Komatsu (*Gastric Surgery Division, National Cancer Center Hospital East, Kashiwa, Chiba, Japan*)

Surgery 9-2 Technical aspect and short-term outcomes of robotic gastrectomy for advanced gastric cancer

Masaya Nakauchi (*Department of Advanced Robotic and Endoscopic Surgery, Fujita Health University-Toyoake, Aichi, Japan*)

Surgery 9-3 Robot-assisted gastrectomy for type 4 gastric cancer

Toshiro Tanioka (*Department of Gastrointestinal Surgery, Tokyo Medical and Dental University, Japan*)

Surgery 9-4 Clinical safety and feasibility of minimally invasive gastrectomy for advanced gastric cancer

Daiki Matsubara (*Department of Digestive Surgery, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan / Department of Digestive Surgery, Mizuru Red Cross Hospital, Kyoto, Japan*)

Surgery 9-5 Robot-assisted completion gastrectomy for remnant gastric cancer -Procedure and clinical outcome-

Noriyuki Inaki (*Gastrointestinal Surgery, Kanazawa University Hospital, Kanazawa, Japan*)

Surgery 9-6 Laparoscopic gastrectomy for T4a gastric cancer: Is it acceptable technique and oncologic outcomes?

Long Duy Vo (*The Gastro-Intestinal Surgery Department, University Medical Center, Ho Chi Minh city, Vietnam*)

Surgery 9-7 Safety of laparoscopic gastrectomy for advanced gastric cancer with greater than serosal invasion depth

Shingo Kanaji (*Division of Gastrointestinal Surgery, Department of Surgery, Graduate School of Medicine, Kobe University, Kobe, Japan*)

June 17 (Sat.) / 10:30-11:45 / Room 3 (502)

Surgery 10 : Navigation surgery for early gastric cancer

Chair: Hiroya Takeuchi (*Department of Surgery, Hamamatsu University School of Medicine, Japan*)

Lin Chen (*Senior Department of General Surgery, The First Medical Center, Chinese PLA General Hospital, China*)

Shoji Natsugoe (*Surgery, Kajiki Onsen Hospital, Japan*)

Surgery 10-1 Concept and current status of sentinel node navigation surgery for early gastric cancer

Satoru Matsuda (*Department of Surgery, Keio University School of Medicine, Japan*)

Surgery 10-2 The survival prognosis of function-preserving curative gastrectomy is better than guideline surgery

Shinichi Kinami (*Department of Surgical Oncology, Kanazawa Medical University, Japan*)

Surgery 10-3 Effectiveness of intraoperative radiography for tumor localization in laparoscopic distal gastrectomy for gastric cancer

Takehiro Wakasugi (*The Department of Gastrointestinal Surgery, Nagoya City University, Nagoya, Japan / Nagoya City University West Medical Center / Nagoya City University Midori Municipal Hospital*)

Surgery 10-4 Impact of anatomy at the suprapancreas on dissection in laparoscopic gastrectomy

Tatsuto Nishigori (*Department of Surgery, Kyoto University, Kyoto, Japan*)

Surgery 10-5 Efficacy of fluorescent clips in Da Vinci assisted gastric cancer surgery

Junji Takahashi (*Department of Surgery, International University of Health and Welfare, Tochigi, Japan*)

June 15 (Thu.) / 10:05-11:20 / Room 2 (501)

Medical Oncology 1 : Biomarker-driven therapeutics for gastric cancer

Chair: Jaffer A Ajani (*GI Medical Oncology, UT M. D. Anderson Cancer Center, U.S.A.*)

Narikazu Boku (*Department of Oncology and General Medicine, IMSUT Hospital, Institute of Medical Science, University of Tokyo, Japan*)

Medical Oncology 1-1 Biomarker-driven therapeutics for gastric cancer

Zev Wainberg (*Oncology, UCLA School of Medicine*)

Medical Oncology 1-2 Claudin 18.2 targeted therapy for gastric and GEJ adenocarcinoma

Kohei Shitara (*Gastroenterology, National Cancer Center Hospital East, Japan*)

Medical Oncology 1-3 Biomarker-driven therapeutics for gastric cancer

Lin Shen (*Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China*)

Medical Oncology 1-4 COLEC12 promotes tumor progression and is correlated with poor prognosis in gastric cancer

Xiangfei Sun (*Department of General Surgery, Zhongshan Hospital, Fudan University School of Medicine, Shanghai, China*)

Medical Oncology 1-5 Changes in the Gustave Roussy Immune Score as a powerful prognostic marker of the therapeutic sensitivity of nivolumab in advanced gastric cancer: A multicenter retrospective study

Nobuhiro Nakazawa (*Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan*)

Medical Oncology 1-6 Change of serum-based inflammatory indicators assists evaluation of response to nivolumab

Tomohiko Nishi (*Department of Surgery, Keiyu Hospital, Yokohama, Japan*)

June 15 (Thu.) / 16:50-18:05 / Room 2 (501)

Medical Oncology 2 : Current status and future perspective of targeted and systemic therapy for gastric cancer

Chair: Kohei Shitara (*Gastroenterology, National Cancer Center Hospital East, Japan*)

Yelena Janjigian (*Department of Medicine, Memorial Sloan Kettering Cancer Center, U.S.A.*)

Medical Oncology 2-1 Targeted and immunotherapy in gastric cancer

Yelena Janjigian (*Department of Medicine, Memorial Sloan Kettering Cancer Center, U.S.A.*)

Medical Oncology 2-2 Current status and future perspective of targeted and systemic therapy for gastric cancer

Do-Youn Oh (*Division of Medical Oncology, Department of Internal Medicine, Seoul National University College of Medicine, Republic of Korea*)

**Medical Oncology 2-3 Trastuzumab duruxtecan for advanced gastric and gastroesophageal cancer
Focus on difficulties in the drug development of AGC**

Kensei Yamaguchi (*Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Japan*)

Medical Oncology 2-4 Dual blockade of MET and VEGFR2 signaling pathways effectively controls peritoneal carcinomatosis with massive ascites in diffuse gastric cancer

Kazuo Yasumoto *(Department of Medical Oncology, Kanazawa Medical University, Ishikawa, Japan)*

Medical Oncology 2-5 Research progress on signal pathways and targeted therapy of α -1,6-fucosyltransferase in tumor

Kaihang Shi *(Wuxi No.2 People's Hospital and Wuxi Clinical College of Nanjing Medical University, China)*

Medical Oncology 2-6 The expand indication of the HER2 targeted therapies by monitoring of circulating tumor cells

Yasuaki Kimura *(Department of Surgery, Jichi Medical University Saitama Medical Center, Saitama, Japan)*

June 16 (Fri.) / 13:35-14:50 / Room 4 (503)

Medical Oncology 3 : Pharmacotherapy for GIST (advanced/recurrent)

Chair: Sun Young Rha *(Department of Medical Oncology, Yonsei Cancer Center, Yonsei University Health System, Republic of Korea)*

Toshirou Nishida *(Department of Surgery, JCHO Osaka Hospital and National Cancer Center Hospital, Japan)*

Medical Oncology 3-1 Development of new agent for advanced gastrointestinal stromal tumor

Yukinori Kurokawa *(Department of Gastroenterological Surgery, Osaka University, Osaka, Japan)*

Medical Oncology 3-2 An updated review of the treatment landscape for advanced gastrointestinal stromal tumors

Toshihiko Doi *(Exploratory Oncology Research & Clinical Trial Center/Hospital East Experimental Therapeutics, National Cancer Center, Japan)*

Medical Oncology 3-3 Pharmacotherapy for advanced or recurrent gastrointestinal stromal tumor (GIST)

Yoon-Koo Kang *(Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea)*

Medical Oncology 3-4 Imatinib induces ferroptosis in gastrointestinal stromal tumors by promoting ubiquitination of GPX4

Xiangfei Sun *(Department of General Surgery, Zhongshan Hospital, Fudan University School of Medicine, Shanghai, China)*

Medical Oncology 3-5 The multimodal therapy mainly on the molecular target agencies for metastatic GIST

Tsuyoshi Takahashi (*Department of Gastroenterological Surgery, Osaka University graduate school of medicine, Osaka, Japan*)

Medical Oncology 3-6 Individualization of pharmacotherapy for metastatic and recurrent GIST based on mutational status

Hirotochi Kikuchi (*Department of Surgery, Hamamatsu University School of Medicine, Japan*)

June 17 (Sat.) / 10:30-12:00 / Room 2 (501)

Medical Oncology 4 : Immunotherapy for gastric cancer

Chair: Kei Muro (*Department of Clinical Oncology, Aichi Cancer Center Hospital, Japan*)

Sylvie Lorenzen (*Department of Hematology and Oncology, Klinikum rechts der Isar, Germany*)

Medical Oncology 4-1 Novel immunotherapy combinational approach in advanced oesophago-gastric adenocarcinoma

Ian Chau (*Department of Medicine, Royal Marsden Hospital, United Kingdom*)

Medical Oncology 4-2 Optimization of immunotherapy for advanced gastric or gastroesophageal junction cancer

Min-Hee Ryu (*Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea*)

Medical Oncology 4-3 Immunotherapy for gastric cancer: a 2023 update

Sylvie Lorenzen (*Department of Hematology and Oncology, Klinikum rechts der Isar, Germany*)

Medical Oncology 4-4 Immunotherapy for gastric cancer

Daisuke Takahari (*Gastrointestinal chemotherapy, Cancer Institute Hospital of JFCR, Japan*)

Medical Oncology 4-5 Dual Immune checkpoint inhibitor improves outcomes peritoneal metastasis in an immune competent mouse model

Sachiyo Nomura (*Department of Gastrointestinal Surgery, The University of Tokyo, Tokyo, Japan*)

Medical Oncology 4-6 Spatial architecture and cellular interactions of tumor immune microenvironment to discover biomarkers and predict immune checkpoint inhibitor response in gastric cancer

Sunho Park (*Department of Artificial Intelligence and Informatics, Mayo Clinic, U.S.A.*)

Medical Oncology 4-7 ACTA2 expression predicts survival and is associated with response to immune checkpoint inhibitors in gastric cancer

Sunho Park (*Department of Artificial Intelligence and Informatics, Mayo Clinic, U.S.A.*)

June 15 (Thu.) / 8:20-9:50 / Room 4 (503)

Endoscopy 1 : Laparoscopy and Endoscopy Cooperative Surgery (LECS) & Endoscopic full thickness resection

Chair: Naoki Hiki (*Department of Upper Gastrointestinal Surgery, Kitasato University School of Medicine, Japan*)

Pradeep Bhandari (*Gastroenterology, Queen Alexandra Hospital, Portsmouth Hospitals University NHS Trust, United Kingdom*)

Endoscopy 1-1 Outcomes of endoscopic full-thickness resection for gastric submucosal tumors

Nobutsugu Abe (*Department of Gastroenterological and General Surgery, Kyorin University Faculty of Medicine, Japan*)

Endoscopy 1-2 Laparoscopy and Endoscopy Cooperative Surgery for gastric and duodenal tumor

Souya Nunobe (*Department of Gastric Surgery, Cancer Institute Hospital, Japan*)

Endoscopy 1-3 Partial gastrectomy for gastric submucosal tumors with emphasis on laparoscopic manipulation

Masaki Aizawa (*Niigata Cancer Center Hospital, Japan*)

Endoscopy 1-4 Outcomes following laparoscopic and endoscopic cooperative surgery for non-ampullary duodenal tumor

Masayuki Urabe (*Department of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan*)

Endoscopy 1-5 The transmesocolic approach of laparoscopic endoscopic cooperative surgery for duodenal neoplasm

Daisuke Matsushita (*Department of digestive surgery, Kagoshima University, Kagoshima, Japan*)

Endoscopy 1-6 Laparoscopic and endoscopic cooperative surgery for gastric cancer patients with severe comorbidities

Kimiyasu Yamazaki (*Division of Gastroenterological and General Surgery, Department of Surgery, School of Medicine, Showa University, Tokyo, Japan*)

Endoscopy 1-7 Outcomes of endoscopic full-thickness resection for gastric submucosal tumors, a prospective study

Noriya Uedo (*Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Japan*)

June 15 (Thu.) / 10:05-10:50 / Room 4 (503)

Endoscopy 2 : Management of Barrett's esophagus

Chair: Tomoyuki Koike (*Division of Gastroenterology, Tohoku University Graduate School of Medicine, Japan*)

Prateek Sharma (*Gastroenterology, University of Kansas School of Medicine, U.S.A.*)

Endoscopy 2-1 The Management of Barrett Esophagus

Khek Yu Ho (*Department of Medicine, National University of Singapore, Singapore*)

Endoscopy 2-2 Endoscopic approaches to Barrett's esophagus in Japan

Noriko Matsuura (*Division of Research and Development for Minimally Invasive Treatment, Cancer Center, Keio University School of Medicine, Japan*)

Endoscopy 2-3 Risk factors for multiple lesions in barrett's esophageal adenocarcinoma

Masahiro Saito (*Division of Gastroenterology, Graduate School of Tohoku University, Sendai, Japan*)

June 16 (Fri.) / 10:05-11:20 / Room 4 (503)

Endoscopy 3 : Endoscopic treatment for gastric and GEJ cancer

Chair: Takuji Gotoda (*Department of Gastroenterology, Nihon University Hospital, Japan*)

Yeong Yeh Lee (*School of Medical Sciences, Universiti Sains Malaysia, Malaysia*)

Endoscopy 3-1 Technical advancement of endoscopic submucosal dissection for various difficult situations of gastric lesions

Naohisa Yahagi (*Cancer Center, Keio University School of Medicine, Japan*)

Endoscopy 3-2 Endoscopic treatment of oesophageal and gastro oesophageal junction lesions

Rajvinder Singh (*Gastroenterology Department, Division of Surgery, Lyell McEwin Hospital & The University of Adelaide, Australia*)

Endoscopy 3-3 Endoscopic Treatment for Gastric and GEJ cancer : the indication and technical advances of ESD

Hiroyuki Ono (*Division of Endoscopy, Shizuoka Cancer Hospital, Japan*)

Endoscopy 3-4 Preoperative invasion depth diagnosis of ulcerated early gastric cancer and endoscopic submucosal dissection after ulcer treatment: a retrospective study

Daisuke Suto (*Department of Gastroenterology, International University of Health and Welfare Hospital, Japan*)

Endoscopy 3-5 Clinical outcomes of delayed perforation after gastric endoscopic submucosal dissection

Hiroshi Ashizawa (*Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan*)

June 17 (Sat.) / 10:30-12:00 / Room 1 (Main Hall)

Endoscopy 4 : Early Detection, screening

Chair: Mitsuhiro Fujishiro (*Department of Gastroenterology, The University of Tokyo, Japan*)

Zili Xiao (*Digestive endoscopic department, Huadong Hospital affiliated to Fudan University, China*)

Endoscopy 4-1 Early detection of gastric cancer

Ryu Ishihara (*Gastrointestinal oncology, Osaka International Cancer Institute, Osaka, Japan*)

Endoscopy 4-2 Barrett's Esophagus and Cancer: Early Detection and Management

Prateek Sharma (*Gastroenterology, University of Kansas School of Medicine, U.S.A.*)

Endoscopy 4-3 Close follow-up strategy effectively detects gastric cancer for 65 months after H.pylori eradication

Fumiaki Ishibashi (*Department of Gastroenterology, International University of Health and Welfare Ichikawa Hospital, Chiba, Japan / Endoscopy Center, Koganei Tsurukame Clinic*)

Endoscopy 4-4 Initiating Gastric Cancer Endoscopic Screening at Age 50 Years Instead of 40 in High-Risk regions

Siyi He (*Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China*)

Endoscopy 4-5 Postoperative follow-up for metachronous remnant gastric cancer after proximal gastrectomy with the double-flap technique (rD-FLAP-rGC Study): A multicenter retrospective study

Michihiro Ishida (*Department of Surgery, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan*)

Endoscopy 4-6 Anti-carcinogenic properties of GPX2 on gastric cancer

Handong Xu (*Department of Gastric surgery, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institutes of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China*)

Endoscopy 4-7 Comparison of Gastric Cancer Detection Rates by Serological Risk Stratification Endoscopy and Barium Screening in Gastric Cancer Screening

Chika Kusano (*Department of Gastroenterology, Kitasato University School of Medicine, Kanagawa, Japan*)

June 15 (Thu.) / 14:30-15:45 / Room 4 (503)

Translational 1 : Artificial intelligence in the management of gastric cancer

Chair: Yoshihiro Kakeji (*Division of Gastrointestinal Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Japan*)

Hisashi Shinohara (*Gastroenterological Surgery, Hyogo Medical University, Japan*)

Translational 1-1 Evaluation of Surgical Difficulty in Robot-assisted Distal Gastrectomy using Artificial Intelligence-based Surgical Procedure Recognition

Masashi Takeuchi (*Department of Surgery, Keio University School of Medicine, Japan*)

Translational 1-2 Development of a surgical vision system that uses artificial intelligence to display landmark anatomies during gastric cancer surgery

Hisashi Shinohara (*Department of Gastroenterological Surgery, Hyogo Medical University, Hyogo, Japan*)

Translational 1-3 Development of prediction model of intra-abdominal infectious complication after gastrectomy with machine learning

Yuya Sato (*Department of Gastrointestinal Surgery, Tokyo Medical and Dental University, Japan*)

Translational 1-4 Systematic review of artificial intelligence in diagnosis and treatment of gastric cancer

Li Jia Yi (*China Medical University, ShenYang, China*)

Translational 1-5 Application of AI in Gastric Cancer Risk Prediction and early screening

Li Jia Yi (*China Medical University, ShenYang, China*)

Translational 1-6 Application of AI in assistant endoscopic diagnosis

Li Jia Yi (*China Medical University, Shenyang, China / China Medical University / Cancer Hospital of Liaoning province*)

June 15 (Thu.) / 16:50-17:35 / Room 4 (503)

Translational 2 : Molecular and pathological classifications of gastric and GEJ cancer

Chair: Takeshi Kuwata (*Department of Genetic Medicine and Services, National Cancer Center Hospital East, Japan*)

Wataru Yasui (*Medical Corporation Hiroshima Health Association, Japan*)

Translational 2-1 Biomarker-directed therapy in advanced oesophago-gastric adenocarcinoma: moving beyond HER2

Ian Chau (*Department of Medicine, Royal Marsden Hospital, United Kingdom*)

Translational 2-2 Molecular classifications and tumor heterogeneity in gastric cancer

Takeshi Kuwata (*Department of Genetic Medicine and Services, National Cancer Center Hospital East, Japan*)

Translational 2-3 Molecular features of scirrhous gastric cancer from 1 case

Keishi Yamashita (*Division of Advanced Surgical Oncology, Kitasato University School of Medicine, Japan / Department of Upper Gastrointestinal Surgery*)

June 16 (Fri.) / 10:05-11:05 / Room 2 (501)

Translational 3 : Updates of liquid biopsy for gastric cancer

Chair: Satoru Matsuda (*Department of Surgery, Keio University School of Medicine, Japan*)

Elizabeth Catherine Smyth (*Oncology, Cambridge, England*)

Translational 3-1 Updates of liquid biopsy for gastric cancer

Elizabeth Catherine Smyth (*Oncology, Cambridge, United Kingdom*)

Translational 3-2 Updates on liquid biopsy with circulating tumor DNA for HER2-positive gastric cancer

Rui-Hua Xu (*Department of Medical Oncology, Sun Yat-sen University Cancer Center, China*)

Translational 3-3 Detection of cell free tumour DNA in peritoneal fluid of gastric cancer patients, a feasibility study

Karen van der Sluis (*Department of Surgical Oncology, Antoni van Leeuwenhoek - Netherlands Cancer Institute, Amsterdam, Netherlands*)

Translational 3-4 New era of microRNA-based liquid biopsy and immunotherapy targeting PD-L1 in gastrointestinal cancer

Hajime Kamiya (*Kyoto Prefectural University of Medicine, Japan*)

June 16 (Fri.) / 13:35-14:35 / Room 2 (501)

Translational 4 : Omics medicine for gastric cancer

Chair: Hiroyuki Mano (*Research Institute, National Cancer Center, Japan*)

Jimmy So (*Surgery, National University of Singapore, Singapore*)

Translational 4-1 Transancestry genomic analysis of gastric cancer

Hiroyuki Aburatani (*Research Center for Advanced Science and Technology, The University of Tokyo, Japan*)

Translational 4-2 Molecular Assessment of Pre-Malignant Lesions in Stomach Cancer

Patrick Tan (*Program in Cancer & Stem Cell Biology, Duke-NUS Medical School, Singapore / Genome Institute of Singapore / Cancer Science Institute of Singapore, NUS*)

Translational 4-3 Long-term Survivors in Advanced Gastric Cancer - LOSAG study.

A multicenter retrospective study of the Italian Research Group for Gastric Cancer (GIRCG).

Preliminary results of genic expression

Silvia Sofia (*University of Turin, Department of Oncology, Surgical Oncology and Digestive Surgery, San Luigi University Hospital, Orbassano, Torino, Italy*)

Translational 4-4 Analysis of targetable neo-angiogenesis factors in hematogenous metastasis of gastric cancer using TCGA data

Jaeun Yoo (*Seoul National University, Republic of Korea*)

June 16 (Fri.) / 8:35-9:50 / Room 4 (503)

Translational 5 : Advances in precision medicine, genomic profiling, and imaging technique

Chair: Hiroshi Nishihara (*Keio Cancer Center, Keio University School of Medicine, Japan*)

Toshikazu Ushijima (*President, Hoshi University, Japan*)

Translational 5-1 Updated precision medicine in advanced gastric cancer treatment

Sun Young Rha (*Department of Medical Oncology, Yonsei Cancer Center, Yonsei University Health System, Republic of Korea*)

Translational 5-2 Dissecting the tumor microenvironment and metastatic niche of gastric cancer peritoneal metastases

Raghav Sundar (*National University Cancer Institute, Singapore*)

Translational 5-3 Comparing the genomic profiling of HER2 positive and negative gastric cancer by next-generation sequencing in a multi-institutional study

Qingjiang Hu (*Department of Surgery and Science, Kyushu University Hospital, Japan*)

Translational 5-4 Mutational landscape and genetic feature of gastric adenocarcinoma in multiple Chinese ethnicities

Liang Zong (*Department of Gastrointestinal Surgery, Changzhi People's Hospital, The Affiliated Hospital of Shanxi Medical University, Changzhi, Shanxi Province, China*)

Translational 5-5 Assessment of contrast-enhanced computed tomography for diagnostic accuracy of clinical diagnosis of pathological stage III gastric cancer: A prospective multicenter study in China (NCT04440605)

Yinkui Wang (*Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, China*)

Translational 5-6 Effect of preoperative CT angiography versus standard assessment on the short-term outcome of patients with BMI ≥ 25.0 kg/m² undergoing laparoscopic gastrectomy (GISSG20-01)

Cheng Meng (*Department of Gastrointestinal Surgery, Affiliated Hospital of Qingdao University, Qingdao, China*)

June 15 (Thu.) / 15:15-16:00 / Room 2 (501)

Radiation Oncology : Updates in radiotherapy

Chair: Yoshinori Ito (*Department of Radiation Oncology, Showa University School of Medicine, Japan*)

Trevor Leong (*Department of Radiation Oncology, Peter MacCallum Cancer Centre, Australia*)

Radiation Oncology -1 Radiotherapy quality assurance in the topgear phase III trial in gastric cancer

Trevor Leong (*Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia / Sir Peter MacCallum Department of Oncology, University of Melbourne*)

Radiation Oncology -2 Adjuvant chemotherapy vs adjuvant chemoradiotherapy following D2 gastrectomy in patients with N3 gastric cancer: Comparison of overall survival, relapse-free survival, and recurrence pattern

WenZhe Kang (*Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, China*)

Radiation Oncology -3 Quality assurance of preoperative radiotherapy in the CRITICS-II gastric cancer trial

Edwin Jansen (*Department of Radiotherapy, Netherlands Cancer Institute, Amsterdam, Netherlands*)

June 15 (Thu.) / 14:30-15:15 / Room 2 (501)

Palliative Care : Remaining issues for gastric cancer care

Chair: Saori Hashiguchi (*Palliative Medicine, St.Marianna University School of Medicine, Japan*)

Takeshi Sano (*Gastroenterological Surgery, Cancer Institute Hospital, Japan*)

Palliative Care -1 Remaining issues in gastric cancer care

Paulo Kassab (*Gastroesophageal and Bariatric Division, Department of Surgery, Santa Casa Hospital and Medical School, Brazil / Oncology Department, Santa Casa Hospital and Medical School*)

Palliative Care -2 Current status and prospects of palliative care for patients with gastric cancer in Japan

Saori Hashiguchi (*Department of Palliative Medicine, St. Marianna University School of Medicine, Kanagawa, Japan*)

Palliative Care -3 Endoscopic self-expandable metal stent placement for malignant obstruction by the gastric cancer peritoneal dissemination recurrence after Roux-en-Y total gastrectomy

Hirohisa Takeuchi (*Department of Surgery, Kyorin University School of Medicine, Japan*)

June 17 (Sat.) / 8:40-9:25 / Room 2 (501)

Pathology : Refining poorly cohesive cancers

Chair: Heike Irmgard Grabsch (*Pathology, (1) Maastricht University Medical Center+, Maastricht, NL and (2) University of Leeds, UK, Netherlands*)

Atsushi Ochiai (*Research Institute for Biomedical Sciences, Tokyo University of Science, Japan*)

Pathology -1 Comparison between JGCA and WHO classification of signet ring cell and poorly cohesive carcinoma

Tomio Arai (*Department of Pathology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan*)

Pathology -2 TBA

Giovanni de Manzoni (*General Surgery, University of Verona, Italy*)

June 15 (Thu.) / 10:50-11:35 / Room 4 (503)

Access to gastric cancer care - financial background of society and centralization -

Chair: Paul F. Mansfield (*Surgical Oncology, U.T. MD Anderson Cancer Center, U.S.A.*)
Masaki Mori (*Department of Surgery, Tokai University, Japan*)

ML1-1 The Chilean screening method follows the Japanese model. When and how did it work? Is it reproducible?

Carlos A. García (*Surgery Department, Hospital San Borja Arriarán, Santiago / University of Chile, Campus Centro / Clinica MEDS / Universidad Finis Terrae, Chile*)

ML1-2 How to make possible the access to advanced molecular/ pathological analysis outside investigative trials in poor countries: Mozambique as an example

Maria de Fátima Machado Henriques Carneiro (*Institute of Molecular Pathology and Immunology of the University of Porto/Faculty of Medicine of the University of Porto/University Hospital Center of São João, Portugal*)

ML1-3 Improving the access to oncologic treatment in a low-income setting

Lucas Vieira dos Santos (*Medical Oncology, Beneficência Portuguesa de São Paulo, Brazil*)

ML1-4 The reality of surgical treatment of gastric cancer in developing countries

Oswaldo Antônio Prado Castro (*Gastroesophageal and Bariatric Division, Department of Surgery, Santa Casa Hospital and Medical School, Brazil*)

June 16 (Fri.) / 9:05-9:50 / Room 2 (501)

Hereditary gastric cancer (prevention and treatment)

Chair: Tomoyuki Irino (*Department of Surgery, Umea University Hospital, Sweden*)
Bas Wijnhoven (*Surgery, Erasmus University Medical Center Rotterdam, Netherlands*)

ML2-1 Hereditary diffuse gastric cancer and CDH1 mutations, current management

Paul F. Mansfield (*Surgical Oncology, UT MD Anderson Cancer Center, U.S.A.*)

ML2-2 Clinical feature of gastric adenocarcinoma and proximal polyposis

Chihiro Matsumoto (*Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan*)

ML2-3 Prophylactic total gastrectomy in 54 consecutive individuals with germline pathogenic mutations in the CDH1 gene

Sam Sunghyun Yoon *(Columbia University Irving Medical Center, U.S.A.)*

June 16 (Fri.) / 16:00-17:00 / Room 4 (503)

Networking sessions for young investigator -sharing optimal treatment strategies-

Chair: Brian Badgwell *(Surgical Oncology, MD Anderson Cancer Center, U.S.A.)*

Masaaki Yamamoto *(Department of Gastroenterological Surgery, Osaka International Cancer Institute, Japan)*

Discussant: Yukiya Narita *(Department of Clinical Oncology, Aichi Cancer Center Hospital, Japan)*

Hon Lyn Tan *(National University Health System, Singapore)*

Hyung-Don Kim *(Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Republic of Korea)*

June 17 (Sat.) / 9:25-10:10 / Room 2 (501)

Contributions of big data science to gastric cancer treatment

Chair: Hiroyuki Konno *(Hamamatsu University School of Medicine, Japan)*

Henk Hartgrink *(Department of Surgery, Leiden University Medical Center, Netherlands)*

ML4-1 Practical use of National Clinical Database in gastric cancer treatment

Yoshihiro Kakeji *(Division of Gastrointestinal Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Japan)*

ML4-2 Improved Survival after Laparoscopic Compared to Open Gastrectomy for Advanced Gastric Cancer

Ioannis Rouvelas *(Division of Surgery, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, Stockholm, Sweden / Division of Surgery, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, Stockholm, Sweden)*

ML4-3 Trends and outcomes of oncologic robotic gastrectomy in the United States

Yuki Hirata *(Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, U.S.A. / Department of Surgery, Keio University School of Medicine)*

June 17 (Sat.) / 8:00-9:00 / Room 4 (503)

Patient Advocacy Session - Part 1: Information for patients

Chair: Hiromi Todoroki (*Chairwoman, Certified non-profit organization KIBOUNOKAI, Japan*)

Paul F. Mansfield (*Surgical Oncology, U.T. MD Anderson Cancer Center, U.S.A.*)

Panelist: Zhenggang Zhu (*Rui-Jin Hospital, Shanghai Jiao Tong University School of Medicine, China*)

Franco Roviello (*Surgical Oncology, University of Siena, Italy*)

Ekaterina Kosyachkova (*Vice-Chair & Co-Founder of My Gut Feeling, and Survivor, Canada*)

Ryo Imura (*Senior Advisor/Guest Professor, TRON FORUM and UC Berkeley, Japan*)

PAS1-1

Mitsuru Sasako (*Surgery, Yodogawa Christian Hospital, Japan*)

PAS1-2

Steve Melen (*Board Member, treasurer, mentor and survivor, Debbie's Dream Foundation: Curing Stomach Cancer, U.S.A.*)

PAS1-3

Hao Zhou (*Survivor, China*)

June 17 (Sat.) / 9:00-10:00 / Room 4 (503)

Patient Advocacy Session - Part 2: 2nd line chemotherapy

Chair: Narikazu Boku (*Department of Oncology and General Medicine, IMSUT Hospital, Institute of Medical Science, University of Tokyo, Japan*)

Florian Lordick (*Department of Medicine and University Cancer Center Leipzig (UCCL), University of Leipzig Medical Center, Germany*)

Panelist: Jaffer A Ajani (*GI Medical Oncology, UT M. D. Anderson Cancer Center, U.S.A.*)

Jimmy So (*Surgery, National University of Singapore, Singapore*)

Amy L. Jacobs (*Patient Advocate, Survivor and Mentor, Debbie's Dream Foundation: Curing Stomach Cancer, Canada*)

Hiromi Todoroki (*Chairwoman, Certified non-profit organization KIBOUNOKAI, Japan*)

PAS2-1

Eishi Baba (*Oncology and Social Medicine, Kyushu University, Graduate School of Medical Sciences, Japan*)

PAS2-2

Amy L. Jacobs (*Patient Advocate, Survivor and Mentor, Debbie's Dream Foundation: Curing Stomach Cancer, U.S.A.*)

June 17 (Sat.) / 10:00-11:00 / Room 4 (503)

Patient Advocacy Session - Part 3: Function preserving surgery

Chair: Han-Kwang Yang (*Department of Surgery, Seoul National University, Republic of Korea*)

Natalie Coburn (*University of Toronto/Sunnybrook Health Sciences Centre, Canada*)

Panelist: Hui Cao (*Renji Hospital, School of Medicine, Shanghai Jiaotong University, China*)

Felix Berlth (*Department of General, Visceral and Transplant Surgery, University Medical Center Mainz, Germany*)

Seungkee Ra (*Upper GI, Function preserving surgery panelist, Republic of Korea*)

Melani Vincelli (*Patient, U.S.A.*)

PAS3-1

Souya Nunobe (*Department of Gastric Surgery, Cancer Institute Hospital, Japan*)

PAS3-2

Ekaterina Kosyachkova (*Vice-Chair & Co-Founder of My Gut Feeling, and a Survivor, Canada*)

PAS3-3

Ryo Imura (*Senior Advisor/Guest Professor, TRON FORUM and UC Berkeley, Japan*)

June 17 (Sat.) / 11:00-12:00 / Room 4 (503)

Patient Advocacy Session - Part 4: QOL evaluation

Chair: Andrea Paula Eidelman (*CEO, Debbie's Dream Foundation: Curing Stomach Cancer, U.S.A.*)

Paulo Kassab (*Surgery, Santa Casa of São Paulo Hospital and Medical School, Brazil*)

Panelist: Richard van Hillegersberg (*Heelkunde, UMC Utrecht, Netherlands*)

Koji Nakada (*Department of Surgery, Kawamura Hospital, Japan*)

Ji-Hyeon Park (*Department of Surgery, Gachon University Gil Medical Center, Republic of Korea*)

Steve Melen (*Board Member, treasurer, mentor and Survivor, Debbie's Dream Foundation: Curing Stomach Cancer, U.S.A.*)

PAS4-1

Gian Luca Baiocchi (*Clinical and Experimental Sciences, University of Brescia, Italy, & ASST Cremona, Italy*)

PAS4-2

Yuichi Inaba (*Survivor, Japan*)

PAS4-3

Teresa Tiano (*Chair & Co-Founder of My Gut Feeling, and Survivor, Canada*)

June 15 (Thu.) / 12:20-13:20 / Room 1 (Main Hall)

Luncheon Seminar 1

Chair: Hiroya Takeuchi (*Department of Surgery, Hamamatsu University School of Medicine, Japan*)

Sponsored by: MSD K.K. Oncology Medical Affairs

LS1-1 Biomarkers in upper GI cancers and the landscape of Esophago-gastric Junctional Cancer

Yu Sunakawa (*Department of Clinical Oncology, St. Marianna University School of Medicine / Oncology Center & Center for Genomic Medicine in St. Marianna University Hospital, Japan*)

June 15 (Thu.) / 12:20-13:20 / Room 2 (501)

Luncheon Seminar 2 : The Past and Future Perspective of Japanese Key Drug in Advanced Gastric Cancer

Chair: Yasuhiro Kodera (*Department of Gastroenterological Surgery (Surgery II) Nagoya University, Graduate School of Medicine, Japan*)

Sponsored by: TAIHO PHARMACEUTICAL CO., LTD.

LS2-1 Evolution of Oral Anticancer Agents and Prospects of FTD/TPI in the Treatment of Gastric Cancer

Eiji Oki (*Department of Surgery and Science, Graduate School of Medical Science, Kyushu University, Japan*)

LS2-2 Clinical Practice and Biomarker Trends for Gastric Cancer in Japan

Hisato Kawakami (*Department of Medical Oncology, Kindai University Faculty of Medicine, Japan*)

June 15 (Thu.) / 12:20-13:20 / Room 3 (502)

Luncheon Seminar 3 : Latest procedures and stylization of esophagogastric junction cancer using VISERA ELITE III system

Chair: Hisashi Shinohara (*Hyogo Medical University, Japan*)

Sponsored by: Olympus Marketing, Inc

LS3-1 -

Noriyuki Inaki (*Kanazawa University, Japan*)

LS3-2 -

Takahiro Kinoshita (*National Cancer Center Hospital East, Japan*)

June 15 (Thu.) / 12:20-13:20 / Room 4 (503)

Luncheon Seminar 4 : Practical Use of hinotori™ Made in Japan

Chair: Masanori Terashima (*Shizuoka Cancer Center, Japan*)

Sponsored by: Mediaroid Corporation / Sysmex Corporation

LS4-1 -

Shuji Takiguchi (*Gastroenterological Surgery, Graduate School of Medical Sciences, Nagoya City University, Japan*)

LS4-2 -

Hirokazu Noshiro (*Department of Surgery, Saga University Faculty of Medicine, Japan*)

June 15 (Thu.) / 12:20-13:20 / Room 5 (414+415)

Luncheon Seminar 5 : Reshaping & Unraveling Surgery for Gastric Cancer, RUS : Surgical Navigation for Minimally Invasive Gastrectomy

Chair: Sang-Uk Han (*Department of Surgery, Ajou University, Suwon, Republic of Korea*)

Kazutaka Obama (*Department of Surgery, Kyoto University, Kyoto, Japan*)

Sponsored by: Hutom

LS5-1 RUS, Saving Novice Surgeon

Jae Hun Chung (*Department of Surgery, Pusan National University, Yangsan, Republic of Korea*)

LS5-2 Easier Gastrectomy Using RUS

Guowei Kim (*Department of Surgery, National University of Singapore, Singapore*)

LS5-3 Knowing the Anatomy Before Surgery, Instead of Doing It Blindly

In Gyu Kwon (*Department of Surgery, Yonsei University, Seoul, Republic of Korea*)

LS5-4 Surgical Navigation(RUS). Is It Necessary Even to an Experienced Surgeon?

Woo Jin Hyung (*Department of Surgery, Yonsei University, Seoul, Republic of Korea*)

June 16 (Fri.) / 12:20-13:20 / Room 1 (Main Hall)

Luncheon Seminar 6

Chair: Yasuhiro Kodera (*Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Japan*)

Sponsored by: Bristol-Myers Squibb K.K. / ONO PHARMACEUTICAL CO., LTD.

LS6-1 How Has Cancer Immunotherapy Changed Gastric Cancer Pharmacotherapy?

Kei Muro (*Department of Clinical Oncology, Aichi Cancer Center Hospital, Japan*)

June 16 (Fri.) / 12:20-13:20 / Room 2 (501)

Luncheon Seminar 7

Chair: Masanori Terashima (*Division of Gastric Surgery Shizuoka Cancer Center, Japan*)

Sponsored by: Chugai Pharmaceutical Co., Ltd.

LS7-1 Treatment strategy for Her-2 positive gastric cancer

Takaki Yoshikawa (*Department of Gastric Surgery National Cancer Center Hospital, Japan*)

June 16 (Fri.) / 12:20-13:20 / Room 4 (503)

Luncheon Seminar 8 : RAS Optimization for Gastric Cancer

Chair: Kazutaka Obama (*Department of Surgery, Kyoto University Graduate School of Medicine, Japan*)

Sponsored by: Covidien Japan Inc.

LS8-1 -

Yukinori Kurokawa (*Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Japan*)

LS8-2 -

Kazuhisa Ehara (*Department of Gastric Surgery, Saitama Prefectural Cancer Center, Japan*)

June 16 (Fri.) / 12:20-13:20 / Room 5 (414+415)

Luncheon Seminar 9 : Taking on the World with Japanese Endoscopic AI

Chair: Yuko Kitagawa (*Department of Surgery, Keio University School of Medicine, Japan*)

Special Remarks: Hisao Tajiri (*World Endoscopy Organization (WEO) / The Jikei University School of Medicine, Japan*)

Sponsored by: AI Medical Service Inc.

LS9-1 The role of AI for endoscopic diagnosis in gastric cancer: current status, challenges, and future perspectives

Ken Namikawa (*Department of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan*)

LS9-2 Evolution of AI Technologies and the Future of Surgery

Naruhiko Ikoma (*Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, U.S.A.*)

LS9-3 The Impact of AI on Tomorrow's Endoscopic Medicine

Tomohiro Tada (*AI Medical Service Inc. / Tada Tomohiro The Institute of Gastroenterology & Proctology, Japan*)

June 17 (Sat.) / 12:20-13:20 / Room 1 (Main Hall)

Luncheon Seminar 10

Chair: Hideo Baba (*Department of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, Japan*)

Sponsored by: MIYARISAN PHARMACEUTICAL CO. LTD.

LS10-1 Surgery for gastric cancer: how to reduce complications, preserve function, and heritage to next generation?

Naoki Hiki (*Department of Upper Gastrointestinal Surgery Kitasato University School of Medicine, Japan*)

June 17 (Sat.) / 12:10-13:20 / Room 3 (502)

**Luncheon Seminar 11 : Proximal gastrectomy:
For better postoperative function**

Chair: Jiafu Ji (*Peking University Cancer Hospital, China*)

Yoshihiro Kakeji (*Kobe University Graduate School of Medicine, Japan*)

Sponsored by: Johnson & Johnson K.K.

LS11-1 Proximal partial gastrectomy with GIRAFFE reconstruction used in 100 patients: a system review

Xiangdong Cheng (*Zhejiang Cancer Hospital, China*)

LS11-2 Laparoscopic double tract reconstruction after proximal gastrectomy for gastric cancer

Zekuan Xu (*The First Affiliated Hospital of Nanjing Medical University, China*)

LS11-3 Reconstruction after proximal gastrectomy: our ingenuity

Kazutaka Obama (*Kyoto University Graduate School of Medicine, Japan*)

LS11-4 "Arch-bridge-type" reconstruction after laparoscopic proximal gastrectomy: a modified Kamikawa method

Ziyu Li (*Peking University Cancer Hospital, China*)

June 17 (Sat.) / 12:20-13:20 / Room 4 (503)

Luncheon Seminar 12

Chair: Taroh Satoh (*Center for Cancer Genomics and Personalized Medicine, Osaka University Hospital, Japan*)

Sponsored by: Eli Lilly Japan K. K.

LS12-1 The latest Treatment in Gastric Cancer and Treatment Sequencing

Kensei Yamaguchi (*Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Japan*)

June 16 (Fri.) / 12:20-13:20 / Room 6 (416+417)

Luncheon Seminar 13 : CGCA Luncheon Seminar

Chair: Jiafu Ji (*Peking University Cancer Hospital & Institute, China*)

Zhenggang Zhu (*Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China*)

Kazuhiro Yoshida (*Department of Gastroenterological Surgery, Gifu University, Japan*)

Sponsored by: Qilu Pharmaceutical Co., Ltd.

LS13-1 Surgical conversion feasibility of sintilimab (PD-1 inhibitor) combined with Nab-PTX, S-1 and Apatinib for the first-line treatment of stage IV gastric cancer

Han Liang (*Tianjin Medical University Cancer Institute & Hospital, China*)

Presided: Yihong Sun (*Zhongshan Hospital Fudan University, China*)

Discussant: Guanghai Dai (*Chinese PLA General Hospital / Chinese PLA Medical School, China*)

Xiang Hu (*The First Affiliated Hospital of Dalian Medical University, China*)

LS13-2 Treatment strategy for Ovarian metastasis of gastric cancer

Xiangdong Cheng (*Zhejiang Cancer Hospital, China*)

Presided: Yanqiao Zhang (*Harbin Medical University Cancer hospital, China*)

Discussant: Yongxiang Li (*The First Affiliated Hospital of Anhui Medical University, China*)

Changqing Jing (*Shandong Provincial Hospital, China*)

June 17 (Sat.) / 12:20-13:20 / Room 5 (414+415)

Luncheon Seminar 14 : CGCA Luncheon Seminar

Chair: Lin Shen (*Peking University Cancer Hospital and Institute, China*)

Han Liang (*Tianjin Medical University Cancer Institute & Hospital, China*)

Narikazu Boku (*IMSUT Hospital, Institute of Medical Science, University of Tokyo, Japan*)

Sponsored by: Qilu Pharmaceutical Co., Ltd.

LS14-1 Future of precise treatment in gastric cancer

Xiaotian Zhang (*Peking University Cancer Hospital and Institute, China*)

Presided: Han Liang (*Tianjin Medical University Cancer Institute & Hospital, China*)

Discussant: Narikazu Boku (*IMSUT Hospital, Institute of Medical Science, University of Tokyo, Japan*)

Yinying Wu (*The First Affiliated Hospital of Xi'an Jiaotong University, China*)

LS14-2 Neoadjuvant immunochemotherapy for locally advanced gastric cancer

Guoxin Li (*Nanfang Hospital, Southern Medical University, China*)

Presided: Leping Li (*Shandong Provincial Hospital, China*)

Discussant: Jingwu Li (*Tangshan People's Hospital, China*)

Jie Chai (*Shandong Cancer Hospital, China*)

June 15 (Thu.) / 7:30-8:30 / Room 2 (501)

Morning Seminar 1

Chair: Takeo Fukagawa (*Department of Surgery, Teikyo University School of Medicine, Japan*)

Sponsored by: Otsuka Pharmaceutical Factory, Inc.

MS1-1 Priority need for elderly vulnerable patients with gastric cancer Radicality? Maintaining nutritional status?

Hiroharu Yamashita (*Division of Digestive Surgery, Department of Surgery, Nihon University School of Medicine, Japan*)

June 16 (Fri.) / 7:30-8:30 / Room 2 (501)

Morning Seminar 2

Chair: Yasuyuki Seto (*Graduate School of Medicine, The University of Tokyo Department of Gastrointestinal Surgery, Japan*)

Sponsored by: DAIICHI SANKYO COMPANY, LIMITED

MS2-1 Biomarker-based Treatment Strategies in Advanced Gastric and Gastroesophageal Junction Cancer

Kei Muro (*Department of Clinical Oncology, Aichi Cancer Center Hospital, Japan*)

June 17 (Sat.) / 7:30-8:30 / Room 2 (501)

Morning Seminar 3

Chair: Hideaki Shimada (*Department of Surgery and Clinical Oncology, Toho University Graduate School of Medicine, Japan*)

Sponsored by: Bristol-Myers Squibb K.K. / ONO PHARMACEUTICAL CO., LTD.

MS3-1 Gastric Cancer Treatment from a Surgeon's Perspective

Koji Kono (*Department of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, Japan*)

June 15 (Thu.) / 16:50-17:50 / Room 5 (414+415)

Evening Seminar 1

Chair: Eishi Baba (*Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University, Japan*)

Sponsored by: Yakult Honsha Co.,Ltd.

ES1-1 Current Insights in Gastric Cancer Chemotherapy

Daisuke Takahari (*Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japan*)

June 16 (Fri.) / 16:00-17:00 / Room 5 (414+415)

Evening Seminar 2

Chair: Yuichiro Doki (*Department of Gastroenterological Surgery Graduate School of Medicine Osaka University, Japan*)

Sponsored by: NIPPON KAYAKU

ES2-1 History of standard chemotherapy for gastric cancer in Japan

Kensei Yamaguchi (*Department of Gastroenterological Chemotherapy, Cancer Institute Hospital Japanese Foundation for Cancer Research, Japan*)

June 15 (Thu.) / 15:55-16:10 / Exhibition Area (301-304)

Booth Seminar

Sponsored by: AI Medical Service Inc.

Current Status and Future of AI in Digestive Disease

Tomohiro Tada (*AI Medical Service Inc. / Tada Tomohiro the Institute of Gastroenterology & Proctology, Japan*)

June 15 (Thu.) / 8:20-9:08 / Room 5 (414+415)

Oral 1 : Advanced gastric cancer

Chair: Chikara Kunisaki (*Surgery, Gastroenterological Center, Yokohama City University, Japan*)

- O1-1 The benefit of multivisceral resections for locally advanced gastric cancer**
Dong Yi Kim (*Department of Surgery, Chonnam National University Medical School, South Korea*)
- O1-2 Validity of spleen-preservation for upper advanced gastric cancer without invasion of the greater curvature**
Masashi Nishino (*Gastric Surgery Division, National Cancer Center Hospital, Tokyo, Japan*)
- O1-3 Para-aortic lymph node dissection for large type 3 or type 4 gastric cancer with extensive lymph node metastasis**
Takeyuki Wada (*Department of Gastric Surgery, National Cancer Center Hospital, Tokyo, Japan*)
- O1-4 Optimal lymph node dissection extent for localized proximal advanced gastric cancer**
Mitsumasa Yoshida (*Gastric Surgery Division, National Cancer Center Hospital East, Japan*)
- O1-5 Prognostic value of restaging CT in stage IV gastric cancer: proposal of new radiological criteria from a prospective Italian registry**
Giulio Bagnacci (*Unit of Diagnostic Imaging, Department of Medical, Surgical and Neuro Sciences and of Radiological Sciences, University of Siena, Azienda Ospedaliero-Universitaria Senese, Siena, Italy / GIRCG Secretary: Department of Medicine, Surgery and Neurosciences, University of Siena, Policlinico Le Scotte, Viale Bracci, Siena, Italy*)
- O1-6 Clinical outcomes and perspective of CY0P1 gastric cancer: a single institution study**
Kotaro Wakamatsu (*Department of Surgery, Toho University Sakura Medical Center, Japan*)

June 15 (Thu.) / 9:18-9:50 / Room 5 (414+415)

Oral 2 : Prognostic factor

Chair: Noriyuki Inaki (*Gastrointestinal Surgery, Kanazawa University, Japan*)

- O2-1 Prognostic significance of microsatellity instability in Western gastric cancer: a propensity score analysis**
Marina Alessandra Pereira (*Instituto do Cancer, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo – Department of Gastroenterology, Brazil*)

O2-2 The effect of body mass index on survival after surgery for gastric cancer - a population-based cohort study in Finland

Aapo Johannes Jalkanen (*Department of Surgery, Abdominal Center, Helsinki University Hospital and University of Helsinki, Finland*)

O2-3 Clinical significance of metastatic lymph nodes of the extra gastric lymph node stations over perigastric stations after curative gastrectomy

Han Hong Lee (*Division of Gastrointestinal Surgery, Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, South Korea*)

O2-4 Risk factors for recurrence after curative resection in patients with pStage II/III gastric cancer

Itaru Yasufuku (*Department of Anatomy, Gifu University Graduate School of Medicine, Gifu, Japan*)

June 15 (Thu.) / 10:05-10:45 / Room 5 (414+415)

Oral 3 : Management of gastric cancer

Chair: Jimmy So (*National University of Singapore, Surgery, Singapore*)

O3-1 Real world compliance of surgical treatment according to the Korean gastric cancer guideline 2018: evaluation from the nationwide survey data 2019 in Korea

Sang Soo Eom (*National Cancer Center, South Korea*)

O3-2 JGCA 2nd edition vs. UICC 8th: a mono-institutional comparison of the TNM staging and survival rate

Paula Strauch Costa (*Santa Casa of Sao Paulo, Medical School and Hospital, Department of Surgery, Gastroesophageal and Bariatric Division, Brazil*)

O3-3 Observational study on gastric cancer risk factors: administration of a risk assessment questionnaire in a western community

Gian Luca Baiocchi (*Department of Surgery, ASST Cremona, Italy / Department of Clinical and Experimental Sciences, University of Brescia, and ASST Cremona, Italy*)

O3-4 Survival benefit of regular follow-up after curative surgery for advanced gastric cancer

Sin Hye Park (*Center for Gastric Cancer, National Cancer Center, South Korea*)

O3-5 Risk score for predicting death from other causes after curative gastrectomy for gastric cancer

Yuki Ito (*Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan*)

June 15 (Thu.) / 10:55-11:35 / Room 5 (414+415)

Oral 4 : Translational research & Biomarker

Chair: Elizabeth Catherine Smyth (*Cambridge University Hospital NHS Foundation Trust, United Kingdom*)

O4-1 High throughput chemotherapeutic drug screening system for gastric cancer (cure-GA)

Jieun Lee (*Department of Surgery, Seoul National University Bundang Hospital, South Korea*)

O4-2 PD-L1 associated single-cell transcriptomic signatures of peritoneal TME in gastric cancer patients

Yanghee Woo (*Division of Surgical Oncology, Department of Surgery, City of Hope National Medical Center, Duarte, California, United States*)

O4-3 Clinical significance of postoperative prognostic nutritional index in total gastrectomy and remnant gastrectomy

Ryoma Haneda (*Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan*)

O4-4 Exploratory analysis of HER2 extracellular domain in HER2 positive gastric cancer treated with SOX plus trastuzumab

Takeru Wakatsuki (*Dep. of Gastrointestinal Medical Oncology, The Cancer Institute Hospital of JFCR, Tokyo, Japan*)

O4-5 Sandwich ELISA for serum exosomal gastrokine 1 (GKN1) protein can serve as a screening tool for early detection of gastric cancer

Jung Hwan Yoon (*Department of Pathology, The Catholic University of Korea, South Korea*)

June 15 (Thu.) / 14:30-15:10 / Room 5 (414+415)

Oral 5 : Surgery 1

Chair: Tomoyuki Irino (*Department of Surgery, Keio University School of Medicine, Japan*)

O5-1 Effects of hyperthermic intraperitoneal chemoperfusion on survival of gastric cancer with peritoneal metastasis

Yutaka Yonemura (*Peritoneal Surface Malignancy Treatment Center, Kishiwada Tokusyukai Hospital, Osaka, Japan*)

O5-2 Surgical quality and prospective quality control of D2-gastrectomy for gastric cancer in the multicenter LOGICA-trial

Lianne Triemstra (*University Medical Center Utrecht, Department of Surgery, Utrecht, Netherlands*)

05-3 Long-term outcomes of minimally invasive total gastrectomy for locally advanced gastric cancer

Ki-Yoon Kim (*Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea / Department of Surgery, Yonsei University College of Medicine, and Gastric Cancer Center*)

05-4 D2 lymph node dissection confers little benefit on the overall survival of older patients with resectable gastric cancer: a propensity score-matching analysis of a multi-institutional dataset

Takahiro Shinozuka (*Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan*)

05-5 Usefulness of intrathoracic double flap technique for esophagogastric cancer

Masahiro Niihara (*Department of Upper Gastrointestinal Surgery, Kitasato University School of Medicine, Sagamihara, Japan*)

June 15 (Thu.) / 15:20-16:00 / Room 5 (414+415)

Oral 6 : Surgery 2

Chair: Flavio Roberto Takeda (*Department of Gastroenterology, University of São Paulo, Brazil*)

06-1 Survival effect of splenic hilar lymph node (no.10) dissection in B4 type gastric carcinoma

Oh Jeong (*Department of Surgery, Chonnam National University Hwasun Hospital, South Korea*)

06-2 Resection margin strategy in gastric cancer surgery: the European REMARCS (Resection MARGin for Cancer of the Stomach) survey

Mickael Chevally (*Division of Digestive and Transplant Surgery, Department of Surgery, University Hospital of Geneva, Geneva, Switzerland*)

06-3 Survival benefit of extended lymphadenectomy for gastric cancer in the elderly and comorbid

Miguel Burch (*Cedars-Sinai Medical Center, Los Angeles, CA, United States*)

06-4 Newly modified esophagogastrectomy after proximal gastrectomy in our institution

Atsushi Yasuda (*Department of surgery, Kindai University Faculty, Osaka, Japan of Medicine, Japan*)

06-5 Long-term outcome of proximal gastrectomy for upper third advanced gastric and Siewert type II esophagogastric junction cancer in comparison with total gastrectomy: a propensity-score matched analysis

Yoon Soo Chae (*Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, South Korea*)

Oral 7 : GIST & Neuroendocrine tumor & Pathology

Chair: Heike Irmgard Grabsch (*Maastricht University Medical Center, the Netherlands*)

Yasuo Hamamoto (*Keio Cancer Center, Keio University School of Medicine, Japan*)

07-1 Comparison of overall survival of malignant gastric neuroendocrine tumor with gastric adenocarcinoma: a propensity score matching study

Benlong Zhang (*Department of General Surgery, the First Medical Center of Chinese PLA General Hospital, Beijing, China*)

07-2 Long-term outcome of the phase II study of neoadjuvant imatinib in large gastric GISTs

Seong-Ho Kong (*Seoul National University Hospital, South Korea*)

07-3 Imatinib In Chinese patients with advanced gastrointestinal stromal tumors: plasma trough concentrations and clinical outcomes

Hao Xu (*Division of Gastric Surgery, Department of General Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China*)

07-4 Lauren's phenotype of gastric and gastroesophageal adenocarcinoma and their correlating genotype

Harrison M. Drebin (*Gastric and Mixed Tumor Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States*)

07-5 Clinicopathological features and prognosis of primary gastric adenosquamous carcinoma: a multicenter retrospective study based on propensity score matching

Haoyu Zhang (*Department of Gastrointestinal Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, China*)

07-6 Tumour infiltrating lymphocytes and survival after adjuvant chemotherapy in patients with gastric cancer: post-hoc analysis of the CLASSIC trial

Drolaiz H.W. Liu (*Department of Pathology, GROW School for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, Netherlands*)

June 15 (Thu.) / 9:18-9:50 / Room 6 (416+417)

Oral 8 : Navigation surgery

Chair: Hiroya Takeuchi (*Department of Surgery, Hamamatsu University School of Medicine, Japan*)

**08-1 Usefulness of navigation surgery using ICG for gastric cancer
-Propensity score matching analysis-**

Naoki Shinno (*Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan*)

**08-2 Long-term outcomes of indocyanine green-guided
lymphadenectomy for gastric cancer**

Qing Zhong (*Department of Gastric Surgery, Fujian Medical University Union Hospital, Fujian, China*)

**08-3 No leakage in 100 cases of RDG delta anastomosis ~ blood flow
evaluation method by ICG using the fire fly function~**

Shunsuke Hayakawa (*Graduate School of Medical Sciences Gastroenterological Surgery, Nagoya City University, Nagoya, Japan*)

**08-4 Prognostic value of molecular cytology OSNA assay of peritoneal
washings in advanced GC**

Wojciech P. Polkowski (*Department of Surgical Oncology, Medical University of Lublin, Lublin, Poland*)

June 15 (Thu.) / 10:05-10:45 / Room 6 (416+417)

Oral 9 : Neoadjuvant therapy 1

Chair: Yukinori Kurokawa (*Department of Gastroenterological Surgery, Osaka University, Japan*)

09-1 Withdrawn

**09-2 Neoadjuvant camrelizumab and apatinib combined with
chemotherapy for locally advanced gastric cancer: a multicenter
randomized controlled trial**

Jian-Xian Lin (*Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China*)

**09-3 Upfront surgery versus neoadjuvant chemotherapy. A retrospective
study with matched treatment comparison**

Rossella Reddavid (*University of Turin, Italy*)

09-4 Analysis and identification of prognostic factors for non-cardia gastric cancer treated with neoadjuvant chemotherapy and radical surgery: a multicentric study

Stefania Angela Piccioni (*Unit of General Surgery and Surgical Oncology, Department of Medicine, Surgery and Neurosciences, University of Siena, Policlinico "Le Scotte", Siena, Italy / GIRCG Scientific Secretary: Department of Medicine, Surgery and Neurosciences, University of Siena, Policlinico Le Scotte, Siena, Italy*)

09-5 Neoadjuvant chemotherapy in older patients with gastric cancer undergoing surgery: a European retrospective study

Kammy Keywani (*Department of Surgery, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands / Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, The Netherlands*)

June 15 (Thu.) / 10:55-11:35 / Room 6 (416+417)

Oral 10 : Neoadjuvant therapy 2

Chair: Takaki Yoshikawa (*Department of Gastric Surgery, National Cancer Center Hospital, Japan*)

O10-1 Dissection of shrinking para-aortic lymph node metastases after chemotherapy

Takumi Habu (*Gastric Surgery Division, National Cancer Center Hospital East, Kashiwa, Japan*)

O10-2 A new approach to assess toxicity in gastric cancer patients undergoing preoperative treatment in the critics trial

Romy van Amelsfoort (*Netherlands Cancer Institute, Department of Radiation Oncology, Amsterdam, The Netherlands*)

O10-3 Prognostic factors and significance of postoperative adjuvant chemotherapy in patients with gastric cancer undergoing neoadjuvant chemotherapy followed by gastrectomy

Masaaki Motoori (*Department of surgery, Osaka General Medical Center, Osaka, Japan*)

O10-4 Evaluation of the prognostic impact of pathologic response to neoadjuvant chemotherapy in gastric cancer

Shoji Shimada (*Gastric and Mixed Tumor Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States*)

O10-5 Short and long-term outcomes after perioperative EOX therapy versus upfront surgery for gastric cancer

Johan Julius Back (*Department of Abdominal Surgery, Helsinki University and Helsinki University Hospital, Finland*)

Oral 11 : Adjuvant therapy & Gastric cancer in elderly patients

Chair: Jiafu Ji (*Department of Surgery, Peking University Cancer Hospital, China*)

Flavio Roberto Takeda (*Department of Gastroenterology, University of São Paulo, Brazil*)

O11-1 Safety and early efficacy results of camrelizumab with docetaxel plus S-1 for stage III (PD-L1+/dMMR/EBV+) gastric cancer after D2 resection: a single-center, prospective, single-arm, phase II trial

Bo Ni (*Department of Gastrointestinal Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China / State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China*)

O11-2 Adjuvant nab-paclitaxel + S-1 versus capecitabine + oxaliplatin in patients with stage III gastric adenocarcinoma after D2 radical resection

Pengfei Yu (*Zhejiang Cancer Hospital (University of Chinese Academy of Sciences Cancer Hospital), Hangzhou, Zhejiang, China*)

O11-3 Gastrectomy for cancer beyond life expectancy-analysis of real life data in Germany from 2008-2018

Daniel Reim (*Department of Surgery, TUM School of Medicine, Germany*)

O11-4 Surgical outcomes and prognostic factors of gastric cancer surgery in octogenarians

Byoung Jo Suh (*Department of Surgery, Inje University Haeundae Paik Hospital, Busan, South Korea*)

O11-5 Significance of minimally invasive surgery for very elderly gastric cancer patients

Eri Yoshida (*Department of gastroenterological surgery, Hirosaki university graduate school of medicine, Aomori, Japan*)

O11-6 Long-term outcomes and prognostic factors of elderly patients who underwent gastrectomy for gastric cancer

Hiroshi Tsuchiya (*Department of Gastroenterological Surgery, Gifu University Graduate School of Medicine, Japan*)

June 15 (Thu.) / 15:28-16:00 / Room 6 (416+417)

Oral 12 : EGJ cancer

Chair: Magnus Nilsson (*Division of Surgery and Oncology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Sweden*)

O12-1 Novel simplified classification based on Lauren histotype in GE-junction cancer

Daniel Reim (*Department of Surgery, TUM School of Medicine, Germany*)

O12-2 Distribution of lymph nodes metastasis and survival of adenocarcinoma of the esophagogastric junction

Motomi Nasu (*Department of Esophageal and Gastroenterological Surgery, Juntendo University Graduate School of Medicine, Tokyo, Japan*)

O12-3 Investigation of efficacy index of lymph node dissection in Siewert type 2 esophagogastric junction adenocarcinoma

Eisuke Booka (*Department of Surgery, Hamamatsu University School of Medicine, Shizuoka, Japan*)

O12-4 Prognostic impact of mediastinal lymph node metastasis in esophagogastric junction cancer

Yudai Higuchi (*The First Department of Surgery, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan*)

June 15 (Thu.) / 16:50-17:22 / Room 6 (416+417)

Oral 13 : Perioperative management & ERAS

Chair: Paulo Kassab (*Santa Casa Hospital and Medical School, Gastroesophageal and Bariatric Division, Surgery, Brazil*)

O13-1 Effect of perioperative probiotic supplements on postoperative short-term outcomes in gastric cancer patients receiving neoadjuvant chemotherapy: a double-blind, randomized controlled trial

Gan Liu (*Department of Gastrointestinal Surgery, the Affiliated Hospital of Qingdao University, Qingdao, China*)

O13-2 The effects of ERAS versus conventional protocol on clinical outcome in gastric cancer patients underwent radical gastrectomy: a pilot study on relevant mechanisms

Cheng Meng (*Department of Gastrointestinal Surgery, Affiliated Hospital of Qingdao University, Qingdao, China*)

O13-3 Randomized controlled trial comparing the short-term outcomes of enhanced recovery after surgery and conventional care in laparoscopic distal gastrectomy (GISSG1901)

Yulong Tian (*Department of General Surgery, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China*)

O13-4 Compliance of early oral feeding in patients with gastrectomy for gastric cancer under ERAS programs

Sejin Lee (*The Department of Surgery, Jeonbuk National University Hospital, Jeonju, South Korea*)

June 16 (Fri.) / 8:28-9:00 / Room 5 (414+415)

Oral 14 : Non-surgical treatment

Chair: Trevor Leong (*Department of Radiation Oncology, Peter MacCallum Cancer Centre, Australia*)

O14-1 Use of Hemostatic Radiotherapy for the treatment of gastric tumors with bleeding

Marcus Fernando Kodama Pertille Ramos (*Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Brazil*)

O14-2 Who is the best candidate for single-fraction palliative radiotherapy for gastric cancer bleeding?: an exploratory research of a multicentric prospective observational study (JROSG 17-3)

Shuhei Sekii (*Department of Radiation Oncology, Kita-Harima Medical Center, Hyogo, Japan*)

O14-3 Prevalence and factors associated with financial toxicity after pancreatectomy and gastrectomy – perspectives from advanced practice providers to mitigate burden

Connie To (*University of Texas MD Anderson Cancer Center*)

O14-4 Advanced practice provider roles in post gastrectomy care contribute to opioid reduction

Elsa M. Arvide (*University of Texas MD Anderson Cancer Center*)

June 16 (Fri.) / 9:10-9:58 / Room 5 (414+415)

Oral 15 : Epidemiology

Chair: Chika Kusano (*Department of Gastroenterology, Kitasato University School of Medicine, Japan*)

O15-1 Risk factors for death from other disease in patients cured of gastric cancer after gastrectomy

Hiroshi Ichikawa (*Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, Japan*)

O15-2 Long-term survivorship between gastrectomy and endoscopic resection for gastric cancer using a nationwide real-world database: 15 years of follow-up

So Hyun Kang (*Seoul National University Bundang Hospital, South Korea*)

O15-3 Defining the age-dependent characteristics of gastric cancer using prefectural cancer registry data

Yujin Xing (*Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Gunma, Japan*)

O15-4 Gastric cancer treatment in the public health system of Sao Paulo State in Brazil: epidemiological profile and survival outcomes according to the level of complexity of the hospital

Marcus Fernando Kodama Pertille Ramos (*Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Brazil*)

O15-5 Gastric cancer in the young adult. New incidence from east to west?

Lorena Torroni (*Unit of Epidemiology and Medical Statistics, Dept. of Diagnostics and Public Health, University of Verona, Verona, Italy*)

O15-6 Epidemiologic Challenges of Gastric Cancer in Latin America

Marcelo Mester (*Discipline of Digestive Surgery, Department of Gastroenterology, University of São Paulo Medical School / Vice-President of the Southeast Region, Brazilian Gastric Cancer Association, Brazil*)

June 16 (Fri.) / 10:05-10:45 / Room 5 (414+415)

Oral 16 : Postoperative complication

Chair: Simon Law (*Department of Surgery, the University of Hong Kong*)

O16-1 Changes of failure to rescue after gastrectomy: a 16-year experience of a large-volume center in Korea

Hyoung-II Kim (*Department of Surgery, Yonsei University, College of Medicine, South Korea*)

O16-2 Reflux esophagitis after laparoscopic pylorus-preserving gastrectomy for gastric cancer

Reiko Otake (*Department of Gastroenterological Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan*)

O16-3 Establishment and data quality control of a multicenter prospective database for the prevalence of abdominal complications after gastroenterological surgery

Qi Wang (*Department of Gastrointestinal Surgery, Peking University Cancer Hospital & Institute, Beijing, China*)

O16-4 Impact of complications on survival after laparoscopic versus open D2-gastrectomy for gastric cancer assessed using comprehensive complication index and Clavien-Dindo grading (LOGICA-trial)

Lianne Triemstra (*Department of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands*)

O16-5 Postoperative outcomes after laparoscopic versus open gastrectomy: European study on behalf of GASTRODATA group

Maria Bencivenga (*General and Upper GI Surgery Division, Department of Surgery, University of Verona, Verona, Italy*)

June 16 (Fri.) / 10:55-11:35 / Room 5 (414+415)

Oral 17 : Function preserving gastrectomy

Chair: Naoki Hiki (*Upper Gastrointestinal Surgery, Kitasato University School of Medicine, Japan*)

O17-1 Feasibility and safety of laparoscopic proximal gastrectomy with double flap technique for early gastric cancer: a phase II single-center, single-arm study

Fanghai Han (*Department of Gastrointestinal Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, China*)

O17-2 Should surgeon continue performing Billroth II with Braun anastomosis after distal gastrectomy? - comparison with Billroth II and Roux-en Y reconstruction: a multi-institutional study

Shin-Hoo Park (*Department of Surgery, Korea University, College of Medicine, Seoul, South Korea / Korea University Anam Hospital*)

O17-3 Long-term survival between laparoscopic proximal gastrectomy and laparoscopic total gastrectomy using a propensity score matching analysis

So Hyun Kang (*Seoul National University Bundang Hospital, South Korea*)

O17-4 The application of nerve monitoring to protect the vagus nerve in indocyanine green labeled radical gastrectomy for gastric cancer: a prospective, randomized controlled trial

Zhibo Yan (*Department of Gastrointestinal Surgery, Qilu hospital of Shandong University, China*)

O17-5 The application of intraoperative neurophysiologic testing and indocyanine green during laparoscopic distal gastrectomy in patients with gastric cancer: a prospective, randomized controlled trial

Zhibo Yan (*Department of Gastrointestinal Surgery, Qilu hospital of Shandong University, China*)

June 16 (Fri.) / 13:35-14:15 / Room 5 (414+415)

Oral 18 : Endoscopy

Chair: Kingo Hirasawa (*Division of Endoscopy, Yokohama City University Medical Center, Japan*)

O18-1 The relationship between the number of fundic gastric gland polyp and gastric neoplasm in patients with familial adenomatous polyposis

Haruka Nakamura (*Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan*)

O18-2 Delayed perforation after gastric endoscopic submucosal dissection: clinical features and management strategy

Tae-Se Kim (*Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea*)

O18-3 Intralesional cross-traction assisted gastric endoscopic submucosal dissection with silicon bands

Mitsuru Esaki (*Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan*)

O18-4 Is additional surgery necessary in all patients after non-curative resection by ESD for early gastric cancer in surgically altered stomach?

Tatsunori Minamide (*Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan*)

O18-5 Predictors of long-term outcomes of endoscopic submucosal dissection of early gastric neoplasia in the west

Mohamed Abdelrahim (*Portsmouth Hospitals NHS University Trust, United Kingdom*)

June 16 (Fri.) / 14:25-15:05 / Room 5 (414+415)

Oral 19 : Molecular biology

Chair: Hirofumi Kawakubo (*Department of Surgery, Keio University School of Medicine, Japan*)

O19-1 **JAK-STAT1 signaling pathway is an early response to Helicobacter pylori infection and contributes to immune escape and gastric carcinogenesis**

Xue Li (*Zhejiang Cancer Hospital, China / Department of Cancer Epidemiology, Peking University Cancer Hospital & Institute, Beijing, 100142, China / Institute for Medical Microbiology, Immunology and Hygiene, School of Medicine, Technical University of Munich (TUM), Munich, 81675, Germany*)

O19-2 **Gamma-aminobutyric acid type a receptor subunit delta as a potential therapeutic target in gastric cancer**

Takahiro Shinozuka (*Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan*)

O19-3 **YAP activation is a mechanism of tumor progression in poorly cohesive gastric cancer**

Maria Bencivenga (*Esophageal and Gastric Surgery Unit, Department of Surgery, University of Verona, Verona, Italy*)

O19-4 **TPL2 aids gastric cancer cell proliferation and chemoresistance through intensifying hypoxia/PPAR β axis**

Meei-Ling Sheu (*Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan / Ph.D. Program in Translational Medicine, Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, Taiwan / Department of Medical Research, Taichung Veterans General Hospital, Taiwan*)

O19-5 **Whole-genome sequencing in CDH1-negative patients with suspected hereditary gastric cancer**

Gianluca Tedaldi (*Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" , Meldola, Italy*)

June 16 (Fri.) / 9:02-9:50 / Room 6 (416+417)

Oral 20 : Robotic surgery 1

Chair: Woo Jin Hyung (*Yonsei University College of Medicine, Department of Surgery, Korea*)

O20-1 **Using a robotic system reduces intra-abdominal infectious complications in patients with visceral obesity and gastric cancer**

Naoshi Kubo (*Department of Gastroenterological Surgery, Osaka City General Hospital, Japan*)

O20-2 Analysis of hospital costs for robotic and open gastrectomy at a cancer center

Heather Lyu (*Department of Surgical Oncology, MD Anderson Cancer Center, Houston, TX, United States / MD Anderson Cancer Center, Houston, TX, USA*)

O20-3 A short-term outcome of minimally invasive surgery for treating advanced gastric cancer after preoperative chemotherapy

Masahiro Yura (*Gastric surgery Division, National Cancer Center Hospital East, Japan*)

O20-4 Intraoperative performance and outcomes of robotic and laparoscopic total gastrectomy for gastric cancer: a high-volume center retrospective propensity score matching study

Zhuoyu Jia (*The Affiliated Hospital of Qingdao University, Department of Gastrointestinal Surgery, China*)

O20-5 Patient-reported and clinical outcomes of locally advanced gastric cancer undergoing robotic versus laparoscopic gastrectomy: a high-volume single center randomized controlled study

Qingrui Wang (*The Department of Gastrointestinal Surgery, Affiliated Hospital of Qingdao University, China*)

O20-6 Feasibility of robotic double flap reconstruction after proximal gastrectomy for gastric cancer

Junya Aoyama (*Department of Surgery, Saiseikai Yokohamashi Tobu Hospital, Kanagawa, Japan*)

June 16 (Fri.) / 10:05-10:45 / Room 6 (416+417)

Oral 21 : Robotic surgery 2

Chair: Richard van Hillegersberg (*UMC Utrecht, Surgery, the Netherlands*)

O21-1 A new method of "gentle" liver elevation to secure a clear surgical view in robot assisted gastrectomy

Masashi Nishino (*Gastric Surgery Division, National Cancer Center Hospital, Tokyo, Japan*)

O21-2 Short-term outcome of robotic distal gastrectomy

Kazuhito Nabeshima (*Department of Gastroenterological Surgery, Tokai University, Isehara, Japan*)

O21-3 Dissection technique by SynchroSeal and mono-polar scissors in robotic gastrectomy

Takaki Yoshikawa (*The Department of Gastric Surgery, National Cancer Institute Hospital, Tokyo, Japan*)

O21-4 Hand-sewn robotic assisted esophagogastric anastomosis during minimally invasive Ivor Lewis esophagectomy: is it time to standardize the technique? The pavia proposal

Jacopo Viganò (*General Surgery 1, Fondazione IRCCS Policlinico San Matteo, Italy*)

O21-5 Reduced-ports robotic pylorus-preserving gastrectomy with intracorporeal hand-sewn gastro-gastrostomy for early gastric cancer

So Hyun Kang (*Seoul National University Bundang Hospital, South Korea*)

June 16 (Fri.) / 10:55-11:35 / Room 6 (416+417)

Oral 22 : Robotic surgery 3

Chair: Takahiro Kinoshita (*Department of Gastric Surgery, National Cancer Center Hospital East, Japan*)

O22-1 Short-term clinical outcomes after laparoscopic and robotic gastrectomy for gastric cancer: a propensity score matching analysis

Yanbing Zhou (*Department of General Surgery, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China*)

O22-2 Long-term oncologic outcomes of robotic total gastrectomy for advanced gastric cancer

Jawon Hwang (*Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea*)

O22-3 Safety assessment of robot-assisted gastrectomy for gastric cancer

Rie Makuuchi (*Department of Gastric Surgery, Cancer Institute Hospital of JFCR, Tokyo, Japan*)

O22-4 Minimally invasive total gastrectomy with spleen-preserving lymph node dissection of the splenic hilum for upper advanced gastric cancer

Junya Kitadani (*Second Department of Surgery, Wakayama Medical University, School of Medicine, Japan*)

O22-5 Clinical outcomes of robotic and laparoscopic gastrectomy using propensity score matching method : data of 5-year period in a Korean high-volume gastric cancer center

Seong-Ho Kong (*Department of Surgery, Seoul National University Hospital, Seoul, South Korea / Department of Surgery, Seoul National University College of Medicine, Seoul, Korea*)

June 16 (Fri.) / 13:35-14:15 / Room 6 (416+417)

Oral 23 : Surgery 3

Chair: Naruhiko Ikoma (*University of Texas M.D. Anderson Cancer Center, U.S.A.*)

O23-1 Peritoneal elastic laminal invasion of gastric cancer

Daiki Terajima (*Gastric Surgery Division, National Cancer Center Hospital East, Kashiwa, Japan*)

O23-2 Factors affecting the survival of clinical T4b gastric cancer in the era of multimodal treatment. A nationwide multicentre retrospective study of the Italian research group for gastric cancer

Lucia Puca (*University of Turin, Italy*)

O23-3 Impact of remnant positive cytology (CY1) at conversion surgery following chemotherapy for stage IV gastric cancer

Kazuyoshi Yamamoto (*Department of Gastroenterological Surgery, Osaka University, Japan*)

O23-4 Overview of surgical treatment of Western gastric cancer: a prospective multicentric study in Brazil

Marcus Fernando Kodama Pertille Ramos (*Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Brazil*)

O23-5 Clinical impact of positive surgical margins in gastric adenocarcinoma in the era of preoperative therapy

Yuki Hirata (*Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States / Department of Surgery, Keio University School of Medicine*)

June 16 (Fri.) / 14:25-15:05 / Room 6 (416+417)

Oral 24 : Surgery 4

Chair: Franco Roviello (*Surgical Oncology, University of Siena, Italy*)

O24-1 Efficacy of chemotherapy combined with surgical resection for gastric cancer with ovarian metastasis: a propensity score matching analysis

Jingquan Fang (*Department of Gastric Surgery, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Zhejiang, China*)

O24-2 The comparison of survival after gastrectomy with or without aberrant left hepatic artery preservation in gastric cancer patients with metastatic lymph node

Ji Eun Jung (*Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea*)

O24-3 Defining Benchmarks for Oncological Gastrectomy - A Global Multicenter Analysis

Jeesun Sunny Kim (*Department of Surgery, Seoul National University Hospital, Seoul, South Korea*)

O24-4 Predictive value of radiologic response (RECIST) and prognostic value of pathologic response (Mandard TRG) for curative-intent surgery in stage IV gastric cancer

Se Yeol Oh (*Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea*)

O24-5 Outcomes of the conversion surgery for gastric cancer with unresectable peritoneal metastasis in our hospital

Shinta Tominaga (*Second Department of Surgery Wakayama Medical University, Japan*)

June 16 (Fri.) / 16:00-16:40 / Room 6 (416+417)

Oral 25 : Chemotherapy

Chair: Kenro Hirata (*Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Japan*)

O25-1 Tolerability of adjuvant chemotherapy with TS-1 or XELOX regimen in elderly patients with stage II or III gastric cancer after D2 gastrectomy

Hee Seok Moon (*Division of Gastroenterology, Department of Internal Medicine, Chungnam National University School of Medicine, South Korea*)

O25-2 Clinical progress in inoperable or recurrent advanced HER2-positive gastric cancer treatment from single institute experiences between 2011 and 2018

Izuma Nakayama (*Department of Gastrointestinal Chemotherapy, Cancer Institute Hospital of the JFCR, Japan*)

O25-3 A phase II single-center single-arm study of PD-1 inhibitor in combination with albumin paclitaxel and apatinib as second-line treatment of metastatic gastric cancer (mGC)

Miaomiao Gou (*Oncology Department of Chinese PLA General Hospital, China*)

O25-4 Withdrawn

O25-5 Phase IB/II trial of combining intraperitoneal chemotherapy and cytoreductive surgery for peritoneal metastasis

Minah Cho (*Department of Surgery, Yonsei University College of Medicine, Seoul, South Korea / Gastric Cancer Center, Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea*)

June 16 (Fri.) / 16:50-17:22 / Room 6 (416+417)

Oral 26 : Clinical study

Chair: Sun Young Rha (*Medical Oncology, Yonsei Cancer Center, Yonsei University Health System, Korea*)

O26-1 A phase 2 study of tislelizumab and bevacizumab in combination with CAPOX as first-line treatment of metastatic gastroesophageal adenocarcinoma with PD-L1 CPS<5

Ru Jia (*Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, China*)

O26-2 D2 radical resection with hyperthermic intraperitoneal chemotherapy(HIPEC) plus systemic chemotherapy vs. Systemic chemotherapy alone in advanced gastric cancer: a randomized controlled trial

Xingmao Huang (*Department of Gastric Surgery, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, China*)

O26-3 Efficacy and safety of camelizumab combined with FLOT in neoadjuvant therapy of locally advanced gastric

Zi Min Liu (*The Affiliated Hospital of Qingdao University, China*)

O26-4 A phase I/II study of ASKB589 (Anti-Claudin 18.2 (CLDN18.2) monoclonal antibody) in patients with solid tumors

Miao Zhang (*Beijing Cancer Hospital, Beijing, China*)

June 17 (Sat.) / 8:40-9:20 / Room 5 (414+415)

Oral 27 : Surgical innovation

Chair: Naruhiko Ikoma (*Surgical Oncology, UT MD Anderson Cancer Center, U.S.A.*)

O27-1 Deep learning-based whole-slide image analysis for the prediction of lymph node metastasis in early gastric cancer

Yujun Park (*Department of Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, South Korea*)

O27-2 Development of an artificial intelligence system in laparoscopic gastrectomy for gastric cancer

Yoshimasa Aoyama (*Department of Gastroenterological and Pediatric Surgery, Oita University Faculty of Medicine, Japan*)

O27-3 Importance of human-machine interaction in detection of Barrett's neoplasia using a novel deep neural network in the evolving era of artificial intelligence

Hein Htet (*Department of Gastroenterology, Queen Alexandra Hospital, Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom*)

O27-4 Development of a tongue image-based machine learning tool for the diagnosis of gastric cancer: a prospective multicentre clinical study

Li Yuan (*Department of Gastric surgery, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China*)

O27-5 Calculation of residual gastric body of gastrectomies using 3D volume rendering tech

Jiyeon Shin (*Cancer Research Institute, Seoul National University, Seoul, South Korea*)

June 17 (Sat.) / 9:30-10:10 / Room 5 (414+415)

Oral 28 : QOL & Biomarker

Chair: Masanori Tokunaga (*Gastrointestinal Surgery, Tokyo Medical and Dental University, Japan*)

O28-1 The relationship between preoperative quality of life and postoperative morbidity in patients undergoing gastrectomy

Sung Eun Kim (*Division of Gastroenterologic Surgery, Department of Surgery, Chonnam National University Hwasun Hospital, Jeollanam-do, South Korea*)

O28-2 Postoperative symptom recovery after gastrectomy

Pamela Lu (*University of Texas MD Anderson Cancer Center, Department of Surgical Oncology, United States*)

O28-3 Persistent postgastrectomy hypoglycemia unawareness in patients with gastric cancer

Takeshi Kubota (*Department of Digestive Surgery, Kyoto Prefectural University of Medicine, Japan*)

O28-4 Single-incision laparoscopic distal gastrectomy improves postoperative quality of life for early gastric cancer

Mira Yoo (*Department of Surgery, Seoul National University Bundang Hospital, Seongnam, South Korea*)

O28-5 Association of D-dimer/soluble fibrin with disease stage, systemic inflammatory and nutritional status in gastric cancer

Ken Hagiwara (*Division of Digestive Surgery, Department of Surgery, Nihon University School of Medicine, Tokyo, Japan*)

June 17 (Sat.) / 10:30-11:10 / Room 5 (414+415)

Oral 29 : Laparoscopic surgery 1

Chair: Naoki Hiki (*Upper Gastrointestinal Surgery, Kitasato University, Japan*)

O29-1 Modified technique of overlap method for esophagojejunostomy after laparoscopic total gastrectomy

Xiaohua Jiang (*Shanghai East Hospital, Tongji University, Shanghai, China*)

O29-2 Multicenter randomized controlled trial about no antimicrobial prophylaxis for patients undergoing totally laparoscopic distal gastrectomy for gastric carcinoma (KSWEET 03 trial)

Mi Ran Jung (*Department of Surgery, Chonnam National University Medical School, Gwangju, South Korea*)

O29-3 Safety and efficacy of single or reduced ports laparoscopic gastrectomy for advanced gastric cancer (SPACE-01) : phase II clinical trial

Eunju Lee (*Department of Surgery, Seoul National University Bundang Hospital, Seongnam-Si, South Korea*)

O29-4 Intraoperative portable radiography for tumor localization of gastric cancer: a novel technique to enhance accuracy and convenience

Joong-Min Park (*Department of Surgery, Chung-Ang University Gwang-Myeong Hospital, Gwangmyeong, South Korea*)

O29-5 Systematization of laparoscopic D2 total gastrectomy in locally advanced gastric cancer

Flávio Silano (*Hospital Aliança / Rede D'or São Luiz, Brazil*)

O29-6 Is there an ideal operating time range that determines the perfectness in laparoscopic gastrectomy?

Ahmad Salem AlRomi (*Ministry of Health Jordan, Jordan / Division of Foregut Surgery, Korea University Anam Hospital, Korea*)

June 17 (Sat.) / 11:20-12:00 / Room 5 (414+415)

Oral 30 : Laparoscopic surgery 2

Chair: Tomoyuki Irino (*Department of Surgery, Keio University School of Medicine, Japan*)

O30-1 Cost-effectiveness of multi-degree of freedom articulating laparoscopic instrument in gastric cancer surgery compared with robotic gastrectomy: Phase II study in a single center

Yeojin Boo (*Department of Surgery, Ajou University School of Medicine, Suwon, South Korea*)

O30-2 Nodes station photo-evaluation for the definition of a proper linfoadenectomy in gastric cancer surgery-PhotoNodes Study

Giorgio Dalmonte (*General Surgery Unit, University Hospital of Parma, Italy / Italian Research Group for Gastric Cancer (GIRCG)*)

O30-3 Intracorporeal hand sewing anastomosis in laparoscopic D2 total gastrectomy for gastric cancer

Veronika Patsko (*National Cancer Institute, Kyiv, Ukraine*)

O30-4 Short-and long-term comparison of robotic and laparoscopic gastrectomy for gastric cancer by the same surgical team: a propensity score matching analysis

Yulong Tian (*Department of General Surgery, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China*)

O30-5 Application of pai shaped esophagojejunostomy in totally laparoscopic total gastrectomy for gastric cancer: a study of 241 cases and short term outcomes

Li Yang (*Division of Gastric Surgery, Department of General Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China*)

June 17 (Sat.) / 8:40-9:20 / Room 6 (416+417)

Oral 31 : Nutrition

Chair: Simon Law (*Department of Surgery, the University of Hong Kong*)

O31-1 Comparison of laboratory results between vitamin B12 replacement intervals after total gastrectomy

Sin Hye Park (*Center for Gastric Cancer, National Cancer Center, Goyang, South Korea*)

O31-2 Impact of preoperative prealbumin on overall survival in patients with gastric cancer after gastrectomy

Ryota Matsui (*Department of Gastroenterological Surgery, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan*)

O31-3 Impact total psoas volume on long-term outcomes in patients undergoing curative resection for gastric cancer

Yuto Maeda (*Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan*)

O31-4 Development and internal/external validation of a prediction model for weight loss following gastric cancer surgery: a multicenter retrospective study

Ji-Hyeon Park (*Department of Surgery, Seoul National University Hospital, Seoul, South Korea / Department of Surgery, Gachon University Gil Medical Center, Incheon, Korea*)

031-5 Phase II study of a multi-center randomized controlled trial to evaluate oral Vitamin B12 treatment for Vitamin B12 deficiency after total gastrectomy in gastric cancer patients

Toru Aoyama (*Department of Surgery, Yokohama City University, Japan / Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan*)

June 17 (Sat.) / 9:30-10:10 / Room 6 (416+417)

Oral 32 : Surgery 5

Chair: Giovanni de Manzoni (*Department of Surgery, Dentistry, Paediatrics and Gynaecology, University of Verona, Italy*)

032-1 Indications and significance of upper mediastinal and cervical lymph node dissection for esophagogastric junction cancer in subtotal esophagectomy

Kenjiro Ishii (*Division of Esophageal surgery, Shizuoka cancer center, Japan*)

032-2 Omentectomy as part of radical surgery for gastric cancer: 5-year follow-up results of a multicenter prospective cohort study

Kammy Keywani (*Department of Surgery, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands*)

032-3 Oligometastatic gastric cancer. The anatomic definition by the META-GASTRO prospective observational register of the Italian research group on gastric cancer (GIRCG). Focus on P and H

Silvia Ministrini (*Department of clinical and sperimental sciences, University of Brescia, Italy*)

032-4 Survival after mutivisceral resection in gastric adenocarcinoma

Anna Clara Hebling Mitidieri (*Santa Casa of Sao Paulo, Medical School and Hospital, Department of Surgery, Gastroesophageal and Bariatric Division, Brazil*)

032-5 Short-term outcomes of robot-assisted vs laparoscopic total gastrectomy: a single-center retrospective cohort study using a propensity score matching

Hiromi Nagata (*National Cancer Center Hospital East, Chiba, Japan*)

June 17 (Sat.) / 10:30-11:10 / Room 6 (416+417)

Oral 33 : Surgery 6

Chair: Stefan Paul Mönig (*Upper-GI-Surgery University Hospital of Geneva, Rue Gabrielle-Perret-Gentil 4, Switzerland*)

O33-1 Is suprapancreatic nodal (#8a, #9, and #11) dissection uniformly needed in additional gastrectomy for the patients diagnosed as pT1b?

Tsutomu Hayashi (*Department of Gastric Surgery, National Cancer Center Hospital, Japan*)

O33-2 Factors for ensuring sufficient proximal margin in early gastric cancer

Sun-Hwi Hwang (*Department of Surgery, Pusan National University Yangsan Hospital, South Korea / Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan-si, Gyeongsangnam-do 50612, Republic of Korea*)

O33-3 LECS in Italy? Yes, we can! Reproducibility of a Japanese-style surgical and endoscopic resection procedure for gastric submucosal tumors in a western setting

Jacopo Viganò (*General Surgery 1, Fondazione IRCCS Policlinico San Matteo, Italy*)

O33-4 Laparoscopy endoscopy cooperative surgery for superficial non ampullary duodenal epithelial tumors

Masaru Hayami (*Department of Gastroenterological Surgery, Cancer Institute Hospital, Tokyo, Japan*)

O33-5 Preliminary report of Non-exposure simple suturing endoscopic full-thickness resection (NESS-EFTR) for early gastric cancer (SENORITA 3 phase 2 study)

Chan Gyoo Kim (*Center for Gastric Cancer, National Cancer Center, Goyang, South Korea*)

June 17 (Sat.) / 11:20-12:00 / Room 6 (416+417)

Oral 34 : Molecular biology & Biomarker

Chair: Daisuke Ichikawa (*First Department of Surgery, University of Yamanashi, Japan*)

O34-1 Unique microbial biomarkers identified in Japanese patients with gastric cancer

Miseker Eshetu Abate (*Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, United States*)

O34-2 Predicting response to immunotherapy in gastric cancer via assessing perineural invasion-mediated inflammation in tumor microenvironment

Xunjun Li (*Southern Medical University, China*)

O34-3 Identification of prognostic gene expression signatures based on tumor microenvironment characterization of gastric cancer

Qingqing Sang (*Department of General Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China*)

O34-4 Tenascin C in tumor stroma is a predictive marker for recurrence in upper gastrointestinal cancers

Tomohiro Murakami (*Department of Surgery, Hamamatsu University School of Medicine, Japan*)

O34-5 CD47-targeted immunotherapy sparks macrophage antitumor response in Epstein-Barr virus-associated gastric cancer

Dazhi Xu (*Department of Gastric Cancer Surgery, Fudan University Shanghai Cancer Center, Shanghai, China*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 1 : Epidemiology

P1-1 Local Epstein-Barr virus infection as a causal factor of gastric cancer: a rapid meta-analysis

Xin-Zu Chen (*West China Hospital, Sichuan University, Chengdu, China*)

P1-2 miR-29c inhibits metastasis of gastric cancer cells by targeting VEGFA

Beiqin Yu (*Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China*)

P1-3 Acceptance and willingness-to-pay for endoscopic screening among high-risk populations for upper digestive tract cancer in urban China

Juan Zhu (*Zhejiang Cancer Hospital, China*)

P1-4 Withdrawn

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 1 : Epidemiology

P1-5 Helicobacter pylori prevalence declined in southwest China through massive screening: longitudinal analysis on multiple cross-sectional studies (SIGES)

Xin-Zu Chen (*Gastric Cancer Center, West China Hospital, Sichuan University, China*)

P1-6 Current status of gastric cancer in regional core hospital from the viewpoint of Hospital-based cancer registry

Toshihiro Tajirika (*Department of Surgery, Matsunami General Hospital, Gifu, Japan*)

P1-7 A analysis on the clinicopathological features of Han nationality and Tong nationality patients with gastric cancer in the border area of Hunan, Guangxi and Guizhou (1080 cases report)

Chaohui Zuo (*The Affiliated Cancer Hospital of Xiangya School of Medicine & Hunan Cancer Hospital, Central South University, China*)

P1-8 Surgical efficacy of radical gastrectomy combined with modified gastric bypass surgery for the treatment of gastric cancer with type 2 diabetes mellitu and its prognostic impact factors

Chaohui Zuo (*The Affiliated Cancer Hospital of Xiangya School of Medicine & Hunan Cancer Hospital, Central South University, China*)

Poster 2 : Molecular biology

- P2-1 The deubiquitinase USP15 drives malignant progression of gastric cancer through glucose metabolism remodeling**
Longtao Huangfu (*Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Division of Gastrointestinal Cancer Translational Research Laboratory, Peking University Cancer Hospital & Institute, Beijing, China*)
- P2-2 Identification of lncRNAs by microarray analysis in gastric cancer with peritoneal metastasis**
Juhee Lee (*Department of Surgery, Hanyang University College of Medicine, South Korea*)
- P2-3 MiR-373-3p inhibits proliferation, invasion and stemness of gastric cancer by targeting CD44**
Benlong Zhang (*Department of General Surgery, the First Medical Center of Chinese PLA General Hospital, Beijing, China*)
- P2-4 MicroRNA-15a-5p regulates wnt/beta-catenin pathway to suppress gastric cancer stemness through targeting Pyruvate Dehydrogenase Kinase 4**
Xingyu Chen (*Department of General Surgery, The Affiliated Wuxi NO.2 People's Hospital of Nanjing Medical University, Wuxi, China*)
- P2-5 Knockdown of PDK4 suppresses cell proliferation and promotes cell death in gastric cancer**
Huiheng Qu (*The Department of General Surgery, Wuxi Second People's Hospital Affiliated to Jiangnan University, Wuxi, China*)
- P2-6 SLC7A9 suppression induces ferroptosis in gastric cancer via inhibiting cysteine transportation and GPX4 synthesis**
Bingya Liu (*Shanghai Institute of Digestive surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China*)
- P2-7 LncRNA LINC00667 regulates PDK4 to promote gastric cancer progression through sponging miR-148a-3p**
Ziyuan Liu (*Department of General Surgery, The Affiliated Wuxi NO.2 People's Hospital of Nanjing Medical University, Wuxi, China*)
- P2-8 KLRG2 regulates malignant phenotypes of gastric cancer via MAPK-ERK1/2 pathway**
Yuki Ito (*Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan*)

P2-9 Antifungal agent terbinafine prevents tumor growth through downstream hedgehog pathway in gastric cancer

Hao Liu (*Department of General Surgery & Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, Guangzhou, China / Department of Health Management, Nanfang Hospital, Southern Medical University, Guangzhou, China*)

P2-10 MRAP2 promotes gastric cancer cell proliferation and inhibits apoptosis by promoting GALNT7/P-ERK

Xiujuan Qu (*Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China*)

P2-11 Exosomal UBE3B from gastric cancer promotes peritoneal metastasis of gastric cancer by inducing peritoneal "niche" through KRT1

Xiujuan Qu (*Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 2 : Molecular biology

P2-12 Circular RNA hsa_circ_0110389 promotes gastric cancer progression through upregulating SORT1 via sponging miR-127-5p and miR-136-5p

Min Liang (*The Fifth Affiliated Hospital of Guangzhou Medical University, China*)

P2-13 Prognostic value of HER2-low expression in gastric cancer

Yi-Lin Chang (*Changhua Christian Hospital, Taiwan*)

P2-14 Downregulation of THBS2 suppresses tumorigenicity and liver metastasis of gastric cancer and increases its sensitivity to trastuzumab

Zhengyao Chang (*General Surgery Department, Chinese PLA General Hospital, Beijing, China*)

P2-15 NSUN2-mediated RNA 5-methylcytosine promotes gastric cancer progression via ALYREF-dependent PDE3A mRNA export

Jialun Lv (*Department of General Surgery, the First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, Jiangsu Province, China*)

P2-16 TRIM29 promotes antitumor immunity through enhancing IGF2BP1 ubiquitination and subsequent PD-L1 downregulation in gastric cancer

Tianlu Jiang (*Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China*)

- P2-17 Characteristics of targeted sequencing circulating tumor DNA in resectable advanced gastric adenocarcinoma**
Nguyen Thuy Doan (*The Gastro-Intestinal Surgery Department, University Medical Center, Ho Chi Minh city, Vietnam*)
- P2-18 Peptide IREB2-268aa encoded by circIREB2 promotes gastric cancer progression via resistance of ferroptosis**
Zai Luo (*Department of Gastrointestinal Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China*)
- P2-19 Resident memory Tcell is associated with favorable prognosis in lymphnode metastasis of gastric cancer**
Masaki Nishiyama (*Department of Gastroenterological Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan*)
- P2-20 Spontaneous vasomotion in human arteries and their ion channel-based mechanism in the smooth muscle**
Dae Hoon Kim (*The Department of Surgery, Chungbuk National University, Cheongju-si, South Korea*)
- P2-21 Withdrawn**
- P2-22 Gastric cancer prevention: An educational action**
Suzana Tyrrasch de Almeida (*Professor of Medicine Federal University of Pernambuco, Brazil*)
- P2-23 The effectiveness of mobile application-based postoperative supportive care after gastrectomy for gastric cancer patients: a pilot study**
Ji-Hyeon Park (*Department of Surgery, Seoul National University Hospital, Seoul, South Korea / Department of Surgery, Gachon University Gil Medical Center, Incheon, Korea*)
- P2-24 MUC1 expressions and its prognostic values in US gastric cancer patients**
Young-Il Kim (*Center for Gastric Cancer, National Cancer Center, Goyang, South Korea / Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas*)
- P2-25 Effect of the COVID-19 pandemic on the surgical treatment of gastric cancer after 2 years**
Marcus Fernando Kodama Pertille Ramos (*Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Brazil*)
- P2-26 Creation of gastric cancer assembloids for drug testing in cancer therapy**
Xinxin Xu (*General Surgery Department and Bio-therapeutic Department, Chinese PLA General Hospital, Beijing, China*)

P2-27 Textbook oncological outcome for gastric adenocarcinoma in a single Western center

Marco Realis Luc (*Digestive Surgery, European Institute of Oncology IRCCS, Milan, Italy*)

P2-28 The analysis and gene expression of esophagogastric junction cancer stem cells

Hiroyuki Inoue (*Division of Digestive Surgery, Department of Surgery, Japan*)

P2-29 The important role of CACNA2D1 in gastric cancer and its potential as a therapeutic target

Naosuke Nakamichi (*Division of Digestive Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 3 : Pathology

P3-1 Withdrawn

P3-2 Association of ARID1A expression with genetic changes and histological type in gastric cancer

Takahisa Nakayama (*Division of Human Pathology, Department of Pathology, Shiga University of Medical Science, Shiga, Japan*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 3 : Pathology

P3-3 Effect of neoadjuvant chemotherapy on the histopathological classification of gastric cancer

Irene Arianne Caspers (*Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands / Department of Pathology, Amsterdam University Medical Centers, Cancer Center Amsterdam, Amsterdam, The Netherlands*)

P3-4 What is the meaning of signet ring cell carcinoma component in Epstein-Barr virus-associated gastric cancer?

An Na Seo (*Department of pathology, School of Medicine, Kyungpook National University, Daegu, South Korea*)

P3-5 Mucinous type gastric cancer: a distinct entity with clinical impact

Irene Arianne Caspers (*Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands / Dept. of Pathology, Amsterdam UMC, Cancer Center Amsterdam, Amsterdam, the Netherlands*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 4 : Genomics

P4-1 Pangenomic analysis of Chinese gastric cancer

Yingyan Yu (*Department of General Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, China*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 5 : Translational research

P5-1 Effect of doublet treatment versus single-agent treatment in gastric cancers with/without MET amplification or a MET exon 14 skipping mutation

Dae Young Zang (*The first Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, South Korea / Hallym Translational Research Institute*)

P5-2 CD40-HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer

Weiin Sun (*Tianjin medical university general hospital, Tianjin, China*)

P5-3 Serum IL-6 level predicts survival and treatment response in gastric and gastroesophageal junction cancer

John D. Karalis (*Department of Surgery, University of Texas Southwestern Medical Center, Dallas, Texas, United States*)

P5-4 Integrin β 6 serves as a potential prognostic serum biomarker for gastric cancer

Zequn Li (*Department of General Surgery, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China*)

P5-5 Molecular characterization of submucosa-penetrating early gastric cancers with different prognoses

Leonardo Solaini (*Department of Medical and Surgical Sciences, University of Bologna, Italy*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 5 : Translational research

P5-6 New biomarkers of response to chemotherapy in locally advanced gastric cancer patients

Chiara Molinari (*IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) «Dino Amadori», Biosciences Laboratory, Meldola, Italy*)

P5-7 Elucidating the role of the transcription factors SOX5 and Twist1 in the resistance to chemotherapy in two different gastric cancer cell lines

Maher Musleh (*Department of Surgery, University of Chile, Clinical Hospital, Chile / Department of Basic and clinic Oncology, School of medicine, University of Chile*)

P5-8 Targeting the YAP/TAZ-TEAD pathway in diffuse gastric cancer

Ryan Hideki Moy (*Department of Medicine, Division of Hematology/Oncology, Columbia University Irving Medical Center, New York, NY, United States*)

P5-9 Patient derived gastric cancer organoids with stromal components used in drug resistance and sensitivity platform reveal potentiation of chemotherapeutics by MEK1/2 inhibitor

Pauli Antero Puolakkainen (*Dept. of Surgery, University of Helsinki, Finland*)

P5-10 KRAS activation in gastric cancer stem-like cells promotes tumor angiogenesis and metastasis

Sam Sunghyun Yoon (*Columbia University Irving Medical Center, United States*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 6 : Biomarker

P6-1 The clinico-pathological significance of Kinesin family member 18B in gastric cancer

Akira Ishikawa (*Department of Molecular Pathology, Hiroshima University, Hiroshima, Japan*)

P6-2 Identification of stool protein biomarkers for the early detection of gastric cancer

Chi-Lee Charlie Ho (*Department of Surgery, Columbia University Irving Medical Center, United States / Cell and Molecular Biology Program, University of Pennsylvania Perelman School of Medicine*)

P6-3 HSA_CIRC_0008434 regulates USP9X expression by sponging miR-6838 to promote gastric cancer progression

Jiwei Yu (*Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, China*)

P6-4 **Withdrawn**

P6-5 **Memorial Sloan Kettering Prognostic Score (MPS) is a predictive index for survival in patients with advanced gastric cancer: a retrospective study**

Mingyu Wan (*Department of Medical Oncology, The First Affiliated Hospital of Zhejiang University, Hangzhou, China*)

P6-6 **Identification of the lysosomal autophagy related prognostic gene signature in stomach adenocarcinoma**

Qiong Wang (*No.1 Medical Center, Chinese PLA General Hospital, China*)

P6-7 **The application of nucleic acid probe detects CLDN 18.2 for precision medicine in stomach cancer**

Xiaoyi Chong (*Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/ Beijing), Peking University Cancer Hospital and Institute, China*)

P6-8 **A novel TNFAIP8L1-based nomogram for predicting overall survival in stage II and III colon cancer**

Hao Yang (*Department of Gastrointestinal Surgery, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, China*)

P6-9 **Relationship between TRPV2 and PD-L1 expression in gastric cancer and its clinical significance**

Tomoyuki Fukami (*Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan*)

P6-10 **Correlation and clinicopathological value of integrin alpha6 and Rac1 expression in gastric cancer**

Junjian Yu (*The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 6 : Biomarker

P6-11 **Analysis of prognostic factors for adenocarcinoma of the esophagogastric junction (AEG)**

Shintaro Uchida (*Gunma University Graduate School of Medicine, Department of General Surgical Science, Gunma, Japan*)

P6-12 **Helicobacter pylori infected gastric cancer cells derived small extracellular vesicles induce lymphangiogenesis and lymphatic remodeling via selectively carrying miR-1246**

Chen Lu (*Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China*)

- P6-13 Development and validation of an individualized m6A regulatory gene pairs prognostic signature in gastric cancer**
Zhouqiao Wu (*Gastrointestinal Cancer Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China*)
- P6-14 Caspases and survivin in gastric cancer patient in Poland**
Ewelina Frejlich (*2nd Department of General surgery and surgical Oncology, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland*)
- P6-15 Identification of hub genes associated with prognosis, miRNA, immune infiltration cells, and therapeutic drug in gastric cancer by integrated analysis**
Xinyi Lei (*Zhejiang Cancer Hospital, China*)
- P6-16 Discovery of MUC-16 as a serum-based prognostic indicator of pro-metastatic gastric cancer**
Jieun Lee (*Department of Surgery, Seoul National University Bundang Hospital, Gyeonggi-do, South Korea*)
- P6-17 A novel risk model construction and immune landscape analysis of gastric cancer based on cuproptosis-related long noncoding RNAs**
Yuanhang Wang (*Department of General Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China*)
- P6-18 Correlation phenotype of immunosuppressive molecule between peripheral blood and gastric tissues of patients with gastric cancer**
So Jung Kim (*Division of Gastrointestinal Surgery, Department of Surgery, College of medicine, The Catholic University of Korea, Seoul, South Korea*)
- P6-19 Clinical significance of GRIIm-score in esophagogastric junction cancer**
Makoto Sohda (*Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan*)
- P6-20 The efficacy of 3D deformable microfilter with a DNA aptamer for detecting CTC For gastric cancer**
Masaaki Iwatsuki (*Department of Gastroenterological Surgery, Kumamoto University, Japan*)
- P6-21 Impact of HER-2 expression and MSI status on prognosis of advanced gastric cancer submitted to neoadjuvant/conversion chemotherapy and surgery: a single Western center study**
Stefania Angela Piccioni (*Unit of General Surgery and Surgical Oncology, Department of Medicine, Surgery and Neurosciences, University of Siena, Policlinico Le Scotte, Siena, Italy*)

P6-22 Study of circulating tumor cell DNA in predicting postoperative recurrence of gastric cancer

Lu Liu (*The first Medical Center of PLA General Hospital Beijing, China*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 7 : Tumor microenvironment

P7-1 The immune features of tumor microenvironment in CD147-positive gastric cancer

Keren Jia (*Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, China*)

P7-2 Dasatinib improves prognosis of epithelial-mesenchymal transition (EMT), angiogenesis and hypoxic subtypes of gastric cancer by affecting cancer-associated fibroblasts

Zedong Li (*Department of Gastric Cancer Center, West China Hospital, Sichuan University, Chengdu, China*)

P7-3 Withdrawn

P7-4 Dynamic single-cell mapping unveils Epstein-Barr virus-imprinted T-cell exhaustion and treatment response

Miaozhen Qiu (*Sun Yat-sen University Cancer Center, China*)

P7-5 Infiltration of T cells in tumor microenvironment are associated with intratumoral microbiota in gastric cancer

Can Hu (*Department of Gastric surgery, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institutes of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China*)

P7-6 TM7SF3 as a novel prognostic biomarker and associated with M2 macrophages infiltration in gastric cancer

Zhenzhan Zhang (*Department of General Surgery & Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, Guangzhou, China / Department of Health Management, Nanfang Hospital, Southern Medical University, Guangzhou, China*)

P7-7 Integrated analysis to identify and validation of a novel integrins-related molecular pattern as a prognostic signature for gastric cancer

Yilin Hu (*Department of Gastrointestinal Surgery, Affiliated Hospital of Nantong University, Jiangsu, China*)

Poster 7 : Tumor microenvironment

P7-8 Calculated tumor-associated neutrophils are associated with tumor-stroma ratio and predict poor prognosis in advanced gastric cancer

Eun Young Kim (*Department of Surgery, Uijeongbu St. Mary Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea*)

P7-9 Identification of T cell-mediated tumor-killing and construction of a practical prognosis signature for immunotherapeutic efficacy on gastric cancer

Yu Peng Zhao (*Nanjing Medical University, NanJing, China*)

P7-10 Characterization of glycometabolism and tumor immune microenvironment for predicting clinical outcomes and therapeutic responses in gastric cancer

Jinyao Shi (*Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China*)

P7-11 Prognostic impact of alfa-SMA and podoplanin in gastric cancer stroma

Kazunori Takahashi (*The First Department of Surgery, University of Yamanashi, Yamanashi, Japan*)

P7-12 MSC-induced NPRA drives fatty acid oxidation to promote stemness and chemoresistance of gastric cancer

Zetian Chen (*Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, Jiangsu Province, China*)

P7-13 GC cell-derived exosomes mediate CXCL8 secretion in macrophages to promote immune escape from NK cells

Mingyu Huo (*The seventh affiliated hospital of Sun Yat-sen University, China*)

P7-14 Prognostic implications of tumor-infiltrating lymphocytes within the tumor microenvironment in gastric cancer

Marina Alessandra Pereira (*Instituto do Cancer, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo - Departament of Gastroenterology, Brazil*)

P7-15 An EBNA1-YAP-CD276 signaling axis drives immune escape in EBV-associated gastric cancer

Binhao Huang (*Department of Gastric Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China / Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China*)

P7-16 A risk model based on cuproptosis-related genes for predicting prognosis in Asian gastric cancer patients

Hongxin Huang (*The First Affiliated Hospital of Nanjing Medical University, China*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 8 : AI

P8-1 A development of artificial intelligence system for estimating blood loss during laparoscopic gastric cancer surgery

Mira Yoo (*Department of Surgery, Seoul National University Bundang Hospital, Seongnam, South Korea*)

P8-2 Neoplasia detection by AI is more than finding lumps and bumps in the mucosa: performance of a dedicated Barrett's CADe for detection of gastric neoplasia

Katie Siggins (*Portsmouth Hospital University NHS Trust, Portsmouth, United Kingdom*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 8 : AI

P8-3 Implementation of information support for patients with gastric cancer. Our center experience

Natalia Boiko (*Saint Petersburg State University, Russia*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 9 : Endoscopic therapy

P9-1 Comparison between surgery and ESD for EGC in a European tertiary referral center

Fausto Rosa (*Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy*)

P9-2 Feasibility of same-day discharge following endoscopic submucosal dissection for esophageal or gastric early cancer

Shijie Li (*Department of endoscopy, Peking University Cancer Hospital, Beijing, China*)

P9-3 Renal dysfunction may not increase bleeding after endoscopic submucosal dissection: a propensity matched analysis

Tae-Se Kim (*Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea*)

P9-4 Outcomes of endoscopic resection for early gastric cancer in very elderly patients

Tae Jun Kim (*Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea*)

P9-5 Local recurrence after endoscopic submucosal dissection of early gastric cancer

Cheol Woong Choi (*Pusan National University Yangsan Hospital, South Korea*)

P9-6 Proper size and timing of endoscopic dilation in anastomotic stricture after near-total esophagectomy

Dae Gon Ryu (*Department of Internal Medicine, Pusan National University School of Medicine and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, South Korea*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 9 : Endoscopic therapy

P9-7 Larger ESD: an alternative tactic in a cirrhotic patient previously submitted to azygos portal disconnection

Anna Clara Hebling Mitidieri (*Department of Surgery Gastroesophageal and Bariatric Division, Santa Casa of Sao Paulo, Medical School and Hospital, Brazil*)

P9-8 Hemostatic ability of spray coagulation mode in endoscopic submucosal dissection for early gastric neoplasms

Kosuke Maehara (*Department of Gastroenterology, Kitakyushu Municipal Medical Center, Fukuoka, Japan*)

P9-9 Endoscopic treatment outcomes of fundic-gland type epithelial tumors comparing with conventional gastric tumors

Tetsuya Suwa (*Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan*)

P9-10 Endoscopic submucosal dissection for gastric superficial neoplastic lesions: a single center experience

Pietro Soru (*Division of Endoscopy, European Institute of Oncology, IRCCS, Milan, Italy*)

P9-11 Conventional versus traction-assisted endoscopic submucosal dissection for upper gastrointestinal lesions- Retrospective review of a local institution

Choi Kwan So (*Department of General Surgery, United Christian Hospital, Hong Kong S.A.R., China*)

P9-12 Antithrombotic therapy increases bleeding after endoscopic submucosal dissection: a propensity matched analysis

Byung-Hoon Min (*Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 10 : Endoscopic diagnosis

P10-1 Difference between reddish and non-reddish gastric neuroendocrine tumor

Takashi Kanesaka (*Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 10 : Endoscopic diagnosis

P10-2 Characteristics of early gastric cancer detected by linked color imaging after white light imaging

Hisashi Matsumoto (*Department of General Internal Medicine, Saitama Medical University, Saitama, Japan*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 11 : Imaging diagnosis

P11-1 Development of new diagnosis using BDFP expression recombinant reovirus for gastric cancer of peritoneal dissemination

Masahiro Kitagawa (*Department of Gastroenterological and Pediatric Surgery, Oita University Faculty of Medicine, Japan*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 11 : Imaging diagnosis

P11-2 Deep learning radio-clinical signatures for predicting neoadjuvant chemotherapy response and prognosis from pretreatment ct images of LAGC patients: a multicenter study

Can Hu (*Zhejiang Cancer Hospital, China*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 12 : H.pylori

P12-1 Mechanism of helicobacter pylori CagA promotes gastric cancer immune escape through p53 regulating exosomal PD-L1

Chaohui Zuo (*The Affiliated Cancer Hospital of Xiangya School of Medicine & Hunan Cancer Hospital (Hunan Province Cancer Institute), Central South University, China*)

P12-2 The impacts of early helicobacter pylori eradication on the risk of colorectal cancer and health resource utilizations

Chia-Yu Kuo (*Kaohsiung Municipal Siaogang Hospital, Kaohsiung Medical University, Kaohsiung Medical University Hospital, Taiwan*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 13 : Progression of gastric cancer

P13-1 Plasma exosomal proteins ILK1 and CD14 correlated with organ specific metastasis of advanced gastric cancer patients

Chenfei Zhou (*Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China / Department of Oncology, Wuxi Branch of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Wuxi, China*)

P13-2 Loss of ATOH1 in pit cell drives stemness and progression of gastric adenocarcinoma by activating AKT/mTOR signaling through GAS1

Qing Zhong (*Department of Gastric Surgery, Fujian Medical University Union Hospital, China*)

P13-3 Progression risk towards gastric cancer increases in high-risk patients with non-neoplastic lesion

Siyi He (*Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China*)

P13-4 m5C methylated lncRNA NR_033928 promotes gastric cancer progression via a positive feedback loop of GLS mediated glutamine reprogramming

Lang Fang (*The First Affiliated Hospital of Nanjing Medical University, China*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 14 : Rare metastasis / Micrometastasis

P14-1 Brain metastasis incidence in gastro-esophageal cancer a meta-analysis

Marwan-Julien Sleiman (*Visceral Surgery Department, University Hospital of Geneva, Geneva, Switzerland*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 14 : Rare metastasis / Micrometastasis

P14-2 The relationship between brain metastasis and HER2 expression status in gastric cancer

Ming-Yu Lai (*Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 16 : Cancer stem cell

P16-1 Identification and characterization of gastric cancer stem-like cells with stemness phenotypes by CD44+Lgr5+

Zhida Chen (*The Department of General Surgery, The PLAGH Hospital, Beijing, China*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 16 : Cancer stem cell

P16-2 Atranorin@SPIONs lead to ferroptosis of gastric cancer stem cells by weakening the mRNA 5-hydroxymethylcytidine modification of the Xc-/GPX4 axis and its expression

Zhentian Ni (*Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 17 : Clinical pathology

P17-1 Clinical features of gastric Signet-Ring Cell Cancer: results from a systematic review and meta-analysis

Mariagiulia Dal Cero (*Section of Gastrointestinal Surgery, Hospital Universitario del Mar, Hospital del Mar Medical Research Institute (IMIM). Department of Surgery, Universitat Autònoma de Barcelona, Barcelona, Spain*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 17 : Clinical pathology

P17-2 Clinicopathological features and prognosis of primary gastric adenosquamous carcinoma

Di Wu (*Department of General Surgery, the First Medical Center of the General Hospital of the People's Liberation Army, Beijing, China*)

P17-3 Gastric triple cancer containing adenocarcinoma with enteroblastic differentiation

Kohei Harigane (*Department of Surgery, Ebina General Hospital, Kanagawa, Japan*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 18 : Prognostic factor

P18-1 Analysis of risk factors for duodenal stump fistula after laparoscopic radical gastrectomy and establishment of Nomogram prediction model

Xufeng Shu (*Department of digestive surgery, digestive disease hospital, the First Affiliated Hospital of Nanchang University, China*)

P18-2 Predictive potential of cancer cachexia index in long-term outcome projections for patients with gastric cancer

Katsunobu Sakurai (*The Department of Gastroenterological Surgery, Osaka City General Hospital, Osaka, Japan*)

P18-3 Prognostic value of combination of preoperative fibrinogen and inflammatory-nutritional index in adenocarcinoma of esophagogastric junction

Ying Qi Song (*The First Medical Center of Chinese PLA General Hospital, China*)

- P18-4 Prognostic effects of primary tumor size on gastric cancer survival for Chinese population in Shanxi**
Yifan Li (*Shanxi Cancer Hospital, China*)
- P18-5 A novel score "Albumin-Bilirubin score" predicts for short- and long-term outcomes of gastric cancer after curative surgery**
Kojiro Eto (*Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Japan*)
- P18-6 Prognostic correlation and predictive factors for return to intended oncologic treatment after curative gastrectomy for advanced gastric cancer: an analysis of 717 Western patients**
Pietro Maria Lombardi (*Division of Minimally Invasive Surgical Oncology, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy*)
- P18-7 Who is the candidate for splenic hilar lymph node dissection in gastric cancer?: An analysis based on therapeutic impact**
Jeesun Sunny Kim (*Department of Surgery, Seoul National University Hospital, Seoul, Korea*)
- P18-8 Genome-wide functional screening identifies a subset of predictive signature and indicates TTF2 is an essential suppressor in gastric cancer**
Jianfang Li (*Department of Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China*)
- P18-9 The prediction model for the risk of lymph node metastasis in early gastric cancer with submucosal invasion: a multicenter study**
Ji Won Seo (*St. Vincent's Hospital, The Catholic University of Korea, South Korea*)
- P18-10 Prognostic and predictive value of m6A eraser related gene signature in gastric cancer**
Xin Xu (*Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, China*)
- P18-11 Helicobacter pylori inhibits CD8+ tumor infiltrating lymphocytes which indicates poor prognosis in gastric cancer**
Zheng Li (*Division of Gastric Surgery, Department of General Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 18 : Prognostic factor

- P18-12 Evaluation of peritoneal CEA as a survival prognostic factor in gastric cancer patients: a single western center experience**
Nicola Natalizi (*University of Perugia, Italy*)

P18-13 Development and validation of nomograms for predicting overall survival and cancer-specific survival in elderly patients with locally advanced gastric cancer: a population-based study

Yuqi Sun (*Department of General Surgery, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China*)

P18-14 Textbook outcome is a good prognostic marker for gastric cancer patients and performance index for gastric cancer surgeon

Eun Younh Kim (*Department of Surgery, Uijeongbu St. Mary Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea*)

P18-15 Intra-operative blood loss has significant influence in long term survival through univariate analysis

Oswaldo Antônio Prado Castro (*Santa Casa of Sao Paulo - Hospital and Medical School, Brazil*)

P18-16 Correlation between pre-treatment NLR and long-term outcomes of patients with unresectable or recurrent gastric cancer treated with nivolumab as third-line or later line treatment

Hirokatsu Hayashi (*Department of Gastroenterological Surgery and Pediatric Surgery, Gifu University Graduate School of Medicine, Gifu, Japan*)

P18-17 Prognostic and clinical significance of specific and serum inflammatory markers in minimally invasive treatment of gastric cancer

Andrei Kopaev (*Moscow Clinical Scientific Center named after Loginov, Russia*)

P18-18 Prognostic factors in advance gastric adenocarcinoma in a Mexican population

Alberto Mitsuo Leon Takahashi (*Gastrointestinal Department, National Cancer Institute, Mexico*)

P18-19 Tumor index predicts recurrences of patients with pathological stage 1 gastric cancer after curative resection

Lei Lian (*Department of Gastrointestinal Surgery, the Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China / Guangdong Institute of Gastroenterology, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, the Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China*)

P18-20 Tryptophan metabolism-associated gene expression profile for the prediction of prognosis and tumor microenvironment in gastric cancer

Linghua Zhu (*Department of General Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China*)

P18-21 Prognostic impact of lymph node micrometastasis in patients with gastric cancer

Atsushi Yamamoto (*First Department of Surgery, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan*)

P18-22 Expression of anoctamin 5 and its relation to tumor progression in gastric cancer

Atsuki Ota (*Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Japan*)

P18-23 Clinical role of F-18 fluorodeoxyglucose uptake in the reticuloendothelial system in gastric cancer

Jeong Won Lee (*Department of Nuclear Medicine, Catholic Kwandong University College of Medicine, International St. Mary's Hospital, South Korea*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 19 : Precision medicine

P19-1 Synergistic cytotoxicity of arsenic and topoisomerase inhibitors to gastric cancer

Ting Kang (*Department of Oncology, Xin Hua Hospital-School of Medicine-Shanghai Jiao Tong University, Shanghai, China*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 20 : Clinical study

P20-1 Long-Limb reconstruction after gastrectomy for cancer with type 2 diabetes: expansion of metabolic surgery to surgical oncology

Hayun Kim (*Department of Medicine, Korea University College of Medicine, Seoul, South Korea*)

P20-2 Interim analysis of phase II study of intraperitoneal paclitaxel combined with S-1 plus oxaliplatin for advanced gastric cancer with peritoneal metastasis: PIPS-GC trial

Jong-Han Kim (*Department of surgery, Korea University College of Medicine, South Korea*)

P20-3 The percentages of signet-ring cells affects the prognosis after radical gastrectomy for gastric cancer

Yubo Ma (*Department of Gastric surgery, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China*)

P20-4 The value of the solute carrier 2A5 expression on the prognosis of gastric cancer and its relationship with immune infiltration

Jing Han (*Department of Gastric surgery, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China*)

P20-5 Clinicopathological features and prognostic significance of mucinous gastric carcinoma

Yubo Ma (*Department of Gastric surgery, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China*)

P20-6 Outcome of gastrectomy for gastric cancer with positive peritoneal cytology

Tasuku Furube (*Department of Surgery, School of Medicine, Keio University, Japan*)

P20-7 Role of surgery versus endoscopic resection among patients with small well differentiated gastric neuroendocrine tumor

Martin Karpeh (*Northwell health, United States*)

P20-8 A study protocol for effect of preoperative CT angiography examination on laparoscopic gastrectomy (GISSG 20-01 study)

Cheng Meng (*Department of Gastrointestinal Surgery, Affiliated Hospital of Qingdao University, Qingdao, China*)

P20-9 The short-term outcomes of gastric cancer patients based on a proposal for a novel classification of perigastric arteries

Yanbing Zhou (*Department of General Surgery, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China*)

P20-10 Effects of robotic and laparoscopic-assisted surgery on lymph node dissection and short-term outcomes in patients with Siewert II adenocarcinoma of esophagogastric junction

Yanbing Zhou (*Department of General Surgery, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 20 : Clinical study

P20-11 Impact of drinking Chinese green tea on postoperative short outcomes for gastric cancer: a randomized controlled trial

Yanbing Zhou (*Department of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China*)

P20-12 Identification and categorization of technical errors and hazard-zones of robotic versus laparoscopic assisted radical distal gastrectomy for gastric cancer

Yanbing Zhou (*Department of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China*)

P20-13 Effects of transcutaneous electrical acupoint stimulation (TEAS) on postoperative recovery in patients with gastric cancer: a randomized controlled trial

Yanbing Zhou (*Department of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China*)

P20-14 Impact of depression and anxiety assessment performed in gastrointestinal cancer patients on postoperative depression and anxiety symptom and mental health service visit

Yanbing Zhou (*Department of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China*)

P20-15 Clinicopathological characteristics and prognosis analysis of 217 patients with carcinoma in the remnant stomach

Yanbing Zhou (*Department of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China*)

P20-16 Adherence to prehabilitation protocol based on abdominal respiratory restriction with the outcome improvement in patients with metabolic syndrome underwent laparoscopic radical gastrectomies

Yanbing Zhou (*Department of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China*)

P20-17 Long-term outcomes of Indocyanine green fluorescence imaging-guided versus conventional laparoscopic lymphadenectomy for gastric cancer: a randomized clinical trial

Qi-Yue Chen (*Fujian medical university union hospital, China*)

P20-18 Feasibility and safety analysis of robot-assisted proximal gastrectomy with the double-flap anastomosis for early gastric cancer

Fanghai Han (*Department of Gastrointestinal Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, China*)

P20-19 Study protocol of hyperthermic intraperitoneal chemotherapy in the treatment of locally advanced gastric cancer: a Phase III multicenter prospective randomized controlled clinical trial (HIPEC)

Xiaodong Liu (*Department of General Surgery, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China*)

P20-20 Different clinicopathological patterns in gastric cancer of the lesser and greater curvature

Nicola Natalizi (*Department of Emergency and General Surgery, University of Perugia, Perugia, Italy*)

Poster 21 : Chemotherapy

- P21-1 The impact of neoadjuvant chemotherapy on gastric cancer patients' postoperative infectious complications and the intestinal barrier dysfunction**
Jianfei Xu (*Department of Gastrointestinal Surgery, the Affiliated Hospital of Qingdao University, Qingdao, China*)
- P21-2 The impact of neoadjuvant chemotherapy on gastric cancer patients' postoperative infectious complications and the intestinal barrier dysfunction**
Jianfei Xu (*Department of Gastrointestinal Surgery, the Affiliated Hospital of Qingdao University, Qingdao, China*)
- P21-3 Outcome of nivolumab as first-line therapy of unresectable or advanced recurrent gastric cancer at our institution**
Satoshi Tabuchi (*Tokyo Medical University Hachioji Medical Center Department of digestive surgery and transplantation surgery, Japan*)
- P21-4 The mechanism of resistance to Trifluridine (FTD) induced by decreased deoxythymidylate kinase (DTYMK) in gastric cancer cells**
Masashi Kuno (*Department of Gastroenterological surgery, Gifu University School of Medicine, Gifu, Japan*)
- P21-5 A case of complete response to chemotherapy containing trastuzumab for HER2-positive gastric cancer**
Yusuke Uchi (*Department of Surgery, Tamakyuryo Hospital, Japan*)
- P21-6 Nivolumab combination chemotherapy for unresectable HER2-negative advanced or recurrent gastric cancer**
Wakana Chikaishi (*Department of Gastroenterological Surgery and Pediatric Surgery, Gifu University Graduate School of Medicine, Gifu, Japan*)
- P21-7 Outcome of combination chemotherapy with Nivolumab as the first line for unresectable advanced or recurrent gastric cancer**
Tsukasa Kubo (*Department of Upper Gastrointestinal Surgery, Dokkyo Medical University, Japan*)
- P21-8 Our experience of chemotherapy with nivolumab for unresectable gastric cancer**
Naruyoshi Soeda (*Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 21 : Chemotherapy

P21-9 Short-term outcomes of nivolumab plus chemotherapy for advanced gastric adenocarcinoma

Tomonari Suetsugu (*Department of Surgery, Gifu prefectural general medical center, Japan*)

P21-10 Association between therapeutic efficacy of immune checkpoint inhibitors and immune-related adverse events in gastric cancer

Masashi Hirota (*Osaka General Medical Center, Japan*)

P21-11 FOLFOX therapy for unresectable or advanced recurrent gastric cancer refractory to oral pyrimidine fluoride

Kentaro Nishida (*The Department of Surgery, Osaka Rousai Hospital, Osaka, Japan*)

P21-12 Importance of conversion surgery in HER2 positive stage IV gastric cancer treated with trastuzumab-based chemotherapy

Koichi Hayano (*Department of Frontier Surgery, Chiba University Graduate School of Medicine, Japan*)

P21-13 Fenbendazole exerts anti-gastric cancer activity in vitro

Daniel Skubleny (*University of Alberta, Canada*)

P21-14 Trastuzumab-containing regimen has potential for abrupt tumor shrinkage causing palliative stent migration

Yuri Yokoi (*The Department of Gastroenterological Surgery, Nagoya City University West Medical Center, Japan*)

P21-15 Nivolumab plus chemotherapy for patients with unresectable, advanced, or recurrent gastric cancer

Yasuo Tsuda (*Department of Gastroenterological Surgery, Clinical Research Institute Cancer Research Division, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 22 : Adjuvant chemotherapy

P22-1 Neutrophil lymphocyte ratio and histological response correlate with prognosis of gastric cancer undergoing neoadjuvant chemotherapy

Naoki Urakawa (*Division of Gastrointestinal Surgery, Department of Surgery Kobe University Graduate School of Medicine, Kobe, Japan*)

- P22-2 Short and long-term outcomes between laparoscopic and open total gastrectomy for advanced gastric cancer after neoadjuvant chemotherapy**
Hao Cui (*The department of general surgery, the Chinese PLA general hospital, Beijing, China*)
- P22-3 Combining neoadjuvant chemotherapy with PD-1/PD-L1 inhibitors for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis**
Zhen Yuan (*Department of General Surgery, The First Medical Center, Chinese PLA General Hospital, Beijing, China*)
- P22-4 The comparison between 3 cycles and 5 to 6 cycles of S-1 combined with oxaliplatin (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer**
Shuo Li (*General Surgery Department, the First Medical Center of Chinese PLA General Hospital, China*)
- P22-5 Comparison of short and long term outcomes between laparoscopic and open gastrectomy for locally advanced gastric cancer following neoadjuvant chemotherapy: a propensity score matching analysis**
Hao Zhong (*Department of Gastrointestinal Surgery, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, China*)
- P22-6 Systematic review of the outcomes following neoadjuvant therapy in upfront resectable gastric cancers compared to surgery alone in phase III randomised controlled trials**
Charleen Yeo (*Tan Tock Seng Hospital, Singapore*)
- P22-7 A retrospective study of neoadjuvant chemotherapy for gastric cancer**
Hiroshi Nakade (*Department of Surgery, Nara Medical University, Japan*)
- P22-8 Perioperative chemotherapy for gastric and esophagogastric junctional cancer in community hospital**
Akio Kaito (*Surgery Division, Tsuchiura Kyodo General Hospital, Ibaraki, Japan*)
- P22-9 Early experience of neoadjuvant chemotherapy for locally advanced gastric cancer at Intermed hospital**
Tserenyudon Shirchinjav (*Intermed Hospital of Mongolia, Mongolia*)

Poster 22 : Adjuvant chemotherapy

P22-10 Perioperative FLOT modification for stage III-IVA gastric cancer: 8 courses in neoadjuvant regimen

Veronika Patsko (*National Cancer Institute, Kyiv, Ukraine*)

P22-11 Research protocol: comparison of perioperative chemotherapy and surgery with adjuvant therapy for locally advanced gastric cancer

Danila Alekseevich Matveychuk (*Moscow Clinical Scientific Center, Russia*)

P22-12 Review Fisher and Halsted's hypothesis from patients with gastric cancer achieving pathologic complete response after neoadjuvant chemotherapy

Chao Lin (*Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China*)

P22-13 Effectiveness and safety of neoadjuvant chemotherapy in gastric cancer vs surgery alone: single-center two-arms prospective study

Kateryna Cherchenko (*Department of minimally invasive and endoscopic surgery, interventional radiology, National Cancer Institute, Kyiv, Ukraine*)

P22-14 Icaritin-loaded PLGA nanoparticles activate immunogenic cell death and facilitate tumor recruitment in mice with gastric cancer

Yao Xiao (*The Fifth Affiliated Hospital of Guangzhou Medical University, China*)

P22-15 Neoadjuvant chemotherapy only benefits locally advanced gastric cancer patients with pathological complete response

Yonghe Chen (*The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China / The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China*)

P22-16 Association between nutritional status and treatment compliance and outcomes in patients undergoing perioperative chemotherapy for resectable gastric (GC) or gastro-oesophageal junction cancer (GEJC)

Jacopo Viganò (*General Surgery Unit 1, IRCCS Policlinico San Matteo Foundation - Pavia, Italy*)

P22-17 Neoadjuvant chemotherapy for treatment of advanced gastric adenocarcinoma with extensive lymph node metastasis

Dat Quang Tran (*Gastro-intestinal Surgery Department, University Medical Center, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 23 : Adjuvant chemotherapy

P23-1 Postoperative early body weight loss is a risk factor for recurrence in patients with gastric cancer

Daisuke Fujimoto (*Department of Surgery, Teikyo University Hospital, Mizonokuchi, Kanagawa, Japan*)

P23-2 FBXW7 regulates imatinib chemoresistance through targeting MCL1 for apoptotic regulation in gastrointestinal stromal tumors

Xiyu Wu (*The Department of Gastroenterological Surgery, Kumamoto University, Kumamoto, Japan*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 23 : Adjuvant chemotherapy

P23-3 Outcomes of adjuvant chemotherapy with S-1 for elderly gastric cancer patients

Hidenori Akaike (*First Department of Surgery, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan*)

P23-4 Prognostic factors and impact of adjuvant chemotherapy for pT3N0 gastric cancer

Hiroki Kondo (*Department of Surgery, Gastroenterological Center, Yokohama City University Medical Center, Japan*)

P23-5 Comparison of long-term outcomes between S-1 + oxaliplatin and S-1 monotherapy for stage III gastric cancer

Kentaro Sato (*Department of Gastroenterological Surgery, Hirosaki University, Japan*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 26 : Intraperitoneal chemotherapy

P26-1 Measuring cisplatin concentration in peritoneal fluid and plasma after intraperitoneal thermal perfusion chemotherapy through high-performance liquid chromatography

Rong Yan (*First affiliated hospital of Xi'an Jiaotong university, China*)

P26-2 Bidirectional approach with PIPAC and systemic chemotherapy for patients with synchronous gastric cancer peritoneal metastases (GCPM)

Maria Bencivenga (*Upper G.I. Surgery Division, University of Verona, Italy*)

P26-3 Efficacy of hyperthermic pressurized intraperitoneal aerosol chemotherapy (HIIPAC) in an in-vitro model using AGS cell-line and abdominal cavity model

Sa-Hong Min (*Department of Surgery, Asan Medical Center, South Korea / Seoul National University, College of Medicine / Seoul National University Bundang Hospital*)

P26-4 Application of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for the treatment of gastric cancer peritoneal carcinomatosis: preliminary single center results

Andrea Cossu (*Department of Gastrointestinal Surgery IRCCS San Raffaele Scientific Institute Milan, Italy*)

P26-5 Phase II trial of intraperitoneal chemotherapy for gastric cancer with peritoneal carcinomatosis

Andre Roncon Dias (*Instituto do Cancer, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Brazil*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 27 : Molecular targeted therapy

P27-1 In vitro study on the inhibitory effect of antibody coupled drug videxetil mAb on gastric cancer cells with different expression levels of HER-2

Jun Zhang (*Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 27 : Molecular targeted therapy

P27-2 Targeting PIK3CA and CDKN2A mutations in esophageal adenocarcinoma

Thomas Joseph Ryan (*Department of Surgery, Division of Surgical Sciences, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, United States*)

P27-3 Inhibition of androgen receptor enhanced the anticancer effects of everolimus through targeting glucose transporter 12

Bo Cao (*Department of General Surgery, Chinese PLA General Hospital, China*)

P27-4 Knockdown of PGM1 enhances anticancer effects of orlistat in gastric cancer under glucose deprivation

Bo Cao (*Department of General Surgery, Chinese PLA General Hospital, China*)

P27-5 A deferasirox-based iron nanochelator for gastric cancer therapy

Bin-Bin Li (*Digestive Diseases Center, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen 518107, Guangdong, China / Guangdong Provincial Key Laboratory of Digestive Cancer Research, The Seventh Affiliated Hospital of Sun Yat-sen University, Sun Yat-Sen University, Shenzhen 518107, Guangdong, People's Republic of China*)

P27-6 Pterostilbene enhances anticancer effect of lapatinib in gastric cancer cell lines

Yukiko Nishiguchi (*Department of Molecular Pathology, Nara Medical University, Nara, Japan*)

P27-7 Resveratrol-modified mesoporous silica nanoparticle for tumor-targeted therapy of gastric cancer

Mingzhen Lin (*Department of Oncology, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China*)

P27-8 A novel natural product targeting STAT3 suppresses tumor growth and metastasis in gastric cancer

Xiaoqing Guan (*The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang, China*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 28 : Immunotherapy

P28-1 The protocol of a prospective real-world study evaluating sensitive prediction of protein profiling in chemotherapy combined with immunotherapy for advanced gastric cancer: specific study

Hao Cui (*The department of general surgery, the Chinese PLA general hospital, Beijing, China*)

P28-2 Re-administration of nivolumab for advanced gastric cancer patients: a case series

Hiroyuki Kodama (*Department of Clinical Oncology, Aichi Cancer Center Hospital, Aichi, Japan*)

P28-3 The AXL receptor in gastric cancer: potential roles and clinical implications

Liyu Zhang (*Department of General Surgery, the First Medical Center of Chinese PLA General Hospital, China*)

P28-4 Cell membrane biomimetic nanocomposites trigger nuclear/ mitochondrial DNA damage and augment cGAS/STING-mediated innate immunity through blockade of efferocytosis

Zhian Chen (*Department of General Surgery, Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, The First School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, PR China, China*)

P28-5 Cancer cell membrane biomimetic mesoporous silica nanotheranostics for enhanced ferroptosis-mediated immunogenic cell death on gastric cancer

Zhenhao Li (*Department of General Surgery, Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, The First School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, PR China, China*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 28 : Immunotherapy

P28-6 IL-21 and IL-33 synergizes to augment expansion and anti-tumor function of CD8+ TILs

Jiameng Liu (*Department of Nuclear Medicine, The Affiliated Hospital of Jiangsu University, Zhenjiang, China*)

P28-7 The first report of MSI-H gastric cancer with neuromyelitis optica treated by concurrent nivolumab and satralizumab

Taisuke Hosokai (*Department of Clinical Oncology, Kyoto University Hospital, Japan*)

P28-8 Clinical assessment of nivolumab in combination with SOX as a 1st line treatment for advanced gastric cancer

Shigefumi Yoshino (*Department of Surgery, National Hospital Organization Kanmon Medical Center, Shimonoseki, Japan*)

P28-9 Inhibition of gastric cancer by a new controlled releasing compound of TLR-7/8 agonist via immune activation in a gastric cancer xenograft mice model

Hyun Myong Kim (*Seoul National University Cancer Research Institute, Seoul National University, South Korea / Department of Surgery, Seoul National University Hospital, Seoul, Korea*)

P28-10 TCF19 regulate terminal exhausted T cells fate decision with resistance to immunotherapy in tumor microenvironment

Fu hui Wang (*The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China*)

P28-11 The efficacy and safety of nivolumab in unresectable advanced or recurrent gastric cancer patients

Haruka Nikai (*Department of Surgery, Iwate Medical University, Iwate, Japan*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 29 : Radiation therapy

P29-1 Neoadjuvant chemoradiotherapy for locally advanced gastric cancer with bulky lymph node metastasis

Eiji Nomura (*Department of Gastroenterological Surgery, Tokai University Hachioji Hospital, Tokyo, Japan*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 29 : Radiation therapy

P29-2 Results of palliative irradiation for unresectable advanced gastric cancer patients

Yusuke Suzuki (*Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 30 : Conversion surgery

P30-1 Transarterial infusion chemotherapy and embolization for patients with unresectable advanced cancer of stomach or gastroesophageal junction: a retrospective study

Zhaoqing Tang (*The Department of General Surgery, Zhongshan Hospital, Fudan University, China*)

P30-2 Two cases of conversion esophagectomy for HER2-positive metastatic esophagogastric junction cancer

Ryota Kobayashi (*Department of Surgery, School of Medicine, Keio University, Japan*)

P30-3 A case of far advanced gastric cancer achieved cure by multiple operation and palliative chemotherapy

Dong Gue Shin (*Department of Surgery, Seoul Red Cross Hospital, Seoul, Korea*)

P30-4 Long-term outcome of conversion surgery for gastric cancer with liver metastasis: report of 7 cases

Tadashi Ogawa (*Dept of Surgery, Surgical Oncology and Science, Sapporo Medical University, Hokkaido, Japan*)

P30-5 The role of staging laparoscopy in cM+ patients

Leonardo Solaini (*General and Oncologic Surgery, Department of Surgery, Forlì, Italy*)

P30-6 Conversion surgery for gastric cancer with peritoneal dissemination

Yosuke Kano (*Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, Japan*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 30 : Conversion surgery

P30-7 Clinical significance of conversion surgery for unresectable advanced gastric cancer

Atsushi Nakao (*Department of Surgery, School of Medicine, Keio University, Japan*)

P30-8 The surgical outcome and prognosis of conversion surgery for stage IV advanced gastric cancer

Haruna Furukawa (*Department of Surgery, Rinku General Medical Center, Osaka, Japan*)

P30-9 Conversion surgery in a CDH-1 negative young patient with bone metastasis

Paula Strauch Costa (*Santa Casa of Sao Paulo, Medical School and Hospital, Department of Surgery, Gastroesophageal and Bariatric Division, Brazil*)

P30-10 Outcomes of conversion gastrectomy after neoadjuvant chemotherapy in gastric cancer with oligometastasis

Shannon Melissa Chan (*Department of Surgery, The Chinese University of Hong Kong, Hong Kong S.A.R., China*)

P30-11 The survival benefit of conversion surgery after neoadjuvant chemotherapy in unresectable gastric cancer patients

Peticha Tanprsert (*Division of Upper Gastrointestinal Surgery and Endoscopy, Department of Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 31 : Surgery

P31-1 Tunnel anastomosis vs double tract jejunal interposition reconstruction after proximal gastrectomy

Rui Peng (*The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China*)

P31-2 Clinical impact of jejunostomy after gastrectomy for the patients with high risk of body weight loss

Takuma Ohashi (*Div. Digestive Surg, Dept. Surg. Kyoto Prefectural Univ. Med., Japan*)

P31-3 Withdrawn

P31-4 Left thoracoabdominal esophagectomy for esophagogastric cancer

Shuhei Mayanagi (*Division of Esophageal Surgery, Shizuoka Cancer Center Hospital, Shizuoka, Japan*)

P31-5 Clinical outcome of left thoracotomy for large submucosal tumor of the esophagogastric junction

Masazumi Inoue (*Shizuoka Cancer Center, Division of Esophageal Surgery, Shizuoka, Japan*)

P31-6 A case of robot-assisted laparoscopic total gastrectomy for gastric cancer as conversion surgery with common hepatic artery passed behind the portal vein

Ryo Okazaki (*Department of Gastroenterological Surgery II, Hokkaido University Faculty of Medicine, Hokkaido, Japan*)

P31-7 Robotic gastrectomy for gastric cancer

Yanbing Zhou (*Department of General Surgery, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China*)

P31-8 Esophago-jejunal reconstruction using the safe parachute technique in the mediastinum after resection of esophagogastric junction cancer

Tadashi Higuchi (*Department of Upper Gastrointestinal Surgery, Kitasato University School of Medicine, Kanagawa, Japan*)

P31-9 Postoperative complications between uncut Roux-en-Y anastomosis and Billroth II anastomosis after D2 distal gastrectomy: an interim report of the CSGC002 Trial

Shi Chen (*Department of Gastrointestinal Surgery, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, P.R., China*)

P31-10 The indications for proximal gastrectomy for locally advanced upper third gastric cancer based on optimal lymph node dissection

Yoshiro Imai (*Department of General and Gastroenterological Surgery, Osaka Medical and Pharmaceutical University, Osaka, Japan*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 31 : Surgery

P31-11 Proximal partial gastrectomy with GIRAFFE reconstruction used in 100 patients: a system review

Xiangdong Cheng (*Zhejiang Cancer Hospital, China*)

P31-12 Analysis of prognostic factors for gastric cancer in the elderly

Tatsuya Ito (*Surgery, Surgical Oncology and Science, Sapporo Medical University, Japan*)

P31-13 What is new about the extension of lymphadenectomy for gastric cancer? A systematic review and meta analysis

Lorena Torroni (*Unit of Epidemiology and Medical Statistics, Dept. of Diagnostics and Public Health, University of Verona, Verona, Italy*)

P31-14 Surgical quality in D2 lymphadenectomy of radical gastrectomy, the 100 first cases in a Mexican population

Alberto Mitsuo Leon Takahashi (*Gastrointestinal Department, National Cancer Institute, Mexico*)

P31-15 Short-term outcomes of robot-assisted laparoscopic proximal gastrectomy

Shigeaki Baba (*Department of Surgery, Iwate Medical University, Japan*)

P31-16 A nomogram for predicting extra-perigastric lymph node metastasis in early gastric cancer patients

Dong Jin Kim (*Department of Surgery, Eunpyeong St. Mary's Hospital, The Catholic University of Korea, South Korea*)

P31-17 Reconstruction after proximal gastrectomy for cardiac gastric cancer

Takashi Kosaka (*Department of Gastroenterological Surgery, Graduate School of Medicine, Yokohama-city University, Japan*)

P31-18 Multivisceral resections for T4 gastric cancer

Myroslava Vinogradova (*The Department of miniinvasive and endoscopic surgery, interventional radiology, National cancer institute, Kyiv, Ukraine*)

P31-19 Duodenal kocherization in D2 gastrectomy

Khin Hsu Hlaing (*Department of surgery, University of Medicine, Yangon, Myanmar*)

P31-20 The long-term efficacy of standardized intracorporeal esophagojejunostomy after laparoscopic total gastrectomy

Akiko Serizawa (*Department of Surgery, Fujita Health University, Aichi, Japan*)

P31-21 Comparative evaluation of the overlap methods for laparoscopic esophagojejunostomy

Naohiko Matsushita (*Department of Surgery, Yokohama City University Medical Center, Gastrointestinal Disease Center, Tokyo, Japan*)

Poster 32 : Laparoscopic surgery

P32-1 Staple line reinforcement reduces time for reconstruction during laparoscopic gastrectomy

Tsutomu Namikawa (*Department of Surgery, Kochi Medical School, Japan*)

P32-2 Duodenal stump reinforcement with purse string suture in distal gastrectomy under laparoscope combined with uncut Roux en Y reconstruction in patients with gastric cancer

Fengyuan Li (*Division of Gastric Surgery, Department of General Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China*)

P32-3 Comparison of short-term efficacy between totally laparoscopic gastrectomy and laparoscopic assisted gastrectomy for elderly patients with gastric cancer

Hao Cui (*The Department of General Surgery, the Chinese PLA General Hospital, Beijing, China / School of Medicine, Nankai University, Tianjin, China*)

P32-4 Endoscopy-assisted laparoscopic wedge gastrectomy for gist instead of LECS in lesions not close to the cardia and pylorus

Flávio Silano (*Hospital Aliança / Rede D'or São Luiz, Brazil*)

P32-5 Single-port plus one Whipple procedure for advanced gastric cancer

So Hyun Kang (*Seoul National University Bundang Hospital, South Korea*)

P32-6 Endoscopy assisted laparoscopic wedge gastrectomy for Gist instead of LECS in lesions not close to the cardia and pylorus

Flávio Silano (*Hospital Aliança / Rede D'or São Luiz, Brazil*)

P32-7 Our procedures of reconstruction after laparoscopic proximal gastrectomy

Yoshihiko Nakamoto (*Department of Surgery, Meiwa Hospital, Nishinomiya, Hyogo, Japan*)

P32-8 A simplified method of the hepatic left lateral segment inversion to secure an optimal surgical view around the esophageal hiatus in laparoscopic gastrectomy for upper gastric cancer

Hiroki Harada (*Department of Gastroenterological Surgery, Gastroenterological Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan*)

P32-9 Application of a new retraction method in laparoscopic gastrectomy for gastric cancer

Shun Zhang (*Department of Gastrointestinal Surgery, Shanghai East Hospital, Tongji University, Shanghai, China*)

P32-10 The impact of reduced port approach on the reduction of surgical trauma in gastrectomy for gastric cancer

Jae Hun Chung (*Department of Surgery, Division of Gastrointestinal Surgery, Pusan National University Yangsan Hospital, Yangsan, South Korea / Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan-si, Gyeongsangnam-do 50612, Republic of Korea*)

P32-11 Safety and feasibility of single incision distal gastrectomy in overweight and obese gastric cancer patients

Eunju Lee (*Department of Surgery, Seoul National University Bundang Hospital, Seongnam-si, South Korea*)

P32-12 The efficacy of fixation of roux limb on duodenal stump after minimally invasive gastrectomy

Sanae Kaji (*Department of Esophageal and Gastroenterological Surgery Juntendo University of Medicine, Japan*)

P32-13 Short-term efficacy of laparoscopic surgery after neoadjuvant chemotherapy for advanced gastric cancer

Lan Lan Shang (*Liaoning Cancer Hospital, China*)

P32-14 Comparison of single-port and conventional port for laparoscopic gastroduodenostomy in gastric cancer patients

Jeong Ho Song (*Department of Surgery, Ajou University School of Medicine, Suwon, South Korea*)

P32-15 Laparoscopic articulating instrument (ArtiSential) promotes technical feasibility of laparoscopic lymph node dissection during gastrectomy : propensity-score matching analysis

Hayemin Lee (*Catholic University of Korea, Seoul, South Korea*)

P32-16 Exploration of minimally invasive surgery for gastric stromal tumor

Wei Zhang (*Xuanwu Hospital, Beijing, China*)

P32-17 Clinical application of indocyanine green fluorescence-guided laparoscopic gastrectomy for gastric cancer

Yize Liang (*General Surgery Department, Qilu Hospital of Shandong University, China*)

P32-18 Laparoscopic total gastrectomy for gastric cancer. Our experience in 100 consecutive cases in a single center

Enrique Norero (*Hospital Sotero del Rio. Esophagogastric Surgery Unit. Pontificia Universidad Católica de Chile, Chile*)

P32-20 Intracorporeal pai shaped esophagojejunostomy with mesenteric pre-separation after totally laparoscopic total gastrectomy in gastric cancer: Feasibility and preliminary experience

Diancai Zhang (*Division of Gastric Surgery, Department of General Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China*)

Poster 32 : Laparoscopic surgery

P32-21 Totally laparoscopic total gastrectomy with linear stapler versus laparoscopic assisted total gastrectomy in gastric cancer

Weizhi Wang (*Division of Gastric Surgery, Department of General Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China*)

P32-22 Short and long-term surgical outcomes of laparoscopic total gastrectomy compared with open total gastrectomy in gastric cancer patients

Sang Soo Eom (*National Cancer Center, South Korea*)

P32-23 Short- and long-term outcomes of laparoscopic gastrectomy for advanced gastric cancer

Sohei Matsumoto (*Department of Surgery, Nara Medical University, Japan*)

P32-24 Reconstruction following LTG: using circular stapler (Orvil), knocks and pitfalls from over 200 cases experience

Hitoshi Satodate (*Department of Surgery, Inagi Municipal Hospital, Tokyo, Japan*)

P32-25 Short-term results of laparoscopic gastrectomy for advanced gastric cancer

Hideki Kawamura (*Department of Surgery, NHO Hokkaido Medical Center, Sapporo, Japan*)

P32-26 Withdrawn

P32-27 Laparoscopic surgery for remnant gastric cancer

Takeyuki Wada (*Department of Gastric Surgery, National Cancer Center Hospital, Tokyo, Japan*)

P32-28 Laparoscopic total gastrectomy for obese patient: technical ingenuities and surgical outcomes

Satoshi Kamiya (*Department of Surgery, Tokyo Dental College Ichikawa General Hospital, Chiba, Japan*)

P32-29 A simplified overlap technique during totally laparoscopic total gastrectomy

Dazhi Xu (*Fudan University Shanghai Cancer Center, China*)

P32-30 The impact of anatomical distance between the pancreas and common hepatic artery bifurcation on postoperative pancreatic fistula in laparoscopic gastrectomy

Atsushi Morito (*Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan*)

P32-31 Comparison of postoperative outcomes and nutritional status of laparoscopy-assisted proximal gastrectomy (LAPG) by reconstruction methods

Tomohiro Kunishige (*Department of Surgery, Nara Medical University, Japan*)

P32-32 Feasibility and safety of laparoscopic reconstruction by jejunal interposition after proximal gastrectomy for gastric cancer

Kenichi Ishizu (*Department of Gastric Surgery, National Cancer Center Hospital, Tokyo, Japan*)

P32-33 Billroth-II modified with antiperistaltic hinged afferent loop versus Roux-en-Y reconstruction after laparoscopic distal gastrectomy: a propensity score - matched analysis

Thong Quang Dang (*Gastro-intestinal Surgery Department, University Medical Center, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam*)

P32-34 Analysis of the safety of lymphadenectomy with preserving an aberrant left hepatic artery in gastrectomy

Yoshihisa Okuchi (*Department of Gastroenterological Surgery and Oncology, Medical Research Institute KITANO HOSPITAL, Japan*)

P32-35 Clinical issues of combined gastrectomy with splenectomy and chemotherapy in type 4 scirrhous gastric cancer

Satoshi Hamada (*Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan*)

P32-36 Extending criteria for laparoscopy to locally advanced gastric cancer resections in elderly patients

Lorenzo Cinelli (*IRCCS San Raffaele Hospital, Italy*)

P32-37 Short-term clinical outcomes of minimal invasive surgery for remnant gastric cancer

Hiroki Ishida (*Department of Gastroenterological Surgery, Gastroenterological Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan*)

P32-38 Esophagogastric delta-shaped anastomosis - A new safe and simple post-proximal gastrectomy reconstruction

Hironori Kawada (*Department of Surgery, Hyogo Prefectural Amagasaki General Medical Center, Japan*)

P32-39 Withdrawn

P32-40 Esophageal jejunal anastomosis using the overlap technique in laparoscopic total gastrectomy

Yasuhito Hisatsune (*Department of Gastrointestinal and General Surgery, St. Marianna University School of Medicine, Japan*)

P32-41 Oncological and nutritional feasibility of laparoscopic subtotal gastrectomy for gastric cancer in the upper gastric body

Akihiro Yamamura (*Department of Surgery, Tohoku University, Japan*)

P32-42 Withdrawn

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 32 : Laparoscopic surgery

P32-43 Real-world data analysis of 3012 patients undergoing laparoscopic radical gastrectomy in a single center over the past 12 years

Linjun Wang (*Division of Gastric Surgery, Department of General Surgery, the First Affiliated Hospital of Nanjing Medical University, China*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 33 : Robot surgery

P33-1 Can a single-port robot be safely used for robotic total gastrectomy for advanced gastric cancer? First experience using the da Vinci SP platform

Hao Cui (*The Department of General Surgery, the Chinese PLA General Hospital, Beijing, China / School of Medicine, Nankai University, Tianjin, China*)

P33-2 Technique and outcome of the double flap method reconstruction in robotic proximal gastrectomy

Ryo Maeyama (*Department of Surgery, JCHO Kyushu Hospital, Fukuoka, Japan*)

P33-3 Robot-assisted valvuloplastic esophagogastrostomy by double-flap technique using a knifeless linear stapler after proximal gastrectomy

Yoshinori Ishida (*Department of Gastroenterological Surgery, Hyogo Medical University, Nishinomiya, Japan*)

P33-4 The short term outcomes of initial hundred cases of robotic gastrectomy

Hideki Sunagawa (*Department of Gastroenterological Surgery, New Tokyo Hospital, Chiba, Japan*)

P33-5 The advantages of robotic over laparoscopic surgeries for gastric cancer

Takashi Matsunaga (*Department of Surgery, Shiga University of Medical Science, Shiga, Japan*)

P33-6 Analysis of safety and usefulness (short-term result) of robot-assisted gastrectomy

Isaya Hashimoto *(Department of Surgery and Science Faculty of Medicine, Academic Assembly, University of Toyama, Japan)*

P33-7 Quality of life after robotic proximal gastrectomy with double tract anastomosis: a single center retrospective study

Zhaoxiong Zhang *(Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, China)*

P33-8 Is robotic distal gastrectomy minimally invasive surgery?

Shiro Iwagami *(Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan)*

P33-9 On demand robotic gastrectomy with Distalmotion DexterTM system

Felix Berlth *(Department of General, Visceral and Transplant Surgery, University Medical Center Mainz, Germany)*

P33-10 The usefulness of robot-assisted gastrectomy for advanced gastric cancer with large type 3, type 4 or bulky lymph node metastasis

Katsuhisa Hirano *(Department of Surgery and Science Faculty of Medicine, Academic Assembly, University of Toyama, Japan)*

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 33 : Robot surgery

P33-11 Short-term outcomes of robot-assisted and laparoscopic proximal gastrectomy for cancer in a single-center Japanese institution

Hidero Yoshimoto *(Department of Surgery, Osaka Medical and Pharmaceutical University, Osaka, Japan)*

P33-12 Technique and short-term results of robot-assisted proximal gastrectomy with reconstruction by double-flap esophagogastric anastomosis

Eiichiro Nakao *(Department of Gastroenterological Surgery, Division of Upper G.I. Surgery, Hyogo Medical University, Hyogo, Japan)*

P33-13 Short-term outcomes of robotic proximal gastrectomy

Kazuya Yamaguchi *(Department of Surgery, Central Japan International Medical Center, Japan)*

P33-14 Short-term postoperative outcomes of robot-assisted gastrectomy for advanced gastric cancer

Yuji Hatanaka *(Central Japan International Medical Center, Surgery, Japan)*

P33-15 Initial short-term results of robot-assisted gastrectomy in our department

Seiichi Nakaya (*The Department of Gastroenterological Surgery, Nagoya City University East Medical Center, Aichi, Japan*)

P33-16 Robotic versus laparoscopic gastrectomy: a case-control study in a Japanese local institution

Reo Sato (*Department of Gastroenterological Surgery, Toyota Memorial Hospital, Toyota, Japan / Department of Gastroenterological Surgery, Nagoya City University, Nagoya, Japan*)

P33-17 The effect of 'Slow and Steady' experience for robotic distal gastrectomy for gastric cancer: analysis of learning curve for surgical outcomes

Ki Bum Park (*St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea*)

P33-18 Robotic double tract reconstruction using both robotic and laparoscopic staplers following proximal gastrectomy

Mikito Inokuchi (*Musashino Red Cross Hospital, Japan*)

P33-19 Robotic gastrectomy using the Vessel Sealer and Maryland Bipolar

Tetsuya Kagawa (*Department of Surgery, Fukuyama City Hospital, Japan*)

P33-20 Withdrawn

P33-21 Systematization of robot assisted D2 total gastrectomy in locally advanced gastric cancer

Flávio Silano (*Hospital Aliança / Rede D'or São Luiz, Brazil*)

P33-22 Comparing the learning curve between laparoscopic and robotic total gastrectomy: a systematic review

Kai Siang Chan (*Department of General Surgery, Tan Tock Seng Hospital, Singapore*)

P33-23 Learning curve of laparoscopic and robotic distal gastrectomy: a systematic review

Aung Myint Oo (*Department of General Surgery, Tan Tock Seng Hospital, Singapore*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 34 : Function-preserving surgery

P34-1 Withdrawn

P34-2 **Short-term clinical efficacy of Kamikawa anastomosis and jejunal interposed double channel anastomosis in laparoscopic proximal gastrectomy**

Wen Qing Hu (*Department of Gastroenterological Surgery, Changzhi People's Hospital Affiliated to Changzhi Medical College, China*)

P34-3 Withdrawn

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 34 : Function-preserving surgery

P34-4 **Subtotal gastrectomy with small remnant stomach improves surgical outcome and long-term QOL in resectable GC**

Masataka Shimonosono (*Department of Digestive, Surgery, Kagoshima University, Kagoshima, Japan*)

P34-5 **Safety and feasibility of needle grasper assisted single incision laparoscopic pylorus-preserving gastrectomy**

Jong Won Kim (*Department of Surgery, Chung-Ang University, South Korea*)

P34-6 **Valvuloplastic esophagogastrostomy using double flap technique after laparoscopic proximal gastrectomy for early gastric cancer**

Masahiko Nishizaki (*Department of Surgery, Tsuyama Chuo Hospital, Japan*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 35 : Cytoreductive surgery

P35-1 **Cytoreduction and hyperthermic intraperitoneal cisplatin and paclitaxel for gastric cancer and peritoneal metastasis**

EeeLN H Buckarma (*Mayo Clinic Department of Surgery, United States*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 35 : Cytoreductive surgery

P35-2 Cytoreductive surgery and HIPEC for gastric carcinomatosis: where do we have to push the limit? A single-team experience

Jacopo Viganò (*General Surgery 1, Fondazione IRCCS Policlinico San Matteo, Italy*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 36 : LECS

P36-1 Laparoscopy and endoscopy cooperative surgery for early duodenal cancer: a report of 2 cases

Fumihiko Kato (*Digestive Disease Center, International University of Health and Welfare, Mita Hospital, Tokyo, Japan*)

P36-2 The combination of endoscopic submucosal dissection and laparoscopic sentinel lymph node dissection in early mucinous gastric cancer: the role of lymph node metastasis

Hua Li (*Department of Surgical Oncology, Affiliated Xing Tai People Hospital of Hebei Medical University, Xingtai 054001, Hebei Province, China*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 36 : LECS

P36-3 None-xposure endolaparoscopic full-thickness resection with simple suturing technique of early gastric cancer

Hua Li (*Department of Surgical Oncology, Affiliated Xing Tai People Hospital of Hebei Medical University, Xingtai 054001, Hebei Province, China*)

P36-4 Efficacy of combined laparo-endoscopic, pure endoscopic and pure laparoscopic approaches to gastric subepithelial tumors - a retrospective cohort study

Hon Chi Yip (*Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong S.A.R., China*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 37 : Surgical navigation

P37-1 Patient-specific virtual three-dimensional surgical navigation for gastric cancer surgery: a prospective study for preoperative planning and intraoperative guidance

Yoo Min Kim (*Yonsei University, College of Medicine, Department of Surgery, South Korea*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 37 : Surgical navigation

P37-2 Short- and long-term outcomes of laparoscopic or robotic radical gastrectomy based on preoperative perigastric artery CTA surgical decision-making

Cheng Meng (*Department of Gastrointestinal Surgery, Affiliated Hospital of Qingdao University, Qingdao, China*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 38 : Postoperative functional assessment

P38-1 The role of 3D reconstruction and modeling in forecasting functional results of jejunogastroplasty (artificial stomach) after total gastrectomy for acute bleeding gastric cancer

Evgen Shepetko (*Kyiv Medical University, Ukraine*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 38 : Postoperative functional assessment

P38-2 Dynamics of perioperative pancreatic exocrine function in patients with gastric cancer

Takashi Nakayama (*The First Department of Surgery, Faculty of Medicine University of Yamanashi, Yamanashi, Japan*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 39 : Postgastrectomy syndrome

P39-1 Effect of probiotics in improving symptoms of post-gastrectomy syndrome

Ye Seob Jee (*Department of Surgery, Dankook University Hospital, South Korea*)

P39-2 Association of postoperative esophageal reflux with body weight loss after surgery for gastric cancer with esophagojejunostomy

Junya Morita (*Department of Surgery, Gastroenterological Center, Yokohama City University Medical Center, Japan*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 39 : Postgastrectomy syndrome

P39-3 Pancreatic volume and pancreatic secretory function are decreased by gastrectomy in gastric cancer patients

Yutaka Kimura (*Department of Surgery, Kindai University Nara Hospital, Japan / Department of Surgery, Kindai University Faculty of Medicine*)

P39-4 Relationship between changes in blood glucose after gastrectomy and occurrence of late dumping syndrome

Satoshi Ida (*Department of Gastric Surgery, Cancer Institute Hospital of JFCR, Tokyo, Japan*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 40 : Perioperative management

P40-1 Preoperative weight loss program for obese patients with early gastric cancer: a single-institution prospective study

Hirofumi Imoto (*Department of Surgery, Tohoku University Graduate School of Medicine, Miyagi, Japan*)

P40-2 Risk factors for blood transfusion and its prognostic implication in curative gastrectomy for gastric cancer

Marcus Fernando Kodama Pertille Ramos (*Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Brazil*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 40 : Perioperative management

P40-3 Efficacy of regular administration of acetaminophen for postoperative pain management in patients with gastric cancer

Ayako Shimada (*Department of Hepato-Biliary-Pancreatic & Gastrointestinal Surgery, International University of Health and Welfare, Japan*)

P40-4 The "weekday effect" on Enhanced Recovery After Surgery protocol for gastrectomy

Jacopo Weindelmayer (*Verona University Hospital, Italy*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 41 : Postoperative complications

P41-1 Effect of preoperative oral steroids on postoperative complications after gastric cancer surgery

Motonari Ri (*Department of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan*)

P41-2 Acute Kidney Injury after radical gastrectomy: incidence, risk factors, and impact on prognosis

Benlong Zhang (*Department of General Surgery, the First Medical Center of Chinese PLA General Hospital, Beijing, China*)

P41-3 Risk factor of anastomotic leakage after transhiatal resection for esophagogastric junction cancer

Akihiko Sano (*Department of General Surgical Science, Gunma University Graduate School of Medicine, Gunma, Japan*)

P41-4 Diagnostic value of drain fluid amylase level on postoperative day one for pancreas-related complications after gastrectomy

Tomoyuki Wakahara (*Department of Surgery, Yodogawa Christian Hospital, Japan*)

P41-5 Wernicke`s encephalopathy after subtotal gastrectomy for gastric cancer: a case report

Kyung-Goo Lee (*Department of Surgery, Myongji Hospital, Goyang, South Korea*)

P41-6 Strangulation necrosis of the alimentary limb after gastrectomy due to Petersen`s hernia: a case report

Shunpei Tonomura (*Department of Surgery, Gifu Prefectural General Medical Center, Japan*)

P41-7 Treatment experience of refractory ascites after surgery for gastric cancer

Takeharu Imai (*Department of Surgery, Gifu Municipal Hospital, Gifu, Japan*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 41 : Postoperative complications

P41-8 A retrospective study of a multi-omics-based liquid microarray detection system for early diagnosis of postoperative abdominal infection in gastrointestinal tumors

Yiding Wang (*Gastrointestinal Cancer Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China*)

P41-9 A comparative study of the safety of complete laparoscopic versus laparoscopic-assisted radical resection of distal gastric cancer in elderly patients

Zhouqiao Wu (*Gastrointestinal Cancer Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China*)

P41-10 The GASTRODATA registry: prospective analysis of complications and mortality after gastrectomy from a European multicenter study

Ilaria Benzoni (*Department of Surgery, ASST Cremona, Italy / Department of Clinical and Experimental Sciences, University of Brescia Italy*)

P41-11 Prediction model for postoperative complications in patients underwent esophagectomy based on Bayesian approach

Seong Chan Gong (*Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, South Korea / Department of Surgery*)

P41-12 Effect of the accessory left hepatic artery resection after gastrectomy

Yoshihiro Kurata (*Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan*)

P41-13 Utility of inflammatory markers in the early detection of infectious complications after curative gastrectomy

Dong Jin Kim (*Department of Surgery, Eunpyeong St. Mary's Hospital, The Catholic University of Korea, South Korea*)

P41-14 A multicenter study on the prediction of postoperative complications of gastric cancer surgery using operation time, blood loss and age: $(t(h+1)age)^{(1/3)}$

Hikota Hayashi (*Department of Digestive and General Surgery, Faculty of Medicine, Shimane University, Japan*)

P41-15 Combined measurements of D-AMyS on POD0 and POD1 enhanced early prediction of PIFC after gastrectomy

Koki Nakanishi (*Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Japan*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 42 : ERAS

P42-1 ERAS protocol in patients undergoing gastrectomies for cancer, reduced hospital stay by almost 50%

Flávio Silano (*Hospital Aliança / Rede D'or São Luiz, Brazil*)

P42-2 Evaluation of early liquid drinking after radical gastrectomy in gastric cancer: a Chinese multicenter propensity score matching analysis

Yue Zhang (*Department of Gastrointestinal Surgery, Department of General Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China / Shantou University Medical College, Shantou 515041, P. R. China*)

P42-3 Multimodal prehabilitation to improve the clinical outcomes of frail elderly patients with gastric cancer: study protocol for a multicentre randomized controlled trial (GISSG+2201)

Yuqi Sun (*Department of General Surgery, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China*)

P42-4 Prediction of postoperative hospital stay following gastric cancer within ERAS based on preoperative variables: a nomogram-based study

Sihan Zhao (*Department of General Surgery, Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China*)

P42-5 A nomogram for prediction of survival in patients after gastrectomy within Enhanced Recovery After Surgery (ERAS): a single-center retrospective study

Zhang Peng (*Department of General Surgery, Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China*)

P42-6 The pathway management of perioperative enhanced recovery after surgery for gastrointestinal tumors in China

Yanbing Zhou (*Department of General Surgery, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 42 : ERAS

P42-7 Prehabilitation for gastrointestinal cancer patients

Yanbing Zhou (*Department of General Surgery, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China*)

P42-8 The effect of perioperative ERAS pathway management on short- and long-term outcomes of gastric cancer patients

Yanbing Zhou (*Department of General Surgery, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China*)

P42-9 Concordance between Watson for Oncology and a multidisciplinary clinical decision-making team for gastric cancer and the prognostic implications: retrospective study

Yulong Tian (*Department of General Surgery, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China*)

P42-10 Short- and long-term outcomes associated with enhanced recovery after surgery protocol vs conventional management in patients undergoing laparoscopic gastrectomy

Yulong Tian (*Department of General Surgery, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China*)

P42-11 Short-term multimodal prehabilitation program in ERAS protocol in gastric cancer surgery. Pilot study

Anastasia Novikova (*Saint Petersburg State University, Russia*)

P42-12 Withdrawn

P42-13 Enhanced recovery after surgery in elderly gastric cancer patients undergoing laparoscopic total gastrectomy

Yanbing Zhou (*Department of General Surgery, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 43 : Navigation Surgery

P43-1 The iGreenGO study: role of ICG in modifying surgeon's conduct during surgery for gastric cancer - study protocol

Pietro Maria Lombardi (*Unit of Foregut Surgery, IRCCS Humanitas Research Hospital, Milan, Italy*)

P43-2 Simultaneous robotic distal gastrectomy and distal pancreatectomy: how to avoid total gastrectomy

Sunao Ito (*Gastroenterological Surgery, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 43 : Navigation Surgery

P43-3 A prospective observational study of near-infrared fluorescent marking clips in laparoscopic gastrectomy

Koshi Kumagai (*Department of Gastroenterological Surgery, The Cancer Institute Hospital of JFCR, Tokyo, Japan*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 44 : Peritoneal dissemination

P44-1 Does D2 lymph node dissection increase the risk of intraperitoneal recurrence of gastric cancer after radical surgery?

Roman Yarema (*Danylo Halytsky Lviv National Medical University, Lviv, Ukraine*)

P44-2 Expression profiles and preliminary application of exosomal Hsa_circ_0005191 in peritoneal metastasis of gastric cancer

Dongbao Li (*Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China / The First Affiliated Hospital of Soochow University*)

P44-3 Identification and validation of crucial lnc-TRIM28-14 and hub genes promoting gastric cancer peritoneal metastasis

Chao Dong (*Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215000, China*)

P44-4 Gastric cancer with peritoneal carcinomatosis: risk scoring system to predict mortality

Andre Roncon Dias (*Instituto do Cancer, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo - Departament of Gastroenterology, Brazil*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 44 : Peritoneal dissemination

P44-5 Proteomic profiling identifies a protein signature predictive for peritoneal dissemination and patient outcome in gastric adenocarcinoma

Yanyan Chen (*Department of Surgical Oncology, First Affiliated Hospital, Zhejiang University School of Medicine, China*)

P44-6 Treatment options of delivering intraperitoneal chemotherapy for patients with advanced gastric cancer and severe peritoneal metastasis

Dong-Wook Kim (*Dankook University Hospital, South Korea*)

P44-7 Gastric cancer patients treated by hyperthermic intraperitoneal chemotherapy with peritoneal cancer index < 12 can benefit from cytoreductive surgery

Shiyang Jin (*Department of Gastrointestinal Surgery, Harbin Medical University Cancer Hospital, China*)

P44-8 Feasibility of staging laparoscopy for detecting peritoneal recurrence for gastric cancer after gastrectomy: multi-institutional prospective study

Atsushi Takeno (*Department of Surgery, Osaka National Hospital, Japan*)

P44-9 Clinical impact of two taxanes in intraperitoneal chemotherapy for peritoneal disseminated gastric cancer

Yasuo Hirono (*Cancer Care Promotion Center, University of Fukui Hospital, Japan / Department of Gastroenterological Surgery, University of Fukui Hospital*)

P44-10 Rapid detection of peritoneal metastasis from gastric cancer by deep learning-based stimulated Raman cytology

Zhouqiao Wu (*Gastrointestinal Cancer Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 45 : CART

P45-1 An overview of the targets and application dilemmas of chimeric antigen receptor T-cell immunotherapy

Binghe Zhao (*PLA General Hospital, Beijing, China / Nankai University*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 45 : CART

P45-2 An overview of the targets and application dilemmas of chimeric antigen receptor T-cell immunotherapy

Binghe Zhao (*Department of General Surgery, the First Medical Center of the General Hospital of the People's Liberation Army, China*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 47 : Liver metastasis

P47-1 Long-term prognosis treated with liposome-Adriamycin via the portal vein for prophylaxis and cure of liver metastasis

Isamu Mizuno (*Surg, MIDORI MUNICIPAL HOSPITAL, NAGOYA CITY UNIVERSITY, Japan*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 47 : Liver metastasis

P47-2 The effect of surgical resection on gastric cancer patients with synchronous liver metastases: a retrospective single center and propensity score-matched (PSM) study

Yu Pingyuan (*Department of Gastric Surgery, Zhejiang Cancer Hospital, Hangzhou, China / Wenzhou Medical University*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 48 : Recurrence

P48-1 Current status of remnant gastric cancer in our institution, from the perspective of ways of reconstruction in the initial gastrectomy, Billroth-I versus Billroth-II

Jun Sakuma (*NTT Medical Center Tokyo, Japan*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 49 : Early gastric cancer

P49-1 A nomogram for predicting lymph node metastasis in early gastric cancer

Hao Cui (*The Department of General Surgery, the Chinese PLA General Hospital, Beijing, China / School of Medicine, Nankai University, Tianjin, China*)

P49-2 Plasma metabolomics and lipidomics reveal potential novel biomarkers in early gastric cancer

Feng Wang (*Department of Endoscopy Center, Peking University First Hospital, Beijing 100034, China*)

P49-3 Early gastric cancer: experience of 40 cases at a private single center in the west

Flávio Silano (*Hospital Aliança / Rede D'or São Luiz, Brazil*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 49 : Early gastric cancer

P49-4 Examination of characteristics in early gastric cancer according to different time periods

Ayaka Takasu (*Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan*)

P49-5 Safety and short-term outcomes in patients with early gastric cancer undergoing vagus nerve preserving gastrectomy

Xinyu Wang (*Tianjin Medical University Cancer Institute and Hospital, Tianjin, China*)

P49-6 Clinicopathological features of metachronous gastric cancer after eradication

Hajime Teshima (*Department of Endoscopy, Hiroshima University Hospital, Hiroshima, Japan*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 50 : Advanced gastric cancer

P50-1 Surgery for locally advanced gastric cancer in a Western tertiary referral center: something new?

Fausto Rosa (*Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy*)

P50-2 Laparoscopic gastrectomy is as safe as open gastrectomy for Borrmann type IV advanced gastric cancer: a retrospective comparative study

Eunju Lee (*Department of Surgery, Seoul National University Bundang Hospital, Seongnam-si, South Korea*)

P50-3 Differentially expressed genes and pathway enrichment analyses in chemo-immunotherapy responders versus non-responders advanced stage gastric cancer patients

Mauricio P. Pinto (*Department of Hematology and Oncology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile*)

P50-4 Clinical outcomes and additional treatment of Stage IV gastric adenocarcinoma with R0 or R1 resection

Ritsuki Takaha (*Department of Surgery, Gifu Prefectural General Medical Center, Japan*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 50 : Advanced gastric cancer

P50-5 Evaluation of the present status of CGP for refractory gastric cancer at provincial core hospital

Hisashi Hara (*Osaka International Cancer Institute, Japan*)

P50-6 Consideration to optimal treatment for gastric cancer with positive peritoneal lavage cytology

Kazuki Asanuma (*Kin-ikyo Chuo Hospital, Sapporo, Japan*)

P50-7 Surgical outcomes of gastrectomy after preoperative chemotherapy for gastric cancer in our hospital

Taisuke Yagi (*Division of Surgery, National Hospital Organization Miyakonojo Medical Center, Japan*)

P50-8 Treatment strategies of conversion surgery for stage IV gastric cancer

Kazuhiko Hisaoka (*Department of Surgery, Saitama Medical University International Medical Center, Japan*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 51 : Scirrhous gastric cancer

P51-1 Survival result of gastrectomy plus adjuvant S-1 therapy for type 4 or large type 3 gastric cancer with CY1

Ryota Sakon (*Department of Gastric Surgery, National Cancer Center Hospital, Tokyo, Japan*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 52 : Gastric stump carcinoma

P52-1 Clinicopathological features of gastric stump carcinoma in our institute

Takahiro Tsuchiya (*Department of Surgery, Tohoku University, Sendai, Japan*)

P52-2 Subtotal gastrectomy with lymph node dissection as surgical treatment for remnant gastric cancer

Lloyd Nario Bordeos (*Department of Surgery, Yonsei University College of Medicine, and Gastric Cancer Center, Seoul, South Korea / Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea / Division of Surgical Oncology, Department of Surgery, Vicente Sotto Memorial Medical Center, Cebu, Philippines*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 52 : Gastric stump carcinoma

P52-3 Evaluating the optimal treatment strategy for early and advanced remnant gastric cancer

Masato Hayashi (*The Department of Surgery, Tochigi Cancer Center, Tochigi, Japan*)

P52-4 Lymph node standards in the remnant gastric adenocarcinoma

Oswaldo Antônio Prado Castro (*Santa Casa of Sao Paulo - Hospital and Medical School, Brazil*)

P52-5 T stage and venous invasion are crucial prognostic factors for long-term survival of patients with remnant gastric cancer

Kentaro Matsuo (*Department of General and Gastroenterological Surgery, Osaka Medical and Pharmaceutical University, Japan*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 54 : Gastric tube cancer

P54-1 Indocyanine green fluorescence imaging for evaluating blood flow in the gastric conduit after esophageal cancer surgery

Tasuku Toihata (*Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 55 : Esophago-gastric junction cancer

P55-1 Clinical characteristics and prognostic outcomes for adenocarcinoma of esophagogastric junction in early-onset patients--a population-based appraisal

Hongkun Lai (*Department of Gastrointestinal Surgery, Guangdong Provincial People's Hospital; Guangdong Academy of Medical Sciences, China / The Second School of Clinical Medicine, Southern Medical University, Guangzhou 510515, Guangdong, China*)

P55-2 Can diffuse-type histology classify Siewert I's as gastric cancer?

Kelly M Mahuron (*Department of Surgery, City of Hope National Medical Center, Duarte, CA, United States*)

P55-3 Surgical treatment and postoperative recurrence for Siewert type 1 and type 2 esophago-gastric adenocarcinoma

Takashi Hashimoto (*Department of Esophageal & Gastroenterological Surgery, Juntendo University Graduate School of Medicine, Tokyo, Japan*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 55 : Esophago-gastric junction cancer

P55-4 Selection of surgical technique in adenocarcinoma of the esophago-gastric junction

Takeshi Miwa (*Department of Surgery and Science, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan*)

P55-5 A case of multimodal treatment of patient with locally advanced GEJ cancer with esophageal stenosis and vascular pathology

Nikolay Semenov (*Moscow Clinical Scientific Center named after A.S. Loginov, Moscow, Russia*)

P55-6 Gastric and bile acids enhance demethylation and lead to chromosomal instability in Barrett's epithelial cell line

Iku Abe (*Department of Surgery, Saitama Medical Center, Jichi Medical University, Saitama, Japan*)

P55-7 Integrative proteomic characterization of adenocarcinoma of esophagogastric junction

Li Yuan (*Department of Gastric Surgery, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institutes of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China*)

P55-8 Total laparoscopic gastrectomy with programmed pi-shaped anastomosis in Siewert type II adenocarcinoma of esophagogastric junction

Li Yang (*Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 56 : Gastric cancer in elderly patients

P56-1 The significance of preservation and reconstruction of the cardia in gastrectomy for elderly gastric cancer patients

Megumi Watanabe (*The Department of Surgery, National Hospital Organization Iwakuni Clinical Center, Japan*)

P56-2 Laparoscopic distal gastrectomy: just an option or the new gold standard for elderly patients?

Jacopo Viganò (*General Surgery 1, Fondazione IRCCS Policlinico San Matteo, Italy*)

P56-3 Laparoscopic gastrectomy for gastric cancer patients aged 80 years or older

Toshiyuki Tanahashi (*Department of Surgery, Gifu Municipal Hospital, Gifu, Japan*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 56 : Gastric cancer in elderly patients

P56-4 Mortality risk of minimally invasive gastrectomy for gastric cancer in the very elderly

Kohei Fujita (*Department of Gastroenterological Surgery, Kariya Toyota general hospital, Japan*)

P56-5 Withdrawn

P56-6 Association between National Clinical Database-based estimated surgical risk and survival duration after laparoscopic distal gastrectomy in patients with gastric cancer aged over 80 years

Shunta Ishizaki (*Department of Surgery, The Jikei University School of Medicine, Japan*)

P56-7 Brief preoperative frailty screening predicts adverse postoperative outcomes in elderly patients with radical gastric cancer surgery

Zi-Yao Xu (*Department of General Surgery, The First Medical Center of Chinese PLA General Hospital, Beijing, China*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 57 : AFP-producing gastric cancer

P57-1 Management of gastric hepatoid adenocarcinoma in the United States: a review of national cancer database

Neha Lalit Lad (*Northwell Health, United States*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 59 : Gastrointestinal stromal tumor

P59-1 Proximal gastrectomy with double-tract reconstruction for a gastrointestinal stromal tumor of the esophago-gastric junction : how we do it in the west

Joao Maia Teixeira (*General Surgery - CHUA Faro, Portugal*)

P59-2 Single incision intragastric wedge resection for gastric subepithelial tumors, tunneling procedure

Duyeong Hwang (*The department of surgery, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, South Korea*)

P59-3 A 13-KG gastric GIST in asymptomatic patient: a rare case of giant GIST and literature review

Flávio Silano (*Hospital Aliança / Rede D'or São Luiz, Brazil*)

P59-4 Comparison of neoadjuvant and adjuvant treatment of gastrointestinal stromal tumor; single center study

Daegeun Park (*Department of General Surgery, Kyung Hee University Hospital, Seoul, South Korea*)

P59-5 OX40L, a new choice of immunotherapy for gastrointestinal stromal tumors

Qiang Zhang (*Department of General Surgery, Zhongshan Hospital, Fudan University, Department of General Surgery, Zhongshan, China*)

P59-6 The efficacy of neoadjuvant chemotherapy for locally advanced gastric gastrointestinal stromal tumor

Toshihiro Soeta (*Department of Surgery, Tohoku University, Sendai, Japan*)

P59-7 Intra-abdominal desmoid tumors after laparoscopic and endoscopic cooperative surgery for gastric GIST

Takeshi Matsubara (*Department of Digestive and General Surgery, Shimane University Faculty of Medicine, Japan*)

P59-8 Surgical resection for focally progressive peritoneal metastatic/recurrent GISTs of the stomach treated with imatinib/sunitinib therapy

Kazuki Inaba (*Department of Advanced Robotic and Endoscopic Surgery, Fujita Health University, Japan*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 59 : Gastrointestinal stromal tumor

P59-9 Withdrawn

P59-10 Construction and validation of a nomogram for patients with primary gastrointestinal stromal tumor after complete cytoreductive surgery

Mingwei Ma (*The Department of General Surgery, Peking Union Medical College Hospital, Beijing, China*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 61 : Gastric neuroendocrine tumor

P61-1 Establishment and validation of a predictive model for lymph node metastasis of gastric neuroendocrine neoplasms

Benlong Zhang (*Department of General Surgery, the First Medical Center of Chinese PLA General Hospital, Beijing, China / General Hospital of the People's Liberation Army, No. 28, Fuxing Road, Wanshou Road, Haidian District, Beijing, 100853*)

P61-2 Establishment and validation of a nomogram prognostic prediction model for 490 gastric neuroendocrine neoplasms in a single center

Benlong Zhang (*Department of General Surgery, the First Medical Center of Chinese PLA General Hospital, Beijing, China*)

P61-3 Clinicopathological characteristics, therapeutic strategy and prognosis analysis of 501 cases of gastric neuroendocrine neoplasms in a single center

Benlong Zhang (*Department of General Surgery, the First Medical Center of Chinese PLA General Hospital, Beijing, China*)

P61-4 The clinicopathological characteristics of malignant gastric neuroendocrine neoplasms and the establishment and validation of a nomogram prognostic model

Benlong Zhang (*Department of General Surgery, the First Medical Center of Chinese PLA General Hospital, Beijing, China*)

P61-5 Prognosis evaluation and molecular typing of gastric neuroendocrine tumors based on proteomics and nonnegative matrix factorization model

Benlong Zhang (*Department of General Surgery, the First Medical Center of Chinese PLA General Hospital, Beijing, China*)

P61-6 Analysis of resected cases of gastric neuroendocrine neoplasms in our institution

Yosuke Morimoto (*Department of Surgery, Keio University School of Medicine, Japan*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 63 : Clinical pathway

P63-1 Surgical starting time of the day and survival in gastric cancer

Lin Chen (*Senior Department of General Surgery, Chinese PLA General Hospital, China*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 67 : Outcome

P67-1 Current status of gastric cancer surgery in elderly patients over 90 years old

Jo Tokuyama (*Department of Surgery, Nerima General Hospital, Tokyo, Japan*)

P67-2 Impact of postoperative NSAIDs (IV-PCA) use on short-term outcomes after laparoscopic gastrectomy for the patients of gastric cancer

So Jung Kim (*Division of Gastrointestinal Surgery, Department of Surgery, College of medicine, The Catholic University of Korea, Seoul, South Korea*)

P67-3 Double tract reconstruction was superior to esophagogastrostomy in postoperative quality of life and maintenance BMI

Wang Zi Jian (*Department of General Surgery, The First Medical Center of Chinese PLA General Hospital, Beijing, China*)

P67-4 Double tract reconstruction was superior to esophagogastrostomy in postoperative quality of life and maintenance BMI

Wang Zi Jian (*Department of General Surgery, The First Medical Center of Chinese PLA General Hospital, Beijing, China*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 67 : Outcome

P67-5 Overall survival of gastrectomy patients and 90-days mortality rate

Enkh-Amgalan Tsiiregzen (*Surgery Department, Intermed Hospital, Ulaanbaatar, Mongolia, Mongolia*)

P67-6 The efficacy of palliative gastrectomy plus chemotherapy in gastric cancer patients with peritoneal metastasis: a retrospective study

Zhihui Jiang (*The Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang, China / Wenzhou Medical University*)

P67-7 Impact of socioeconomic factors on deviation from intended treatment in non-metastatic gastric cancer patients: an institutional experience

Matthew Porembka (*University of Texas Southwestern Medical Center, United States*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 68 : QOL assessment

P68-1 Different methods of minimally invasive esophagojejunostomy after total gastrectomy for gastric cancer: outcomes from two experienced centers

Yongjia Yan (*The Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, China*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 68 : QOL assessment

P68-2 Western validation of KOQUSS-40 questionnaire assessing QoL of gastric cancer patients after gastrectomy

Federica Filippini (*Department of Surgical, Odontostomatologic, Maternal and Child Sciences, University of Verona, Italy*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 69 : Cachexia

P69-1 Soluble PD-L1 reflects cachexia status in gastric cancer patients and is a independent prognostic marker for relapse-free survival after radical surgery

Shinichiro Iida (*Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Japan*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 70 : Nutrition

P70-1 Risk factors in psoas muscle volume reduction 1 year after robotic/laparoscopic gastrectomy for gastric cancer

Sachiko Kaida (*Department of Surgery, Shiga University of Medical Science, Japan*)

P70-2 Comparing the change in body composition as a nutritional status between reconstruction methods after PG

Erica Nishimura (*Department of Surgery, Keio University School of Medicine, Tokyo, Japan*)

P70-3 External validation of prediction model for screening patients at risk of malnutrition after gastric cancer surgery

Ji-Hyeon Park (*Department of Surgery, Seoul National University Hospital, Seoul, Korea, South Korea / Department of Surgery, Gachon University Gil Medical Center, Incheon, Korea*)

P70-4 Malnutrition associated with postoperative complications following gastrectomy in patients with gastric cancer

Hsin-Chia Angela Lin (*Department of Surgery, Chang Gung Memorial Hospital at Chiayi, Taiwan*)

P70-5 Weight and body composition changes after radical gastrectomy in obese patients: using artificial intelligence software

Seong-A Jeong (*Division of Gastrointestinal Surgery, Department of General Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea*)

P70-6 Examination of early administration of BCAA-enriched PPN after gastrectomy

Mikiko Sakuraya (*Department of Upper Gastrointestinal Surgery, Kitasato University School of Medicine, Japan*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 70 : Nutrition

P70-7 Nurturing nutrition - inspiring patients and caregivers to embrace nutrition as an integral part of their recovery and overall health

Hans Jochem Rueffert (*Gastric Cancer Foundation, United States*)

P70-8 Five-year results of nutritional status after gastrectomy in patients with gastric cancer

Jong Hyuk Yun (*The department of surgery, Soonchunhyang university cheonan hospital, Cheonan, Korea, South Korea*)

P70-9 Reconstruction with distal gastrectomy affects postoperative nutrition in elderly patient or not

Saburou Sugita (*Surgery, Toyota Memorial Hospital, Aichi, Japan*)

P70-10 The necessity and safety of early oral feeding in fast-track program among patients after gastrectomy for stomach cancer

Rostislav Pavlov (*Saint Petersburg State Unoversity, Russia*)

P70-11 The primary outcomes of our new perioperative nutrition care program for resected gastric cancer patients

Mai Tsutsui (*Department of Gastroenterological Surgery, Tachikawa Hospital, Tokyo, Japan*)

P70-12 Impact of sarcopenia on long term survival for gastric cancer patients performed total gastrectomy

Takahiro Muroya (*Gastroenterological Surgery, Hirosaki University Graduate School of Medicine, Aomori, Japan*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 71 : Obesity

P71-1 Withdrawn

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 71 : Obesity

P71-2 One-year outcome of Laparoscopic sleeve gastrectomy plus jejunojejunal bypass for obese patients: a multicenter propensity score-matched analysis

Yongquan Chen (*Department of Gastrointestinal Surgery, Department of General Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, PR, China*)

P71-3 A picture of body mass index (BMI) in gastric cancer treatment: the Italian group of gastric cancer research (GIRCG) experience

Lorena Torroni (*Unit of Epidemiology and Medical Statistics, Department of Diagnostics and Public Health, University of Verona, Verona, Italy*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 72 : Case report

P72-1 Totally laparoscopic wedge resection of bronchogenic cyst at the esophagogastric junction : a case report

Sung Il Choi (*Department of Surgery, Kyung Hee University Hospital at Gangdong, Seoul, South Korea*)

P72-2 Synchronous early gastric cancer: how important is a meticulous endoscopic examination?

Flávio Silano (*Hospital Aliança / Rede D'or São Luiz, Brazil*)

P72-3 Gastric adenocarcinoma with enteroblastic differentiation: a report of three cases

Hideyuki Wada (*Department of Surgery, Hakodate National Hospital, Hokkaido, Japan / Department of Gastroenterological Surgery II, Hokkaido University Faculty of Medicine, Hokkaido, Japan*)

P72-4 A case of mesenteric fibromatosis (desmoid tumor) mimicking recurrent gastrointestinal stromal tumor during imatinib treatment

Daegeun Park (*Department of General Surgery, Kyung Hee University Hospital, Seoul, South Korea*)

P72-5 Laparoscopic excision for ectopic peritoneal paragonimiasis mimicking a gastric duplication cyst: a case report

Chulkyu Roh (*National Police Hospital, South Korea*)

P72-6 Three cases of gastric cancer in the elderly in which the patient's and family's wishes were confirmed and the treatment method was selected on the basis of continuous ACP

Naoto Kurihara (*Department of Surgery, Nerima General Hospital, Tokyo, Japan*)

P72-7 Multiple skin metastases as the initial presentation of gastric adenocarcinoma

Paula Strauch Costa (*Santa Casa of Sao Paulo, Medical School and Hospital. Gastroesophageal and Bariatric Division, Brazil*)

P72-8 Surprisingly important signs of pathological regression in a patient who did not receive neoadjuvant chemotherapy

Anna Clara Hebling Mitidieri (*Santa Casa of Sao Paulo, Medical School and Hospital. Department of Surgery Gastroesophageal and Bariatric Division, Brazil*)

P72-9 Hepatoid adenocarcinoma of the stomach: a case report of a rare subtype of gastric cancer

Geum Jong Song (*Department of Surgery, Soonchunhyang University Cheonan Hospital, Cheonan, South Korea*)

P72-10 The effectiveness of naso-esophageal extraluminal drainage for esophagojejunal anastomotic leakage after laparoscopic total gastrectomy: a case report

Yuriko Uehara (*Department of Gastroenterological Surgery, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan*)

P72-11 Recurrence after ESD curative resection for early gastric cancer

Ayako Kamiya (*Department of Gastric Surgery, National Cancer Center Hospital, Tokyo, Japan*)

P72-12 Brain-only metastasis and 10-year survival after curative gastric cancer resection: a case report

Woo Yong Lee (*The Department of Surgery, University of Inje Haeundae Paik Hospital, South Korea*)

P72-13 A rare surgical case of gastric idiopathic abdominal apoplexy

Mai Okawa (*Department of Surgery, Gifu Municipal Hospital, Gifu, Japan*)

P72-14 Procedure and short-term results of transmediastinal esophagectomy for esophago-gastric junction cancer

Yasushi Rino (*Department of Surgery, Yokohama City University, Yokohama, Japan*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 72 : Case report

P72-15 A case of gastric calcifying fibrous tumor which presented clinically malignant findings treated with laparoscopic partial gastrectomy

Emiri Sugiyama (*Department of Gastroenterological and Pediatric Surgery, Gifu University Graduate School of Medicine, Gifu, Japan*)

P72-16 A case of laparoscopic distal gastrectomy for advanced gastric cancer with situs inversus totalis

Shunsuke Fujita (*Department of Gastroenterological and Pediatric Surgery, Oita University Faculty of Medicine, Oita, Japan*)

P72-17 A case of gastrointestinal stromal tumor with a diverticulum-like structure

Denda Yuki (*Department of Gastroenterological Surgery, Toyota Memorial Hospital, Japan / Nagoya city University Hospital*)

P72-18 Diagnostic sign of Petersen's hernia on CT imaging: two case reports

Mizuki Fukuda (*Department of Surgery, The Jikei University School of Medicine, Japan*)

P72-19 What makes the lymph node invasion be so different? Case report of two patients

Anna Clara Hebling Mitidieri (*Santa Casa of Sao Paulo, Medical School and Hospital, Department of Surgery, Gastroesophageal and Bariatric Division, Brazil*)

P72-20 A case of squamous cell carcinoma of the stomach

Yu Ueta (*Department of Surgery, Dokkyo Medical University Nikko Medical Center, Japan / Surgical Oncology, Graduate School of Medicine, Dokkyo Medical University*)

P72-21 A case of neuroendocrine carcinoma of the esophagogastric junction

Yusuke Seki (*Surgical Oncology, Graduate School of Medicine, Dokkyo Medical University, Japan*)

P72-22 Feeding gastrostomy after spontaneous stomach perforation by L- tube

Sangchul Yun (*Department of surgery, Soonchunhyang University, Seoul, South Korea*)

P72-23 Lymphoepithelioma-like gastric carcinoma with persistent elevation of tumor markers:a case report

Isabela Couto Mendonça (*Clinical Hospital, Federal University of Goiás, Brazil*)

P72-24 Ectopic pancreas and Brunner's gland bulky hyperplasia mimetizing gastric tumor: a case report

Isabela Couto Mendonça (*Clinical Hospital, Federal University of Goiás, Brazil*)

P72-25 Surgical outcome and recurrence treatment for GIST of the stomach

Shota Hoshino (*Department of Surgery, Keio University School of Medicine, Tokyo, Japan*)

P72-26 Gastric lymphoma with acute perforation and abdominal hemorrhage: a case report

Isabela Couto Mendonça (*Clinical Hospital, Federal University of Goiás, Brazil*)

P72-27 Gastric adenocarcinoma with portal vein thrombosis: a case report

Isabela Couto Mendonça (*Clinical Hospital, Federal University of Goiás, Brazil*)

P72-28 A case of gel immersion endoscopic mucosal resection of a gastric hyperplastic polyp with adenocarcinoma

Kohei Shigeta (*Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan*)

P72-29 Massive gastric polyposis, Is there another case of Cronkhite-Canada syndrome?: a case report

Lea Spalova (*Department Of Surgery, Hospital AGEL Novy Jicin, a.s., Czech Republic*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 74 : Multidisciplinary treatment

P74-1 Long-term outcome of gastric cancer treatment in patients with oligometastasis

Kentaro Hara (*The Department of Gastric Surgery, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan*)

P74-2 Radical surgery in negative preoperative histology in gastric cancer and the relation to perioperative chemotherapy - case series

Petra Ochmanová (*Department of Surgery I, University Hospital Olomouc, Czech Republic / Faculty of Medicine and Dentistry, Palacký University Olomouc, Czech Republic*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 74 : Multidisciplinary treatment

P74-3 Comparison of pathological results and long-term survival of patients with gastric cancer operated in a reference center versus non-specialized centers

Marcus Fernando Kodama Pertille Ramos (*Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Brazil*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 75 : Palliative therapy

P75-1 Prognostic role of primary tumor resection among metastatic adenocarcinoma of the esophagogastric junction and construction of a predictive nomogram: a population-based study

Wenfei Diao (*Department of Gastrointestinal Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 75 : Palliative therapy

P75-2 Withdrawn

P75-3 Shenqi Fuzheng Injection combined with chemotherapy for gastric cancer: an overview of systematic reviews and meta-analyses

Jing Xu (*Department of Hematology and oncology, Dongzhimen Hospital Affiliated with Beijing University of Chinese Medicine, China*)

P75-4 Feasibility, safety and efficacy of partially covered self-expandable metal stents for leaks after esophageal or gastric resection for malignancies: a single center experience

Ivana Bravi (*Division of Endoscopy, European Institute of Oncology, IRCCS, Milan, Italy*)

June 15 (Thu.) / 16:10-16:40 / 3F (Poster Viewing)

Poster 76 : Team approach

P76-1 Psycho-oncology as neoadjuvant treatment for gastrointestinal cancers

Joel D Marcus (*University of Texas Health Center at Tyler, United States*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 77 : Patient Advocacy

P77-1 Gastric Cancer Foundation - forging alliances and partnerships to advocate for gastric cancer patients and scientific research

Hans Jochem Rueffert (*Gastric Cancer Foundation, United States*)

June 16 (Fri.) / 15:20-15:50 / 3F (Poster Viewing)

Poster 78 : Remnant gastric cancer

P78-1 Long-term prognosis of patients undergoing surgery for remnant gastric cancer

Keiso Ho (*Department of Surgery, School of Medicine, Keio University, Japan*)

M _____
 Malheiros, Carlos Alberto Multidisciplinary 8
 Mano, Hiroyuki Translational 4
 Mansfield, Paul F. Multidisciplinary 6, ML1, PAS1
 Matsuda, Satoru Translational 3
 Melen, Steve PAS4
 Mönig, Stefan Paul Multidisciplinary 2, O33
 Mori, Masaki ML1
 Muro, Kei Medical Oncology 4

N _____
 Nakada, Koji PAS4
 Narita, Yukiya
 Networking sessions for young investigator
 Natsugoe, Shoji Surgery 10
 Nilsson, Magnus Multidisciplinary 9, O12
 Nishida, Toshirou Medical Oncology 3
 Nishihara, Hiroshi Translational 5
 NOH, SUNG HOON Multidisciplinary 1

O _____
 Obama, Kazutaka LS5, LS8
 Ochiai, Atsushi Pathology

P _____
 Park, Do Joong Surgery 5
 Park, Ji-Hyeon PAS4

R _____
 Ra, Seungkee PAS3
 Rha, Sun Young Medical Oncology 3, O26
 Roviello, Franco Surgery 4, PAS1, O24

S _____
 Sano, Takeshi
 PL, Multidisciplinary 1, Palliative Care
 Sasako, Mitsuru Multidisciplinary 2
 Satoh, Taroh LS12
 Seto, Yasuyuki Multidisciplinary 9, MS2
 Sharma, Prateek Endoscopy 2
 Shen, Lin LS14
 Shimada, Hideaki MS3
 Shinohara, Hisashi Translational 1, LS3
 Shitara, Kohei Medical Oncology 2
 Smyth, Elizabeth Catherine Translational 3, O4
 So, Jimmy
 Multidisciplinary 6, Translational 4, PAS2, O3
 Sun, Yihong LS13

T _____
 Tajiri, Hisao LS9
 Takeda, Flavio Roberto O6, O11
 Takeuchi, Hiroya Surgery 10, O8, LS1
 Takiguchi, Shuji Surgery 3
 Tan, Hon Lyn
 Networking sessions for young investigator
 Terashima, Masanori Multidisciplinary 7, LS4, LS7
 Todoroki, Hiromi PAS1, PAS2
 Tokunaga, Masanori O28

U _____
 Ushijima, Toshikazu Translational 5

Uyama, Ichiro Surgery 1

V _____
 van Hilleegersberg, Richard
 Multidisciplinary 10, Surgery 8, PAS4, O21
 Vincelli, Melani PAS3

W _____
 Wijnhoven, Bas GI, Multidisciplinary 7, ML2
 Wu, Yinying LS14

X _____
 Xiao, Zili Endoscopy 4

Y _____
 Yamamoto, Masaaki
 Networking sessions for young investigator
 Yang, Han-Kwang JPK, PAS3
 Yasui, Wataru Translational 2
 Yoshida, Kazuhiro LS13
 Yoshikawa, Takaki Multidisciplinary 3, O10

Z _____
 Zhang, Yanqiao LS13
 Zhu, Zhenggang PAS1, LS13

Speakers

GI = Upper GI Summit	ML1 = Access to gastric cancer care	O = Oral
NT = Nishi-Takahashi Lecture	ML2 = Hereditary gastric cancer (prevention and treatment)	P = Poster
JPK = Jin Pok Kim Lecture	ML4 = Contributions of big data science to gastric cancer treatment	LS = Luncheon Seminar
PL = Presidential Lecture		MS = Morning Seminar
MK = Masaki Kitajima Memorial Lecture		ES = Evening Seminar
PS = Plenary Session	PAS = Patient Advocacy Session	

A

Abate, Misker Eshetu	O34-1
Abdelrahim, Mohamed	O18-5
Abe, Iku	P55-6
Abe, Nobutsugu	Endoscopy 1-1
Aburatani, Hiroyuki	Translational 4-1
Aizawa, Masaki	Endoscopy 1-3
Ajani, Jaffer A	Multidisciplinary 4-3
Akaike, Hidenori	P23-3
AlRomi, Ahmad Salem	O29-6
Aoyama, Junya	O20-6
Aoyama, Toru	O31-5
Aoyama, Yoshimasa	O27-2
Arai, Tomio	Pathology -1
Arakawa, Hiroshi	Multidisciplinary 8-5
Arigami, Takaaki	Multidisciplinary 3-1
Arvide, Elsa M.	O14-4
Asanuma, Kazuki	P50-6
Ashizawa, Hiroshi	Endoscopy 3-5

B

Baba, Eishi	PAS2-1
Baba, Shigeaki	P31-15
Back, Johan Julius	O10-5
Bagnacci, Giulio	O1-5
Baiocchi, Gian Luca	PAS4-1, O3-3
Bencivenga, Maria	O16-5, O19-3, P26-2
Benzoni, Ilaria	P41-10
Berlth, Felix	P33-9
Boiko, Natalia	P8-3
Boku, Narikazu	Multidisciplinary 1-2
Boo, Yeojin	O30-1
Booka, Eisuke	O12-3
Bordeos, Lloyd Nario	P52-2
Brasset, Camille	Surgery 5-5
Bravi, Ivana	P75-4
Buckarma, EeeLN H	P35-1
Burch, Miguel	O6-3

C

Cao, Bo	P27-3, P27-4
Caspers, Irene Arianne	P3-3, P3-5
Castro, Osvaldo Antônio Prado	ML1-4, P18-15, P52-4
Chae, Yoon Soo	O6-5
Chan, Kai Siang	P33-22
Chan, Shannon Melissa	P30-10
Chang, Yi-Lin	P2-13

Chang, Zhengyao	P2-14
Chau, Ian	Medical Oncology 4-1, Translational 2-1
Chen, Lin	Multidisciplinary 5-5, P63-1
Chen, Qi-Yue	P20-17
Chen, Shi	P31-9
Chen, Xingyu	P2-4
Chen, Xin-Zu	P1-1, P1-5
Chen, Yanyan	P44-5
Chen, Yonghe	P22-15
Chen, Yongquan	P71-2
Chen, Zetian	P7-12
Chen, Zhian	P28-4
Chen, Zhida	P16-1
Cheng, Xiangdong	P31-11, LS11-1, LS13-2
Cherchenko, Kateryna	P22-13
Chevallay, Mickael	O6-2
Chikaishi, Wakana	P21-6
Cho, Minah	O25-5
Choi, Cheol Woong	P9-5
Choi, Sung Il	P72-1
Chong, Xiaoyi	P6-7
Chung, Jae Hun	P32-10, LS5-1
Cinelli, Lorenzo	P32-36
Cossu, Andrea	P26-4
Costa, Paula Strauch	O3-2, P30-9, P72-7
Couto Mendonça, Isabela	P72-23, P72-24, P72-26, P72-27
Cui, Hao	P22-2, P28-1, P32-3, P33-1, P49-1

D

Dal Cero, Mariagiulia	P17-1
Dalmonte, Giorgio	O30-2
Dang, Thong Quang	P32-33
de Almeida, Suzana Tyrrasch	P2-22
de Manzoni, Giovanni	JPK, Pathology-2
Diao, Wenfei	P75-1
Dias, Andre Roncon	P26-5, P44-4
Doan, Nguyen Thuy	P2-17
Doi, Toshihiko	Medical Oncology 3-2
Dong, Chao	P44-3
Drebin, Harrison M.	O7-4

E

Ehara, Kazuhisa	LS8-2
Endo, Shunji	Multidisciplinary 10-1
Eom, Bang Wool	PS5
Eom, Sang Soo	O3-1, P32-22
Esaki, Mitsuru	O18-3
Eto, Kojiro	P18-5

Etoh, Tsuyoshi Multidisciplinary 2-3

F

Fang, Jingquan O24-1
Fang, Lang P13-4
Filippini, Federica P68-2
Frejlich, Ewelina P6-14
Fujimoto, Daisuke P23-1
Fujita, Kohei P56-4
Fujita, Shunsuke P72-16
Fukagawa, Takeo Multidisciplinary 8-1
Fukami, Tomoyuki P6-9
Fukuda, Mizuki P72-18
Furube, Tasuku P20-6
Furukawa, Haruna P30-8

G

García, Carlos A. ML1-1
Giacopuzzi, Simone PS6
Gong, Seong Chan P41-11
Gou, Miaomiao O25-3
Guan, Xiaoqing P27-8

H

Habu, Takumi O10-1
Hagiwara, Ken O28-5
Hamada, Satoshi P32-35
Han, Fanghai O17-1, P20-18
Han, Jing P20-4
Haneda, Ryoma O4-3
Hara, Hisashi P50-5
Hara, Kentaro P74-1
Harada, Hiroki P32-8
Harada, Hitoshi Multidisciplinary 8-6
Harigane, Kohei P17-3
Hartgrink, Henk Multidisciplinary 2-1
Hashiguchi, Saori Palliative Care -2
Hashimoto, Isaya P33-6
Hashimoto, Takashi P55-3
Hatanaka, Yuji P33-14
Hayakawa, Shunsuke O8-3
Hayami, Masaru O33-4
Hayano, Koichi P21-12
Hayashi, Hikota P41-14
Hayashi, Hirokatsu P18-16
Hayashi, Masato P52-3
Hayashi, Tsutomu Surgery 8-4, O33-1
He, Siyi Endoscopy 4-4, P13-3
Higuchi, Tadashi P31-8
Higuchi, Yudai O12-4
Hiki, Naoki LS10-1
Hirano, Katsuhisa P33-10
Hirata, Yuki ML4-3, O23-5
Hirono, Yasuo P44-9
Hirota, Masashi P21-10
Hisaoka, Kazuhiko P50-8
Hisatsune, Yasuhito P32-40
Hlaing, Khin Hsu P31-19
Ho, Chi-Lee Charlie P6-2
Ho, Keiso P78-1
Ho, Khek Yu Endoscopy 2-1

Hofstetter, Wayne L.

Multidisciplinary 9-1, Multidisciplinary 11-2
Hoshino, Shota P72-25
Hosokai, Taisuke P28-7
Htet, Hein O27-3
Hu, Can P7-5, P11-2
Hu, Qingjiang Translational 5-3
Hu, Wen Qing P34-2
Hu, Yilin P7-7
Huang, Binhao P7-15
Huang, Hongxin P7-16
Huang, Xingmao O26-2
Huangfu, Longtao P2-1
Huo, Mingyu P7-13
Hwang, Duyeong P59-2
Hwang, Jawon O22-2
Hwang, Sun-Hwi O33-2
Hyung, Woo Jin Surgery 3-1, LS5-4

I

Ichikawa, Daisuke Surgery 7-2
Ichikawa, Hiroshi O15-1
Ida, Satoshi P39-4
Iida, Shinichiro P69-1
Ikoma, Naruhiko Surgery 3-4, Surgery 4-1, LS9-2
Imai, Takeharu P41-7
Imai, Yoshiro P31-10
Immanuel, Arul Multidisciplinary 6-1
Imoto, Hirofumi P40-1
Imura, Ryo PAS3-3
Inaba, Kazuki P59-8
Inaba, Yuichi PAS4-2
Inaki, Noriyuki Surgery 6-3, Surgery 9-5, LS3-1
Inokuchi, Mikito P33-18
Inoue, Hiroyuki P2-28
Inoue, Masazumi P31-5
Ishibashi, Fumiaki Endoscopy 4-3
Ishida, Hiroki P32-37
Ishida, Michihiro Endoscopy 4-5
Ishida, Ryo Multidisciplinary 3-4
Ishida, Yoshinori P33-3
Ishigami, Hironori Multidisciplinary 6-2
Ishihara, Ryu Endoscopy 4-1
Ishii, Kenjiro O32-1
Ishikawa, Akira P6-1
Ishizaki, Shunta P56-6
Ishizu, Kenichi P32-32
Ito, Sunao P43-2
Ito, Tatsuya P31-12
Ito, Yuki O3-5, P2-8
Iwagami, Shiro P33-8
Iwatsuki, Masaaki P6-20

J

Jacobs, Amy L. PAS2-2
Jagric, Tomaz Surgery 4-4, Surgery 5-1
Jalkanen, Aapo Johannes O2-2
Janjigian, Yelena Medical Oncology 2-1
Jansen, Edwin Radiation Oncology -3
Jee, Ye Seob P39-1
Jeong, Oh O6-1

Jeong, Seong-A P70-5
 Ji, Jiafu Multidisciplinary 8-2
 Jia, Keren P7-1
 Jia, Ru O26-1
 Jia, Zhuoyu O20-4
 Jian, Wang Zi P67-3, P67-4
 Jiang, Tianlu P2-16
 Jiang, Xiaohua O29-1
 Jiang, Zhihui P67-6
 Jin, Shiyang P44-7
 Jung, Ji Eun O24-2
 Jung, Mi Ran O29-2

K

Kagawa, Tetsuya P33-19
 Kaida, Sachiko P70-1
 Kaito, Akio P22-8
 Kaji, Sanae P32-12
 Kakeji, Yoshihiro ML4-1
 Kamiya, Ayako Surgery 4-5, P72-11
 Kamiya, Hajime
 Multidisciplinary 9-4, Translational 3-4
 Kamiya, Satoshi Multidisciplinary 3-5, P32-28
 Kanaji, Shingo Surgery 9-7
 Kanda, Mitsuro Multidisciplinary 11-1
 Kanesaka, Takashi P10-1
 Kang, So Hyun O15-2, O17-3, O21-5, P32-5
 Kang, Ting P19-1
 Kang, WenZhe Radiation Oncology -2
 Kang, Yoon-Koo Medical Oncology 3-3
 Kano, Yosuke P30-6
 Karalis, John D. P5-3
 Karpeh, Martin P20-7
 Kassab, Paulo Palliative Care -1
 Kato, Fumihiko P36-1
 Kato, Ken Multidisciplinary 4-1
 Kawada, Hironori P32-38
 Kawaguchi, Yoshihiko Surgery 5-6
 Kawakami, Hisato Multidisciplinary 7-1, LS2-2
 Kawakubo, Hirofumi Surgery 2-1
 Kawamura, Hideki P32-25
 Keywani, Kammy O9-5, O32-2
 Kikuchi, Hirotoshi Medical Oncology 3-6
 Kim, Chan Gyoo O33-5
 Kim, Dae Hoon P2-20
 Kim, Dong Jin P31-16, P41-13
 Kim, Dong Yi O1-1
 Kim, Dong-Wook P44-6
 Kim, Eun Young P7-8
 Kim, Eun Younh P18-14
 Kim, Guowei Surgery 1-3, LS5-2
 Kim, Hayun P20-1
 Kim, Hyung-II O16-1
 Kim, Hyun Myong P28-9
 Kim, Jeesun Sunny O24-3, P18-7
 Kim, Jong Won P34-5
 Kim, Jong-Han P20-2
 Kim, Ki-Yoon O5-3
 Kim, So Jung P6-18, P67-2
 Kim, Sung Eun O28-1
 Kim, Tae Jun P9-4

Kim, Tae-Se O18-2, P9-3
 Kim, Yoo Min P37-1
 Kim, Young-II P2-24
 Kimura, Yasuaki Medical Oncology 2-6
 Kimura, Yutaka P39-3
 Kinami, Shinichi Surgery 10-2
 Kinoshita, Takahiro Surgery 3-2, LS3-2
 Kitadani, Junya O22-4
 Kitagawa, Masahiro P11-1
 Kitagawa, Yuko PL
 Kitano, Seigo MK1
 Kitayama, Joji Multidisciplinary 5-6
 Kobayashi, Ryota P30-2
 Kodama, Hiroyuki P28-2
 Koder, Yasuhiro Multidisciplinary 1-4
 Komatsu, Masaru Surgery 9-1
 Komatsu, Shuhei Surgery 8-5
 Kondo, Hiroki P23-4
 Kong, Seong-Ho O7-2, O22-5
 Konishi, Tomoki Surgery 7-5
 Kono, Koji MS3-1
 Kopaev, Andrei P18-17
 Kosaka, Takashi P31-17
 Kosyachkova, Ekaterina PAS3-2
 Kubo, Naoshi O20-1
 Kubo, Tsukasa P21-7
 Kubota, Takeshi O28-3
 Kumagai, Koshi P43-3
 Kunishige, Tomohiro P32-31
 Kuno, Masashi P21-4
 Kuo, Chia-Yu P12-2
 Kurata, Yoshihiro P41-12
 Kurihara, Naoto P72-6
 Kurokawa, Yukinori GI, Surgery 6-2,
 Medical Oncology 3-1, LS8-1
 Kusano, Chika Endoscopy 4-7
 Kuwata, Takeshi Translational 2-2
 Kwon, In Gyu LS5-3

L

Lad, Neha Lalit P57-1
 Lai, Hongkun P55-1
 Lai, Ming-Yu P14-2
 Lee, Eunju O29-3, P32-11, P50-2
 Lee, Han Hong O2-3
 Lee, Hayemin P32-15
 Lee, Hyuk-Joon Multidisciplinary 5-3
 Lee, Jeong Won P18-23
 Lee, Jieun O4-1, P6-16
 Lee, Juhee P2-2
 Lee, Kyung-Goo P41-5
 Lee, Sejin O13-4
 Lee, Woo Yong P72-12
 Lei, Xinyi P6-15
 Leon Takahashi, Alberto Mitsuo P18-18, P31-14
 Leong, Trevor Radiation Oncology -1
 Li, Bin-Bin P27-5
 Li, Dongbao P44-2
 Li, Fengyuan P32-2
 Li, Guoxin LS14-2
 Li, Hua P36-2, P36-3

Nishigori, Tatsuto Surgery 10-4
 Nishiguchi, Yukiko P27-6
 Nishimura, Erica P70-2
 Nishino, Masashi O1-2, O21-1
 Nishiyama, Masaki P2-19
 Nishizaki, Masahiko P34-6
 Nobuhisa, Tetsuji Surgery 8-6
 Nomura, Eiji P29-1
 Nomura, Sachiyo Medical Oncology 4-5
 Norero, Enrique P32-18
 Noshiro, Hirokazu Surgery 2-3, LS4-2
 Novikova, Anastasia P42-11
 Nunobe, Souya Surgery 3-3, Endoscopy 1-2, PAS3-1

O

Obama, Kazutaka Surgery 1-2, LS11-3
 Ochmanová, Petra P74-2
 Ogawa, Tadashi P30-4
 Oh, Do-Youn Medical Oncology 2-2
 Oh, Se Yeol O24-4
 Ohashi, Takuma P31-2
 Okabe, Hiroshi Surgery 5-2
 Okawa, Mai P72-13
 Okazaki, Ryo P31-6
 Oki, Eiji LS2-1
 Okuchi, Yoshihisa P32-34
 Omori, Takeshi Surgery 2-4
 Ono, Hiroyuki Endoscopy 3-3
 Oo, Aung Myint P33-23
 Ota, Atsuki P18-22
 Otake, Reiko O16-2

P

Park, Daegeun P59-4, P72-4
 Park, Ji-Hyeon O31-4, P2-23, P70-3
 Park, Joong-Min O29-4
 Park, Ki Bum P33-17
 Park, Shin-Hoo O17-2
 Park, Sin Hye O3-4, O31-1
 Park, Sunho Medical Oncology 4-6, Medical Oncology 4-7
 Park, Yujun O27-1
 Patsko, Veronika O30-3, P22-10
 Pavlov, Rostislav P70-10
 Peng, Cheng-Ming Surgery 6-4
 Peng, Rui P31-1
 Peng, Zhang P42-5
 Pereira, Marina Alessandra O2-1, P7-14
 Piccioni, Stefania Angela O9-4, P6-21
 Pingyuan, Yu P47-2
 Pinto, Mauricio P. P50-3
 Polkowski, Wojciech P. O8-4
 Porembka, Matthew P67-7
 Puca, Lucia O23-2
 Puolakkainen, Pauli Antero P5-9

Q

Qiu, Miaozhen P7-4
 Qu, Huiheng P2-5
 Qu, Xiujian P2-10, P2-11

R

Ramos, Marcus Fernando Kodama Pertille O14-1, O15-4, O23-4, P2-25, P40-2, P74-3
 Rau, Beate Multidisciplinary 6-6
 Realis Luc, Marco P2-27
 Reddavid, Rossella O9-3
 Reim, Daniel O11-3, O12-1
 Rha, Sun Young Translational 5-1
 Ri, Motonari P41-1
 Rino, Yasushi P72-14
 Roh, Chulkyu P72-5
 Rosa, Fausto P9-1, P50-1
 Rouvelas, Ioannis ML4-2
 Rouvelas, Ioannis Multidisciplinary 3-6
 Roviello, Franco Surgery 7-1
 Rueffert, Hans Jochem P70-7, P77-1
 Ryan, Thomas Joseph P27-2
 Ryu, Dae Gon P9-6
 Ryu, Min-Hee Medical Oncology 4-2

S

Saeki, Hiroshi Surgery 4-2
 Sagawa, Hiroyuki Surgery 5-4
 Saito, Masahiro Endoscopy 2-3
 Saito, Masaki Surgery 8-7
 Saito, Takuro PS2
 Sakon, Ryota P51-1
 Sakuma, Jun P48-1
 Sakurai, Katsunobu P18-2
 Sakuraya, Mikiko P70-6
 Sang, Qingqing O34-3
 Sano, Akihiko P41-3
 Sano, Takeshi NT
 Santos, Lucas Vieira dos ML1-3
 Sasako, Mitsuru PAS1-1
 Sato, Kentaro P23-5
 Sato, Reo P33-16
 Sato, Sho Multidisciplinary 3-2
 Sato, Yuya Translational 1-3
 Satodate, Hitoshi P32-24
 Seki, Yusuke P72-21
 Sekii, Shuhei O14-2
 Semenov, Nikolay P55-5
 Seo, An Na P3-4
 Seo, Ji Won P18-9
 Serizawa, Akiko P31-20
 Shang, Lan Lan P32-13
 Sharma, Prateek Endoscopy 4-2
 Shen, Lin Medical Oncology 1-3
 Shepetko, Evgen P38-1
 Sheu, Meei-Ling O19-4
 Shi, Jinyao P7-10
 Shi, Kaihang Medical Oncology 2-5
 Shibasaki, Susumu Surgery 8-3
 Shigeta, Kohei P72-28
 Shimada, Ayako P40-3
 Shimada, Shoji O10-4
 Shimonosono, Masataka P34-4
 Shin, Dong Gue P30-3
 Shin, Jiyeon O27-5

Shinno, Naoki	O8-1	Tanahashi, Toshiyuki	P56-3
Shinohara, Hisashi	Translational 1-2	Tanaka, Ryo	Multidisciplinary 10-4
Shinozuka, Takahiro	O5-4, O19-2	Tanaka, Tsuyoshi	Surgery 5-3
Shirchinjav, Tserenyudon	P22-9	Tang, Zhaoqing	P30-1
Shitara, Kohei	Medical Oncology 1-2	Tanioka, Toshiro	Surgery 9-3
Shoji, Hirokazu	PS4	Tanprsert, Peticha	P30-11
Shoji, Yoshiaki	Multidisciplinary 9-3	Tedaldi, Gianluca	O19-5
Shu, Xufeng	P18-1	Teixeira, Joao Maia	P59-1
Siggins, Katie	P8-2	Terada, Mitsumi	Surgery 4-3
Silano, Flávio	O29-5, P32-4, P32-6, P33-21, P42-1, P49-3, P59-3, P72-2	Terajima, Daiki	O23-1
Singh, Rajvinder	Endoscopy 3-2	Terashima, Masanori	Multidisciplinary 2-2
Skubleny, Daniel	P21-13	Terayama, Masayoshi	Multidisciplinary 8-4
Sleiman, Marwan-Julien	P14-1	Teshima, Hajime	P49-6
Smyth, Elizabeth Catherine	Translational 3-1	Tian, Yulong	PS3, O13-3, O30-4, P42-9, P42-10
So, Choi Kwan	P9-11	Tiano, Teresa	PAS4-3
So, Jimmy	Multidisciplinary 6-3	To, Connie	O14-3
Soeda, Naruyoshi	P21-8	Toihata, Tasuku	P54-1
Soeta, Toshihiro	P59-6	Tokunaga, Masanori	Multidisciplinary 8-3
Sofia, Silvia	Translational 4-3	Tokuyama, Jo	P67-1
Sohda, Makoto	P6-19	Tominaga, Shinta	O24-5
Solaini, Leonardo	P5-5, P30-5	Tonomura, Shunpei	P41-6
Song, Geum Jong	P72-9	Torrioni, Lorena	O15-5, P31-13, P71-3
Song, Jeong Ho	P32-14	Tran, Dat Quang	P22-17
Song, Ying Qi	P18-3	Triemstra, Lianne	O5-2, O16-4
Soru, Pietro	P9-10	Tsiiregzen, Enkh-Amgalan	P67-5
Spalova, Lea	P72-29	Tsuchiya, Hiroshi	O11-6
Strong, Vivian	Surgery 4-6	Tsuchiya, Takahiro	P52-1
Suda, Koichi	Surgery 1-1	Tsuda, Yasuo	P21-15
Suetsugu, Tomonari	P21-9	Tsutsui, Mai	P70-11
Sugita, Saburo	P70-9		
Sugiyama, Emiri	P72-15	U	
Suh, Byoung Jo	O11-4	Uchi, Yusuke	P21-5
Sun, Weiin	P5-2	Uchida, Shintaro	P6-11
Sun, Xiangfei		Ueda, Yoshitake	Multidisciplinary 10-2
Medical Oncology 1-4, Medical Oncology 3-4		Uedo, Noriya	Endoscopy 1-7
Sun, Yuqi	P18-13, P42-3	Uehara, Yuriko	P72-10
Sunagawa, Hideki	P33-4	Ueta, Yu	P72-20
Sunakawa, Yu	LS1-1	Urabe, Masayuki	Endoscopy 1-4
Sundar, Raghav	Translational 5-2	Urakawa, Naoki	P22-1
Suto, Daisuke	Endoscopy 3-4		
Suwa, Tetsuya	P9-9	V	
Suzuki, Yusuke	P29-2	van Amelsfoort, Romy	O10-2
		van der Sluis, Karen	
T		Multidisciplinary 2-4, Translational 3-3	
Tabuchi, Satoshi	P21-3	Verheij, Marcel	Multidisciplinary 7-5
Tada, Tomohiro	LS9-3, Booth Seminar	Viganò, Jacopo	O21-4, O33-3, P22-16, P35-2, P56-2
Tajirika, Toshihiro	P1-6	Vinogradova, Myroslava	P31-18
Takaha, Ritsuki	P50-4	Vo, Long Duy	Surgery 8-8, Surgery 9-6
Takahari, Daisuke	Medical Oncology 4-4, ES1-1		
Takahashi, Junji	Surgery 10-5	W	
Takahashi, Kazunori	P7-11	Wada, Hideyuki	P72-3
Takahashi, Tsuyoshi	Medical Oncology 3-5	Wada, Takeyuki	Multidisciplinary 5-4, O1-3, P32-27
Takasu, Ayaka	P49-4	Wainberg, Zev	Medical Oncology 1-1
Takeno, Atsushi	P44-8	Wakahara, Tomoyuki	P41-4
Takeuchi, Hirohisa	Palliative Care -3	Wakamatsu, Kotaro	O1-6
Takeuchi, Hiroya	PS1, Surgery 6-1	Wakasugi, Takehiro	Surgery 10-3
Takeuchi, Masashi	Translational 1-1	Wakatsuki, Takeru	O4-4
Takiguchi, Shuji	LS4-1	Wan, Mingyu	P6-5
Tan, Lijie	Surgery 2-2	Wang, Feng	P49-2
Tan, Patrick	Translational 4-2	Wang, Fu hui	P28-10
		Wang, Linjun	P32-43

Wang, Qi O16-3
 Wang, Qingrui O20-5
 Wang, Qiong P6-6
 Wang, Weizhi P32-21
 Wang, Xinyu P49-5
 Wang, Yiding P41-8
 Wang, Yinkui Surgery 8-2, Translational 5-5
 Wang, Yuanhang P6-17
 Watanabe, Megumi P56-1
 Weindelmayer, Jacopo P40-4
 Wijnhoven, Bas Multidisciplinary 1-3
 Woo, Yanghee O4-2
 Wu, Di P17-2
 Wu, Xiyu P23-2
 Wu, Zhouqiao P6-13, P41-9, P44-10

X

Xiao, Yao P22-14
 Xing, Yujin O15-3
 Xu, Dazhi O34-5, P32-29
 Xu, Handong Endoscopy 4-6
 Xu, Hao O7-3
 Xu, Jianfei P21-1, P21-2
 Xu, Jing P75-3
 Xu, Rui-Hua Translational 3-2
 Xu, Xin P18-10
 Xu, Xinxin P2-26
 Xu, Zekuan LS11-2
 Xu, Zi-Yao P56-7

Y

Yagi, Taisuke P50-7
 Yahagi, Naohisa Endoscopy 3-1
 Yamagata, Yukinori Surgery 7-3
 Yamaguchi, Hironori Multidisciplinary 6-5
 Yamaguchi, Kazuya P33-13
 Yamaguchi, Kensei
 Medical Oncology 2-3, LS12-1, ES2-1
 Yamamoto, Atsushi P18-21
 Yamamoto, Kazuyoshi O23-3
 Yamamura, Akihiro P32-41
 Yamashita, Hiroharu MS1-1
 Yamashita, Keishi Translational 2-3
 Yamazaki, Kimiyasu Endoscopy 1-6
 Yan, Rong P26-1
 Yan, Yongjia Multidisciplinary 7-4, P68-1
 Yan, Zhibo O17-4, O17-5
 Yang, Han-Kwang MK2
 Yang, Hao P6-8
 Yang, Li O30-5, P55-8
 Yarema, Roman P44-1
 Yasuda, Atsushi O6-4
 Yasufuku, Itaru O2-4
 Yasumoto, Kazuo Medical Oncology 2-4
 Yeo, Charleen P22-6
 Yi, Li Jia Translational 1-4,
 Translational 1-5, Translational 1-6
 Yip, Hon Chi P36-4
 Yokoi, Yuri P21-14
 Yonemura, Yutaka O5-1
 Yoo, Jaeun Translational 4-4

Yoo, Mira O28-4, P8-1
 Yoon, Jung Hwan O4-5
 Yoon, Sam Sunghyun ML2-3, P5-10
 Yoshida, Eri O11-5
 Yoshida, Kazuhiro Multidisciplinary 5-2
 Yoshida, Mitsumasa O1-4
 Yoshikawa, Takaki
 Multidisciplinary 7-3, O21-3, LS7-1
 Yoshimoto, Hidero P33-11
 Yoshino, Shigefumi P28-8
 Yu, Beiqin P1-2
 Yu, Jiwei P6-3
 Yu, Junjian P6-10
 Yu, Pengfei O11-2
 Yu, Yingyan P4-1
 Yuan, Li O27-4, P55-7
 Yuan, Zhen P22-3
 Yuki, Denda P72-17
 Yun, Jong Hyuk P70-8
 Yun, Sangchul P72-22
 Yura, Masahiro O20-3

Z

Zang, Dae Young P5-1
 Zhang, Benlong O7-1, P2-3, P41-2, P61-1,
 P61-2, P61-3, P61-4, P61-5
 Zhang, Diancai P32-20
 Zhang, Haoyu O7-5
 Zhang, Jun P27-1
 Zhang, Liyu P28-3
 Zhang, Miao O26-4
 Zhang, Qiang P59-5
 Zhang, Shun P32-9
 Zhang, Wei P32-16
 Zhang, Xiaotian LS14-1
 Zhang, Yue P42-2
 Zhang, Zhaoxiong P33-7
 Zhang, Zhenzhan P7-6
 Zhao, Binghe P45-1, P45-2
 Zhao, Sihan P42-4
 Zhao, Yu Peng P7-9
 Zhong, Hao P22-5
 Zhong, Qing O8-2, P13-2
 Zhou, Chenfei P13-1
 Zhou, Hao PAS1-3
 Zhou, Yanbing O22-1, P20-9, P20-10, P20-11,
 P20-12, P20-13, P20-14, P20-15, P20-16,
 P31-7, P42-6, P42-7, P42-8, P42-13
 Zhu, Juan P1-3
 Zhu, Linghua P18-20
 Zong, Liang Translational 5-4
 Zuo, Chaohui P1-7, P1-8, P12-1

Sponsorship

Gold Sponsor

Bristol-Myers Squibb K.K. / ONO PHARMACEUTICAL CO., LTD.

Silver Sponsor

Covidien Japan, Inc.
Medicaroid Corporation / Sysmex Corporation
MSD K.K.
TAIHO PHARMACEUTICAL CO., LTD.

Bronze Sponsor

Johnson & Johnson K. K.
Qilu Pharmaceutical Co., Ltd.

AI Medical Service Inc.

Asahi Kasei Pharma Corporation

Astellas Pharma Inc.

Chugai Pharmaceutical Co., Ltd.

CONMED Japan K.K.

DAIICHI SANKYO COMPANY, LIMITED

Debbie's Dream Foundation: Curing Stomach Cancer

Eli Lilly Japan K. K.

Ferronova

GUNZE MEDICAL LIMITED

Hutom

Intuitive Surgical G.K.

KAKEN PHARMACEUTICAL CO., LTD.

Korean Gastric Cancer Association

MIYARISAN PHARMACEUTICAL CO. LTD.

NIPPON KAYAKU

Olympus Marketing, Inc


Otsuka Pharmaceutical Factory, Inc.

Stryker Japan K.K.

TERUMO CORPORATION

Yakult Honsha Co.,Ltd.

AIRSEAL ROBOTIC SOLUTION



CONMED

CONMED Japan KK
Shintora South Bldg, 8F, 5-20-4 Shinbashi, Minato-ku, Tokyo, Japan
CONMED.com

製造販売元：コンメッド・ジャパン株式会社 製品名：トライルメシ ハイフアクターヘッドフィルターチューブセット 販売名：エアシール用フィルターチューブセット 販売番号：1381X10241001037
8mm プレアドレスオプティカルエアシールドロカー dV100mm エアシール dV トロカー 認定番号：303ADRZ00085000
製造販売元：インテグリティパージカラム株式会社 製品名：インストゥルメントカニューラ 8mm Xi 販売名：da Vinci シリーズカニューラ 販売番号：1381X10126000002

INTUITIVE

Da Vinci SP

Move surgery forward. Again.

詳細は以下のお問い合わせ先、または弊社営業担当へご確認ください。

お問い合わせ先

インテュイティブサージカル合同会社

東京都港区赤坂一丁目12番32号アーク森ビル

Tel. (03) 5575 - 1419 (営業部)

Tel. (03) 5575 - 1326 (マーケティング部)

Tel. (03) 5575 - 1362 (音声案内で3を選択)

(0120) 56 - 5635 (音声案内で3を選択) (カスタマーサービス)

販売名: da Vinci SP サージカルシステム (承認番号: 30400BZX00220000)

©2023 インテュイティブサージカル合同会社

無断複写・複製・転載を禁じます。製品名は各社の商標または登録商標です。

PN 1110236 JP Rev.A 12/22



GUNZE MEDICAL

グンゼメディカル株式会社



TENALEAF

癒着防止吸収性バリア テナリーフ®

強さとしなやかさを兼ね備え、
操作性を追求しました

- 割れにくく、展開しやすい適度なコシ
- 腹腔内の水分でゲル化し、組織になじむ
- 点接触により、適度な付着力を実現

販売名: テナリーフ 高度管理医療機器 承認番号 30300BZX00289000

保険適用: 100 合成吸収性癒着防止材 (1) シート型

※合成吸収性癒着防止材を、女子性器手術後の卵管及び

卵管采の通過・開存性の維持以外の目的で使用した場合には、
373.38cm²を限度として算定できる

製造販売業者 **グンゼメディカル株式会社**

〒105-7315 東京都港区東新橋1丁目9番1号 東京汐留ビルディング15F

GUNZE



凹凸形状 (イメージ)

※テナリーフ®はグンゼ株式会社の登録商標です。

※製品をご使用の際は添付文書をご参照ください。

商品に関する詳しい情報は弊社HPでご覧いただけます。

各種資料の請求・サンプル試用・購入その他のお問い合わせは
グンゼメディカル株式会社までご連絡ください。
TEL:06-4796-3151



人も地球も健康に
Yakult

抗悪性腫瘍剤

毒薬・処方箋医薬品* *注意—医師等の処方箋により使用すること

薬価基準収載

エルプラット[®] 点滴静注液

50mg
100mg
200mg

一般名：オキサリプラチン

製造販売元（資料請求先）

株式会社ヤクルト本社

〒105-8660 東京都港区海岸1-10-30

☎ 0120-589601（医薬営業部 くすり相談室）

【受付時間】10:00～16:00（土・日・祝日ならびに当社休日を除く）

2022年5月作成

※「効能又は効果」、「用法及び用量」、「警告・禁忌を含む注意事項等情報」等については電子化された添付文書をご参照ください。

Creating for Tomorrow

The commitment of the Asahi Kasei Group:

To do all that we can in every era to help the people of the world make the most of life and attain fulfillment in living.

Since our founding, we have always been deeply committed to contributing to the development of society, boldly anticipating the emergence of new needs.

This is what we mean by “Creating for Tomorrow.”

ASAHI KASEI PHARMA CORPORATION
1-1-2 Yurakucho, Chiyoda-ku, Tokyo 100-0006 JAPAN

AsahiKASEI



The Korean
Gastric Cancer Association

www.kingca.org

Exciting Journey to a New Dimension

KINGCA WEEK 2023

The Korea International
Gastric Cancer Week 2023

10th Anniversary of KINGCA WEEK

September 14 ~ 16, 2023

Lotte Hotel Seoul, Seoul, Korea

stryker

1688 AIM (Advanced Imaging Modalities) 4K platform

Native 4K SPY Fluorescence Imaging Technology

- SPY Overlay
- SPY ENV
- SPY Contrast

Auto light



医療機器認証 / 届出番号	販売名
13B1X10209000926	1688 AIM 4Kカメラ
13B1X10209000961	1688 AIM 4Kマイクロスコープカメラヘッド
13B1X10209000927	L11 光源装置
230AFBZX00074000	ニューモクリア気腹装置
13B1X10209000892	PINPOINT カラー蛍光イメージングシステム - SPY PHI
13B1X10209000891	PINPOINT カラー蛍光内視鏡システム
13B1X10209000936	Connected OR Hub システム

製造販売業者

日本ストライカー株式会社

112-0004 東京都文京区後楽2-6-1 飯田橋ファーストタワー

P 03 6894 0000

※本製品に関するお問い合わせは弊社営業までお願い致します。